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ROLE OF VASCULAR HYPERPOLARIZATION IN MUSCLE BLOOD FLOW 
REGULATION IN HEALTHY HUMANS 
 
 The following investigation composes a series of experiments with the overall aim of 
determining the role for vascular hyperpolarization via activation of inwardly-rectifying 
potassium (KIR) channels and Na
+/K+-ATPase in the regulation of vascular tone in response to 
muscle contractions and ischaemia in young, healthy humans.  We tested the general hypothesis 
that activation of KIR channels and Na
+/K+-ATPase contributes in large part to the vasodilatory, 
hyperaemic, and sympatholytic responses observed in these conditions and this contribution is 
greater than that of other vasodilators, specifically nitric oxide (NO) and prostaglandins (PGs).  
The specific aims of each experiment were: 1) to determine whether K+-stimulated vascular 
hyperpolarization via activation of KIR channels and Na
+/K+-ATPase mediates contraction-
induced rapid vasodilatation in the human forearm; 2) to determine whether vascular 
hyperpolarization via activation of KIR channels and Na
+/K+-ATPase contributes to the 
hyperaemic response at the onset of repeated muscle contractions, as well as to steady-state 
forearm blood flow during rhythmic handgrip exercise; 3) to determine whether vascular 
hyperpolarization via activation of KIR channels and Na
+/K+-ATPase contributes to the observed 
blunting of sympathetically-mediated vasoconstriction that occurs during moderate intensity 
rhythmic forearm exercise; and 4) to determine whether vascular hyperpolarization via activation 
of KIR channels and Na
+/K+-ATPase contributes to the observed reactive hyperaemia that occurs 
in the human forearm following release of temporary ischaemia.   Our collective findings 
 iii
demonstrate a significant contribution of KIR channels and Na
+/K+-ATPase activation to rapid 
vasodilatation following a single muscle contraction, the onset of exercise hyperaemia in 
response to repeated muscle contractions, steady-state muscle blood flow during rhythmic 
handgrip exercise and reactive hyperaemia following temporary ischaemia.  In contrast to our 
hypothesis, we did not observe a significant contribution of KIR channels and Na
+/K+-ATPase to 
the observed blunting of sympathetic α-adrenergic vasoconstriction that occurs during handgrip 
exercise.  In all studies, any role of NO and PGs was modest, if present at all.  Taken together, 
our findings indicate that during a variety of vasodilatory stimuli, there is a large contribution of 
pathways that are independent of NO and PGs, specifically activation of KIR channels and 
Na+/K+-ATPase. Hyperpolarization via activation of KIR channels and Na
+/K+-ATPase represents 
a novel mechanistic pathway in the understanding of in vivo regulation of muscle blood flow in 
response to contractions and ischaemia.  These findings may provide insight into understanding 
impaired vascular function in patient populations and as such, could represent a novel therapeutic 
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CHAPTER I – INTRODUCTION AND EXPERIMENTAL AIMS 
 Skeletal muscle comprises the largest tissue mass in the human body and has a high 
capacity for increased metabolism.  During exercise, muscle blood flow can increase up to 20 
fold and receive a large proportion (~85%) of total cardiac output and thus can have a significant 
effect on total peripheral resistance.  As mean arterial pressure is determined by total peripheral 
resistance and cardiac output, the understanding of muscle blood flow regulation is important in 
understanding overall cardiovascular control.   
 At the local tissue level, blood flow is the product of the pressure gradient across the 
tissue (ΔP = Parterial - Pvenous) and the vascular conductance.  According to Poiseuille’s equation, 
given a constant viscosity, conductance is proportional to the radius of a vessel to the fourth 
power.  Taken together, if perfusion pressure is fairly constant, it is the calibre of the resistance 
vessels that largely determines tissue blood flow.  A given arteriolar diameter represents the 
integrative balance between a variety of vasodilating and vasoconstricting stimuli.  These stimuli 
have diverse categorization, from neural, hormonal, metabolic, to mechanical, as well as varied 
origin, stemming from nerve, skeletal muscle, vascular smooth muscle, endothelial, and blood 
cell sources.  Ultimately, the contractile state of vascular smooth muscle cells is determined by 
intracellular [Ca2+] with greater [Ca2+]i resulting in contraction and vasoconstriction and 
decreased [Ca2+]i resulting in relaxation and vasodilatation.  Vascular smooth muscle cell [Ca
2+]i 
can be affected by changes in second messenger signaling [i.e. cyclic adenosine monophosphate 
(cAMP), cyclic guanosine monophosphate (cGMP)] and related kinases as well as direct 
alterations in [Ca2+] via calcium ion channel activity.  Of most relevance, the open state of 
voltage-dependent calcium channels is determined by the membrane potential of vascular 
smooth muscle cells.  Hyperpolarization of vascular smooth muscle cells inhibits voltage-
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dependent calcium channels, decreasing [Ca2+]i resulting in vascular smooth muscle cell 
relaxation and vasodilatation.  Characteristic of hyperpolarization-induced vasodilatation is that 
it is conducted, and with respect to tissue blood flow control, spreads upstream from the site of 
stimulus and this is thought to be important in regulating profound changes in arteriolar 
resistance. 
 The vasoactive signaling pathways that contribute to vascular tone during a variety of 
conditions have been well-studied in humans.  Many signaling pathways involve the innermost 
lining of blood vessels, a monolayer of cells critical in vascular control, known as the 
endothelium.  An important role for endothelium-dependent vasodilating substances has been 
realized, and endothelial health relates to cardiovascular disease morbidity and mortality.  
Muscle contractions, or exercise, stimulate a variety of responses that span all of the regulatory 
levels (neural, hormonal, metabolic, mechanical) of muscle blood flow control.  Attempts have 
been made to characterize this complex and integrative regulation, but our understanding of the 
specific signaling pathways involved remains unclear, particularly at the level of local 
vasodilator signaling.  Investigations have utilized additional stimuli other than muscle 
contraction such as temporary ischaemia in order to experimentally 1) create a mismatch in 
oxygen delivery and demand, independent of muscle contractions and evoke local vasodilatation, 
and 2) serve as a marker of vascular health and responsiveness.  However, similar to exercise, 
the underlying signaling pathways that contribute to the reactive hyperaemic response to arterial 
occlusion is also uncertain.   
 In addition to a variety of signals for vasodilatation and vascular smooth muscle cell 
relaxation, repeated muscle contractions present an additional challenge in understanding 
vascular regulation.  In order to appropriately regulate mean blood pressure given the 
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aforementioned significant capacity to increase blood flow to skeletal muscle during exercise, 
sympathetic activation increases with progressive exercise intensity.  Sympathetic activation 
results in increased noradrenaline release and subsequent binding to α-adrenergic receptors on 
vascular smooth muscle cells, eliciting vasoconstriction which in turn, limits the decrease in total 
peripheral resistance.  Sympathetic vasoconstrictor activity increases throughout the body, 
including in the active muscle vasculature.  However, contracting skeletal muscle has a unique 
ability to somewhat blunt the vasoconstrictor stimulus (as compared to the same stimulus at rest), 
as a means of preserving oxygen delivery to the active tissue.  This phenomenon, classically 
termed “functional sympatholysis”, is graded with exercise intensity and occurs through post-
junctional modification of both α1 and α2-adrenergic receptors.  The exact signaling pathways 
involved in the modulation of sympathetic constriction that occurs in contracting skeletal muscle 
are also largely undetermined in humans. 
 The development of various pharmacological agents has led to the in vivo ability to 
enzymatically inhibit the synthesis of two primary vascular signaling pathways, nitric oxide 
(NO) and prostaglandins (PGs) that predominantly stimulate vasodilatation by local changes in 
vascular smooth muscle cell [Ca2+]i via alterations in cyclic-guanosine monophosphate 
dependent protein kinase (PKG) and cyclic-adenosine monophosphate dependent protein kinase 
(PKA), respectively.  As stated, [Ca2+]i can also be modulated by changes in smooth muscle cell 
membrane potential and this mechanism of vasodilatation has been challenging to investigate, 
particularly in humans.  It has been shown in animal models that stimulation of inwardly-
rectifying potassium (KIR) channels and Na
+/K+-ATPase leads to hyperpolarization, and we have 
recently demonstrated the ability to inhibit these pathways in the human forearm.   
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 Therefore, this body of work comprises four specific hypotheses with the general aim of 
understanding the role of vascular hyperpolarization via KIR channels and Na
+/K+-ATPase in the 
regulation of vascular tone in human skeletal muscle in response to muscle contractions and 
temporary ischaemia.  
 
Overall hypothesis: Vascular hyperpolarization via activation of KIR channels and Na
+/K+-
ATPase has a significant role in the control of vascular tone in young healthy humans.  
Specifically, these pathways contribute to rapid vasodilatation following a single muscle 
contraction and the hyperaemic response to repeated muscle contractions and ischaemia. Further, 
these pathways are able to modulate sympathetically-mediated vasoconstriction during repeated 
muscle contractions.     
 
Specific Aims 
Experiment #1:  to determine whether vascular K+-stimulated hyperpolarization via activation 
of KIR channels and Na
+/K+-ATPase mediates rapid vasodilatation in the forearm of young 
adults. 
 
Experiment #2:  to determine whether vascular hyperpolarization via activation of KIR channels 
and Na+/K+-ATPase contributes to the hyperaemic response at the onset of repeated muscle 
contractions, as well as to steady-state forearm blood flow during rhythmic handgrip exercise in 




Experiment #3:  to determine whether vascular hyperpolarization via activation of KIR channels 
and Na+/K+-ATPase contributes to the observed blunting of sympathetically-mediated 
vasoconstriction that occurs during moderate intensity rhythmic forearm exercise in young, 
healthy humans.   
 
Experiment #4:  to determine whether vascular hyperpolarization via activation of KIR channels 
and Na+/K+-ATPase contributes to the observed reactive hyperaemia that occurs in the forearm 
of young, healthy humans following release of temporary ischaemia. 
 
To the best of our knowledge, this collection of work presents novel and significant 
insight into a highly-involved vascular signaling pathway in human skeletal muscle.  We show 
that activation of KIR channels and Na
+/K+-ATPase significantly contributes to rapid 
vasodilatation following a single muscle contraction, the onset and steady-state hyperaemia 
observed with repeated muscle contractions and the reactive hyperaemic response to temporary 
ischaemia.  Further, the contribution of NO and PGs is minimal to non-existent under these 
conditions.  Contrary to our hypothesis, we did not observe a significant role for KIR channel and 
Na+/K+-ATPase activation in the ability to modulate sympathetic vasoconstriction during muscle 
contractions, and thus the signaling pathways regulating functional sympatholysis remain 
undetermined.  However, the collective evidence from the contained study and literature suggests 
that vascular hyperpolarization, beyond KIR channels and Na
+/K+-ATPase may be involved.  
Taken together, our findings and the profound magnitude of some of the observed effects of 
inhibiting KIR channels and Na
+/K+-ATPase activation indicate that vascular hyperpolarization is 
essential to vascular control in humans in response to vasoactive stimuli.   
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CHAPTER II – MANUSCRIPT I 
 
Mechanisms of rapid vasodilatation following a brief contraction in  
human skeletal muscle1 
 
Summary 
A monophasic increase in skeletal muscle blood flow is observed following a brief single 
forearm contraction in humans, yet the underlying vascular signaling pathways contributing to 
this response remain largely undetermined.  Evidence from experimental animals indicates an 
obligatory role of vasodilatation via smooth muscle hyperpolarization and human data suggests 
little-to-no independent role for nitric oxide (NO) or vasodilating prostaglandins (PGs).  Recent 
in situ data suggest that potassium (K+) release during a single muscle contraction activates both 
inwardly-rectifying potassium (KIR) channels and Na
+/K+-ATPase, and thus may initiate the 
observed vasodilatation.  We tested the hypothesis that K+-mediated vascular hyperpolarization 
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occurring via activation of KIR channels and Na
+/K+-ATPase underlies the vasodilatation 
following a brief single contraction in humans and that combined inhibition of NO and PGs 
would have a minimal effect on this response.  We measured forearm blood flow (Doppler 
ultrasound) and calculated vascular conductance 10 sec prior to, and for 30 sec after a single 1-
sec dynamic forearm contraction at 10, 20, and 40% maximum voluntary contraction (MVC) in 
16 young adults.  Inhibition of K+-mediated vasodilatation was achieved through combined 
inhibition of KIR channels and Na
+/K+-ATPase via intra-arterial infusion of barium chloride 
(BaCl2) and ouabain, respectively. Combined enzymatic inhibition of NO and PG synthesis 
occurred via L-NMMA (NO synthase) and ketorolac (cyclooxygenase), respectively.  In Protocol 
1 (n=8), BaCl2+ouabain reduced the magnitude of the peak vasodilator response at all intensities 
(P<0.05; range = 30-45%) and total post-contraction vasodilatation (area under the curve; AUC) 
was attenuated ~55-75% from control.  Contrary to our hypothesis, L-NMMA+ketorolac further 
reduced peak vasodilatation and AUC by ~60% and ~80%, respectively, from control.  Thus, in 
Protocol 2 (n=8), we first administered L-NMMA+ketorolac and observed a reduced peak 
vasodilatation (P<0.05; range = 25-35%) and AUC ~25-40% from control at all contraction 
intensities.  BaCl2+ouabain further attenuated the response and the total effect of all four 
inhibitors was similar to Protocol 1.  We conclude that K+-mediated hyperpolarization and NO 
and PGs, in combination, significantly contribute to contraction-induced rapid vasodilatation and 
inhibition of all four pathways nearly abolishes this phenomenon in humans. 
 
Introduction 
Regulation of skeletal muscle hyperaemia during muscle contractions is complex and 
involves a variety of signals that control both the arterio-venous perfusion pressure gradient and 
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arteriolar calibre (Clifford & Hellsten, 2004; Calbet & Joyner, 2010).  In an attempt to isolate the 
local mechanisms underlying exercise hyperaemia, early experiments utilized a single brief 
muscle contraction to allow for contraction-induced hyperaemia without the continuous 
interruption of the blood flow response or further stimulus for hyperaemia, as occurs with 
repeated contractions (Corcondilas et al., 1964).  In this regard, the single contraction model can 
serve as a tool to examine feed-forward mechanisms of hyperaemia that are largely independent 
of changes in tissue oxidative metabolism (Mohrman et al., 1973).  The typical response is 
characterized by an intensity-dependent, rapid, monophasic increase in blood flow that occurs 
immediately (within one cardiac cycle) following contraction, achieves full magnitude in ~5 
cardiac cycles, and then declines towards baseline. To date, the essential underlying mechanisms 
for this rapid hyperaemia, and thus feed-forward regulation of muscle blood flow, have yet to be 
determined in humans. 
Given the rapid nature of single contraction-induced hyperaemia, some investigators have 
suggested that this response is due to changes in the arterio-venous perfusion pressure gradient 
(Laughlin, 1987; Sheriff et al., 1993; Tschakovsky et al., 1996); however, several lines of 
evidence now clearly demonstrate vasodilatation is obligatory to observe this hyperaemic 
phenomenon (Hamann et al., 2003; Hamann et al., 2004; Tschakovsky et al., 2004) and a portion 
of this response is attributable to the mechanical compression of the vasculature that occurs 
during muscle contraction (Clifford et al., 2006; Kirby et al., 2007).  Over the last century, a 
multitude of vasodilating factors have been suggested to contribute to contraction-induced 
vasodilatation, yet in humans, none have been found obligatory to observe a significant increase 
in muscle blood flow (Clifford, 2007; Joyner & Wilkins, 2007).   
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Interestingly, evidence in animals indicates that the potassium ion (K+) released during 
muscle contractions activates both inwardly-rectifying K+ (KIR) channels and Na
+/K+-ATPase to 
evoke vascular smooth muscle cell hyperpolarization and subsequent rapid vasodilatation 
(Armstrong et al., 2007).  These data substantiate early observations that changes in interstitial 
[K+] following brief muscle contraction has the appropriate magnitude and time course to have a 
significant involvement in the hyperaemic response (Mohrman & Sparks, 1974b; Duling, 1975; 
Murray & Sparks, 1978; Hazeyama & Sparks, 1979; Murray et al., 1979; Kiens et al., 1989)  and 
that smooth muscle vascular hyperpolarization may be essential to observe rapid vasodilatation 
(Hamann et al., 2004).  Whether K+-mediated vasodilatation via KIR channel and Na
+/K+-
ATPase activation contributes to contraction-induced rapid vasodilatation in humans is 
unknown.   
In an attempt to understand the contributing vasoactive pathways to rapid vasodilatation 
in human subjects, investigators have targeted acetylcholine released from motor nerves as well 
as “traditional” substances synthesized by the vascular endothelium.  In this context, 
acetylcholine spillover from motor neurons is not obligatory to observe the vasodilator response, 
(Brock et al., 1998), and further, independent inhibition of nitric oxide (NO) (Brock et al., 1998) 
or vasodilating prostaglandin (PG) synthesis (Shoemaker et al., 1996) does not impact rapid 
vasodilatation.  However, despite evidence indicating considerable interaction between NO and 
PGs in the control of vascular tone in response to a variety of stimuli (Vanhoutte, 1992; Schrage 
et al., 2004; Nicholson et al., 2009; Markwald et al., 2011), no studies to date have determined 




Given this information as background, we sought to determine the underlying signaling 
mechanisms of muscle contraction-induced rapid vasodilatation in humans.  We tested the 
hypothesis that K+-stimulated vascular hyperpolarization mediated by activation of KIR channels 
and Na+/K+-ATPase underlies the vasodilatation following a brief single contraction in humans 




With Institutional Review Board approval and after written informed consent, a total of 
16 young healthy adults (13 men, 3 women; age = 23±1 years old; weight = 72.3±2.4 kg; height 
= 176±2 cm; body mass index = 23.4±0.5 kg m-2; means ± SEM) participated in the present 
study.  All subjects were sedentary to moderately active, non-smokers, non-obese, normotensive 
(resting blood pressure <140/90 mmHg), and not taking any medications.  Studies were 
performed after an overnight fast and 24 hour abstention from caffeine and exercise.  The 
subjects were in the supine position with the experimental arm abducted to 90° and slightly 
elevated above heart level upon a tilt-adjustable table.  Female subjects were studied during the 
early follicular phase of their menstrual cycle or placebo phase of oral contraceptive use to 
minimize any potential cardiovascular effects of sex-specific hormones.  All studies were 
performed according to the Declaration of Helsinki. 
 
Arterial Catheterization, Arterial Blood Pressure, and Heart Rate 
A 20 gauge, 7.6 cm catheter was placed in the brachial artery of the non-dominant arm 
under aseptic conditions after local anesthesia (2% lidocaine) for local administration of study 
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drugs and blood sampling.  The catheter was connected to a 3-port connector as well as a 
pressure transducer for mean arterial pressure (MAP) measurement and continuously flushed at 3 
ml hr-1 with heparinized saline.  The two side ports were used for drug infusions of vasoactive 
drugs (Kirby et al., 2008; Crecelius et al., 2010).   Heart rate was determined using a 3-lead ECG 
(Cardiocap/5, Datex-Ohmeda Louisville, CO, USA). 
 
Forearm Blood Flow and Vascular Conductance 
A 4 MHz pulsed Doppler probe (Model 500M, Multigon Industries, Mt. Vernon, NY, 
USA) was used to measure brachial artery mean blood velocity (MBV) with the probe securely 
fixed to the skin over the brachial artery proximal to the catheter insertion site as previously 
described by our laboratory (Dinenno & Joyner, 2003; Kirby et al., 2007).  The probe insonation 
angle relative to the skin was 45 degrees.  A linear 12 MHz echo Doppler ultrasound probe (GE 
Vingmed Ultrasound Vivid7, Horten, Norway) was placed in a holder securely fixed to the skin 
immediately proximal to the velocity probe to measure brachial artery diameter.  Brachial artery 
diameter was measured in triplicate prior to any contractions under all experimental conditions, 
as we and others have shown that brachial diameter does not change in response to this stimulus 
(Tschakovsky et al., 2004; Carlson et al., 2008).   Forearm blood flow was calculated as: 
FBF = MBV × π (brachial artery diameter/2)2 × 60, where the FBF is in ml min-1, the MBV is in 
cm s-1, the brachial diameter is in cm, and 60 is used to convert from ml s-1 to ml min-1.  Forearm 
vascular conductance (FVC) was calculated as (FBF/MAP) × 100, and expressed as ml min-1 100 





Single Dynamic Forearm Contractions 
Maximum voluntary contraction (MVC) was determined for the experimental arm as the average 
of three maximal squeezes of a handgrip dynamometer (Stoelting, Chicago, IL, USA) that were 
within 3% of each other.  Brief, dynamic forearm contractions were performed at 10, 20, and 
40% of the subject’s MVC using a handgrip pulley system attached to weights corresponding to 
each workload.  The weight was lifted 4-5 cm over the pulley for a single, 1-second dynamic 
contraction as previously described (Carlson et al., 2008).  These mild-to-moderate contraction 
intensities were chosen to limit the contribution of systemic haemodynamics to forearm 
vasodilator responses and to eliminate reflex increases in sympathetic nervous system activity, 
and thus isolate the local effects of muscle contraction on vascular tone (Carlson et al., 2008).  
At least 1.5 minutes of relaxation were given between each contraction to allow continuous 
measures of forearm haemodynamics post-contraction, as well as ample time for haemodynamics 
to return to baseline values (Tschakovsky et al., 2004; Kirby et al., 2007; Carlson et al., 2008)  
Workload intensity was randomized and counterbalanced across subjects to eliminate any order 
effect and trials were performed in triplicate to calculate an average response for each subject.  
Pilot studies in our laboratory have determined that MVC is not affected by any of the vasoactive 
substances, particularly barium chloride and ouabain, administered in these studies (n=12; pre: 
41±2 kg vs post: 40±2 kg; P=0.43). 
 
Vasoactive Drug Infusion 
All drug infusions occurred via brachial artery catheter to create a local effect in the 
forearm.  In order to inhibit K+-mediated hyperpolarization, ouabain octahydrate (Sigma 03125, 
St. Louis, MO, USA) was infused at 2.7 nmol min-1 for 15 minutes as a loading dose to inhibit 
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Na+/K+-ATPase combined with barium chloride (BaCl2; 10% w/v BDH3238, EMD Chemicals, 
Gibbstown, NJ, USA), infused at 0.45 μmol dl FAV-1 min-1 with a minimum dose of 4 μmol min-
1 to a maximum dose of 5 μmol min-1 for 3 minutes as a loading dose to inhibit KIR channels 
(Dawes et al., 2002; Burns et al., 2004; Dwivedi et al., 2005; Jantzi et al., 2006; Crecelius et al., 
2012).  This dose of BaCl2 has been adjusted to forearm volume as compared to our previous 
study (Crecelius et al., 2012) in order to maximize efficacy while still remaining within doses 
safe for human administration and specific for KIR channels (Dawes et al., 2002; Jackson, 2005).  
Ouabain and BaCl2 were prepared in saline and confirmed sterile and free of fungus/endotoxin 
and particulate matter with a standard microbiology report (JCB-Analytical Research Labs, 
Wichita, KS, USA) prior to use.  To inhibit “traditional” endothelium-dependent vasodilatation, 
NG-monomethyl-L-arginine (L-NMMA; Bachem, Germany) was administered to inhibit nitric 
oxide synthase-mediated production of NO in combination with ketorolac (Hospira, Lake Forest, 
IL, USA) to inhibit cyclooxygenase-mediated synthesis of PGs.  Loading doses of L-NMMA and 
ketorolac were 25 mg (5 mg min-1 for 5 minutes) and 6 mg (600 µg min-1 for 10 min), 
respectively (Crecelius et al., 2011b; Crecelius et al., 2012).  Depending on the protocol, 
maintenance doses of either BaCl2 (0.45 μmol dl FAV
-1 min-1), ouabain (2.7 nmol min-1), L-
NMMA (1.25 mg min-1), or ketorolac (150 µg min-1) were infused for 3 minutes prior to each set 
of single contractions to ensure continuous blockade (see Experimental Protocol below).  
Forearm volume used for normalization for specific vasoactive drugs was determined from 
regional analysis of whole-body dual-energy X-ray absorptiometry scans (QDR series software, 
Hologic, Inc, Bedford, MA, USA).  Three single contractions at the respective workload were 
performed at 15, 30, and 45 seconds of the 3 min loading infusion prior to each set of single 




Two separate groups of 8 subjects were studied, with the primary difference being the 
order in which pharmacological inhibitors were administered.  The experimental timeline is 
depicted in Figure 1.  To establish control contraction-induced rapid vasodilatory responses, 
subjects performed single, brief forearm contractions in triplicate at 10, 20, or 40% MVC for 1-
second with a minimum of 1.5 minutes of rest between contractions.  Between contraction 
intensities, saline was infused for 3 minutes prior to the first contraction (Figure 1).  
 
Protocol 1:  To address our primary hypothesis regarding K+-stimulated vascular 
hyperpolarization via KIR channel and Na
+/K+-ATPase activation as the predominant signaling 
pathway involved in rapid vasodilatation, in 8 subjects (MVC = 52±3 kg) following control 
responses, single contraction bouts were performed at each exercise intensity after combined 
infusion of BaCl2 and ouabain.  Next, in attempt to further elucidate the underlying signaling of 
rapid vasodilatation, we addressed endothelium-dependent vasodilators.  The combined 
contribution of NO and PGs was assessed with combined administration of L-NMMA and 
ketorolac, respectively, and the single contractions were repeated. 
 
Protocol 2:  Given the unexpected findings from Protocol 1 regarding an effect of combined 
inhibition of NO and PGs on rapid vasodilation (see Results), in 8 different subjects (MVC = 
42±4 kg), the order of inhibition was reversed so that after control responses were obtained, L-
NMMA and ketorolac were infused to assess the combined contribution of NO and PGs, 
respectively, to contraction-induced rapid vasodilatation.  The third set of single contractions was 




hyperpolarization via KIR channel and Na
+/K+-ATPase activation in the presence of combined 
NO and PG inhibition. 
 
Control Experiments:  In a subset of subjects (n=6), sodium nitroprusside (SNP; Nitropress, 
Hospira Inc.) was infused at 2 µg 100ml FAV-1 min-1 for 5 minutes (Kirby et al., 2010) in control 
(saline) conditions and after prior administration of all four antagonists (BaCl2, ouabain, L-
NMMA and ketorolac) as a negative control to confirm intact capacity of the forearm resistance 
vasculature to vasodilate.  
In a different subset of subjects (n=4), prior to any pharmacological inhibition, 
phenylephrine (PE; Baxter, Irvine, CA, USA) was infused at 6.25 ng 100ml FAV-1 min-1 for 2 
minutes to pre-constrict the vasculature (Kirby et al., 2008) prior to performance of a bout of 
40% MVC single contractions to determine the impact of reduced basal vascular tone per se on 
forearm rapid vasodilatation.  This dose of PE was selected in order to reduce basal forearm 
vascular conductance to a similar level (~20-30%) as we typically observe with infusion of the 
antagonists utilized in the experimental protocols (Crecelius et al., 2011a; Crecelius et al., 2012).  
Time control experiments were not performed in this study as we have previously 
demonstrated that rapid vasodilatation to a single contraction is repeatable over the course of an 
experiment of similar duration (~2-3 hours) (Kirby et al., 2009). 
 
Data Acquisition and Analysis 
Data were collected and stored on computer at 250 Hz and analyzed off-line with signal-
processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  Baseline FBF, FVC, 
MAP, and HR represent an average of the last 10 seconds of the resting time period prior to 
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muscle contraction.  The post-contraction data represent beat-by-beat analysis beginning with the 
first unimpeded cardiac cycle immediately after release of the contraction for a total of 30 
cardiac cycles (Tschakovsky et al., 2004; Kirby et al., 2007; Carlson et al., 2008).  The data 
presented for SNP trials represent an average of the final 30 seconds of pre-drug and post-drug 
infusion.  Percent changes in FVC were calculated as: ((FVC post – FVC pre)/(FVC pre)) × 100 
as this tracks changes in blood vessel radius independent of the initial level of vascular tone and 
is therefore the most appropriate index of changes in vasomotor tone (Buckwalter & Clifford, 
2001).   The total contraction-induced vasodilator response (area under the curve; AUC) was 
calculated as the sum of absolute FVC (ml min-1) following contraction for 30 cardiac cycles 
minus pre-contraction FVC.   
 
Statistics 
All values are reported as means ± SEM.  Baseline haemodynamics and total 
vasodilatation (AUC) values for each intensity (10, 20, 40% MVC) were assessed by one-way 
repeated measures ANOVA for drug condition.  We chose to analyze each intensity separately 
due to differences in the magnitude of these values and to limit our analysis to only the relevant 
comparisons.  For the change in peak vasodilatation, a two-way (condition × intensity) repeated 
measures ANOVA was used.  Student-Newman-Keuls post hoc testing was performed when a 
significant F was observed.  Comparisons in the control protocols were made with paired 








Baseline haemodynamics for both experimental protocols are presented in Table 1.  
Figure 2 presents the dynamic absolute forearm vascular conductance (A, C, E) and the 
vasodilatory response (%FVC; B, D, F) to single muscle contractions at 10%, 20%, and 40% 
MVC.  These responses followed the typical temporal pattern of vasodilatation, comprised of an 
immediate rise in FVC in all trials that peaked in an intensity-dependent manner within ~4-5 
cardiac cycles and then returned to baseline levels.  It is these dynamic responses from which we 
calculate our main variables of interest (peak vasodilatation and total vasodilatation).  We have 
not performed statistical analysis on these dynamic curves, but present them in an effort to be 
comprehensive. 
Infusion of BaCl2+ouabain reduced resting forearm vascular conductance (Table 1; 
Figure 2), and significantly reduced the magnitude of the peak vasodilatory response at all 
intensities (P<0.05; Figure 3; range = 30-45%).  Similarly, total post-contraction vasodilatation 
(AUC) was reduced from control following BaCl2+ouabain for all intensities (10%: -74±8%; 
20%: -59±10%; 40%:-55±4%; P<0.05; Figure 4). 
 Addition of L-NMMA+ketorolac tended to further reduce baseline forearm vascular 
conductance (P=0.12; Table 1; Figure 2) and contrary to our hypothesis, also attenuated the 
vasodilatory response following a single contraction (Figure 2).  The peak post-contraction 
vasodilatory response was further reduced by L-NMMA and ketorolac for 20% and 40% MVC 
(P< 0.05; Figure 3), but only approached significance at 10% MVC (P = 0.065).  Similarly, L-
NMMA+ketorolac further reduced total post-contraction vasodilatation from the BaCl2+ouabain 
condition at 20% and 40% (P<0.05) but not at 10% (P=0.2; Figure 4).  The presence of all 
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inhibitors (BaCl2+ouabain+L-NMMA+ketorolac) reduced the peak vasodilatation by ~60% and 
total vasodilatory response (AUC) by ~80% on average for the 3 contraction intensities, thus 
explaining nearly all of the rapid vasodilatation in response to a single muscle contraction.  In all 
conditions and exercise intensities, systemic haemodynamics did not change post-contraction.   
 
Protocol 2 
Given the findings of Protocol 1 regarding an effect of combined inhibition of NO and 
PGs, we reversed the order of pharmacological inhibition in Protocol 2 in order to address the 
combined role of these pathways without prior inhibition of vascular hyperpolarization via KIR 
channel and Na+/K+-ATPase activation.  As anticipated, L-NMMA+ketorolac significantly 
reduced baseline FBF and FVC (Table 1).  The dynamic absolute forearm vascular conductance 
(A, C, E) and the vasodilatory response (%FVC B, D, F) to single muscle contractions at 10%, 
20%, and 40% MVC for Protocol 2 are presented in Figure 5.  Similar to Protocol 1, these 
responses followed the typical temporal pattern of vasodilatation observed and prior infusion of 
L-NMMA+ketorolac significantly reduced the magnitude of the peak vasodilatory response at all 
intensities (P<0.05; Figure 6; range = 27-34%).  Total post-contraction vasodilatation (AUC) 
was also reduced from pre-blockade following L-NMMA+ketorolac at all intensities (10%: -
34±14%; 20%: -25±12%; 40%:-40±7%; P<0.05; Figure 7). 
 Addition of BaCl2+ouabain further reduced baseline vascular conductance (Table 1) and 
also attenuated the vasodilatory response following a single contraction (Figure 5).  The peak 
post-contraction vasodilatory response was significantly impacted by the addition of 
BaCl2+ouabain, approximately doubling the effect from L-NMMA+ketorolac at all contraction 
intensities (Figure 6).  Similarly, BaCl2+ouabain further reduced total post-contraction 
19 
 
vasodilatation from the L-NMMA+ketorolac condition at all intensities (Figure 7; P< 0.05).  
Remarkably similar to Protocol 1, the presence of all inhibitors (BaCl2+ouabain+L-
NMMA+ketorolac) reduced the peak vasodilatation by ~60% and total vasodilatory response 
(AUC) by ~80% on average for the 3 contraction intensities again explaining nearly all of the 
rapid vasodilatation in response to a single muscle contraction.  In all conditions and exercise 
intensities, systemic haemodynamics did not change post-contraction.   
 
Control Experiments 
In order to confirm preserved vasodilator capacity after administration of 
BaCl2+ouabain+L-NMMA+ketorolac, SNP was administered pre-blockade and at the end of the 
experimental protocol in a subgroup of 6 subjects.  SNP caused significant vasodilatation that 
was unaffected by BaCl2+ouabain+L-NMMA+ketorolac, despite a reduction in baseline FVC 
(Table 2).   
 As stated above and presented in Table 1, changes in baseline FVC were observed 
following administration of the experimental antagonists.  In order to determine whether there is 
a direct effect of reduced baseline FVC per se on the vasodilator response to a single contraction, 
we pre-constricted the forearm vasculature with phenylephrine (α1-adrenergic agonist) and had 4 
subjects perform single contractions at 40% MVC and compared this to the control (pre-
blockade) condition.  As shown in Figure 8, we were successful in reducing baseline forearm 
vascular conductance to a similar extent as occurred in our experimental protocols (~30%; Panel 
A).  In contrast to what was observed in our experimental conditions (BaCl2+ouabain, L-
NMMA+ketorolac, and BaCl2+ouabain+L-NMMA+ketorolac), pre-constricting with 
phenylephrine did not reduce the dynamic vasodilator response to a single contraction (Figure 
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8B), nor did it impact the total post-contraction vasodilatation (Control: 1585±258 ml 100mmHg-
1 vs Pre-Constricted: 1497±188 ml 100mmHg-1; P=0.7). 
  
Discussion 
The purpose of the current study was to determine the primary vasodilator signaling 
pathways involved in response to a single muscle contraction.  Specifically, based on prior work, 
we were interested in the contribution of K+-stimulated vascular hyperpolarization via activation 
of KIR channels and Na
+/K+-ATPase and the effect of combined inhibition of NO and PGs 
synthesis.  The primary novel findings of the present study support a significant combined role of 
KIR channel and Na
+/K+-ATPase activation, likely stimulated by K+ efflux from contracting 
skeletal muscle, in all facets of the rapid vasodilator response.  Inhibition of K+-mediated 
vascular hyperpolarization significantly reduces peak and total vasodilatation in response to three 
increasing intensities of single muscle contractions.  Additionally, and contrary to our original 
hypothesis, we demonstrate that combined inhibition of NO and PGs synthesis significantly 
reduces the peak and total vasodilatation following a single contraction.  When all four signaling 
pathways were inhibited, the peak and total vasodilatory responses were reduced remarkably by 
~60 and ~80%, respectively compared with control conditions, thus explaining the majority of 
the response.  Our collective findings identify for the first time that inhibition of K+-mediated 
vascular hyperpolarization, along with NO and PG synthesis, nearly abolishes the rapid 
vasodilator response to a single muscle contraction and that these pathways largely explain this 





Contraction-induced Rapid Vasodilatation and Contributing Signaling Pathways 
Early studies investigating muscle blood flow regulation in response to muscle 
contractions appreciated the rapid nature with which hyperaemia occurs following even a brief 
contraction (Anrep & von Saalfeld, 1935).  Many different theories of what contributed to the 
rapid response were put forth including contributions of a mechanical effect of the muscle pump 
to alter perfusion pressure (Folkow et al., 1970; Folkow et al., 1971; Laughlin, 1987), direct 
mechanically-induced vasodilatation via arteriole compression/distortion (Gray et al., 1967; 
Mohrman & Sparks, 1974a; Clifford et al., 2006; Kirby et al., 2007), neurally-mediated 
vasodilatation (Buckwalter et al., 1997; Welsh & Segal, 1997; Buckwalter et al., 1998) and 
metabolic vasodilatation (Gorczynski et al., 1978).  Near the end of the 20th century, a key study 
by Tschakovsky and colleagues eloquently demonstrated that mechanical effects of a contraction 
and resultant changes in perfusion pressure could not fully explain the hyperaemic response and 
vasodilatation of the vasculature did in fact occur in response to a single contraction in humans 
(Tschakovsky et al., 1996).  These findings were confirmed by studies in experimental animals 
where changes in arteriolar diameter can be directly determined (Hamann et al., 2004; Mihok & 
Murrant, 2004; VanTeeffelen & Segal, 2006; Armstrong et al., 2007).  Despite the acceptance of 
this immediate rapid vasodilatation, studies in humans designed to understand the signaling 
mechanisms have yielded largely negative results.  Typically performed in the forearm, human 
studies have shown little-to-no independent role for acetylcholine (Brock et al., 1998), NO 
(Brock et al., 1998), or PGs (Shoemaker et al., 1996) in mediating rapid vasodilatation.  To date, 
the most convincing evidence regarding the mechanism of rapid vasodilatation comes from 
animal models and suggests that K+ from muscle released during contraction diffuses to vascular 
smooth muscle to activate both KIR channels and Na
+/K+-ATPase and cause hyperpolarization 
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and subsequent rapid vasodilatation (Hamann et al., 2004; Armstrong et al., 2007).  However, 
prior to the current study, this hypothesized mechanism of K+-mediated vascular 
hyperpolarization had not been tested in humans. 
Recently, we demonstrated the ability to abolish exogenous K+-mediated (intra-arterial 
KCl) vascular hyperpolarization and vasodilatation with combined BaCl2 to inhibit KIR channels 
and ouabain to inhibit Na+/K+-ATPase (Crecelius et al., 2012).  Thus, building upon this 
established pharmacology and recent findings in experimental animals, we tested the hypothesis 
that K+-stimulated vascular hyperpolarization via activation of KIR channels and Na
+/K+-ATPase 
contributes to contraction-induced rapid vasodilatation in humans.   In Protocol 1, we 
demonstrate that combined blockade of KIR channels and Na
+/K+-ATPase significantly reduces 
both the peak and total rapid vasodilatory response (Figures 2-4).  In addition to a ~30-45% 
reduction in the peak change in vascular conductance (Figure 3), we observed a ~55-75% 
attenuation in the total vasodilatation following a single muscle contraction (Figure 4).  Taken 
together, the impact of inhibiting both KIR channel and Na/K
+-ATPase activation on the total 
vasodilatation occurring post-contraction was profound, and is by far the largest in magnitude of 
any prior pharmacological inhibition of the rapid vasodilatory response in humans (Shoemaker et 
al., 1996; Brock et al., 1998).   
In Protocol 1, given prior observations in humans indicating little-to-no independent role 
for NO nor PGs in single contraction-induced rapid vasodilatation (Shoemaker et al., 1996; 
Brock et al., 1998), we were somewhat surprised to observe a significant reduction in the 
response with combined inhibition of these substance (Figures 3 and 4).  Specifically, we 
demonstrate that combined inhibition of NO and PGs further reduced the peak dilatory response 
from the BaCl2+ouabain condition (~55-65% from control; Figure 3) as well as the total 
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vasodilatation (~80% from control; Figure 4).  These results contrast previous findings in 
response to brief muscle contractions when each substance was independently inhibited 
(Shoemaker et al., 1996; Brock et al., 1998), but on the other hand, are consistent with what has 
been demonstrated during continuous steady-state exercise (Schrage et al., 2004; Mortensen et 
al., 2007).  Based on the findings from Protocol 1, we next sought to determine the combined 
role of NO and PGs to contraction-induced rapid vasodilatation prior to inhibition of K+-
mediated vascular hyperpolarization via KIR channels and Na/K
+-ATPase. 
In Protocol 2, we reversed the order of drug infusions and found that combined inhibition 
of NO and PGs reduced the peak response by ~25-35%, whereas the total vasodilatory response 
was reduced by ~20-40%.  These data are the first to clearly demonstrate a combined active role 
for these substances in contraction-induced rapid vasodilatation in humans.  When BaCl2 and 
ouabain were infused after inhibition of NO and PGs, the peak response was further attenuated 
(~60-70% from control; Figure 6) as was the total vasodilatory response (~80% from control; 
Figure 7).  Thus, in both Protocols 1 and 2, the impact of all four inhibitors on the rapid 
vasodilatory response was profound, and our data provide clear evidence for the combined 
importance of K+-mediated vascular hyperpolarization, NO, and PGs in mediating this response 
in healthy human subjects. 
  The collective data from our experiments support K+-mediated vascular 
hyperpolarization via stimulation of KIR channels and Na
+/K+-ATPase, as well as a combined 
role for the autocoids NO and PGs, in mediating the rapid dilatory response to a single muscle 
contraction.  In general, the magnitude of reduction in the total vasodilatation appears to be 
somewhat greater when K+-mediated vascular hyperpolarization is inhibited as compared to NO 
and PGs; however, we lack the power to make an appropriate statistical comparison between 
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these 2 different subject groups.  It also appears that the order in which combined inhibition of 
KIR channels and Na
+/K+-ATPase or of NO and PGs occurs does not impact the magnitude of the 
effects on peak or total vasodilatation (Figure 9).   
 
Potential Stimuli for Vasodilatation Following a Single Muscle Contraction 
The evidence from the present study clearly supports a profound effect of combined 
inhibition of KIR channels, Na
+/K+-ATPase, NO and PGs on contraction-induced  rapid 
vasodilatation; however, the exact stimulus for the activation of these signaling pathways is 
unclear.  Armstrong and colleagues (2007) demonstrated that both BaCl2 and ouabain can 
independently inhibit arteriolar vasodilatation observed in response to muscle contractions 
evoked via electrical stimulation and that these pathways were activated by K+ efflux from 
skeletal muscle into the interstitial space.  In this model, they were able to pharmacologically 
inhibit voltage-gated K+ channels to specifically address skeletal muscle K+ as the stimulus to 
activate KIR channels and Na
+/K+-ATPase.  Unfortunately, in our human forearm model, we are 
not able inhibit K+ efflux from contracting muscle, and thus base our conclusions related to K+-
mediated activation of KIR channels and Na
+/K+-ATPase on our previous observations that 
inhibition of KIR channels and Na
+/K+-ATPase via BaCl2 and ouabain, respectively, abolishes 
KCl-mediated vasodilatation in humans (Crecelius et al., 2012).   The potassium ion is an 
attractive candidate for the stimulus of rapid vasodilatation as the timecourse is appropriate and it 
would serve as a feedforward mechanism that couples rapid vasomotor responses with muscle 
activation (Murray et al., 1979; De Clerck et al., 2003; Burns et al., 2004).  Additionally, some 
animal studies report that K+-mediated vasodilation is most often transient in nature (Burns et al., 
2004), and this may in part contribute to the distinct temporal pattern of the response.   
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While K+ is a strong candidate for stimulating KIR channels and Na
+/K+-ATPase and 
supports our primary hypothesis regarding the mechanisms of rapid vasodilatation, K+ would not 
explain the unexpected combined involvement of NO and PGs that we observed (Crecelius et al., 
2012).  Recently, extracellular production of adenosine, resultant from degradation of adenine 
nucleotides via ecto 5’ nucleotidase, was shown to contribute to rapid vasodilatation following 
electrically stimulated contraction of the hamster cremaster muscle (Ross et al., 2013).  Previous 
evidence would also suggest that adenosine is capable of stimulating NO and PG production in 
humans (Mortensen et al., 2009; Nyberg et al., 2010).  It is also possible that acetylcholine, 
released at the neuromuscular junction could diffuse to nearby capillary and stimulate NO and 
PG production (Domeier & Segal, 2007).  However, data in humans utilizing atropine to inhibit 
muscarinic receptors have shown little role for acetylcholine in rapid vasodilatation (Brock et al., 
1998), and thus, this latter possibility is unlikely.  Finally, endothelial cell changes in 
intracellular [Ca2
+] may be directly sensitive to the mechanical compression/distortion of the 
vasculature or changes in shear stress resultant from muscle contraction and thus could also 
stimulate NO and PG production (Gray et al., 1967; Koller et al., 1994; Osanai et al., 2000; 
Clifford et al., 2006; Kirby et al., 2007).   
 
Experimental Considerations  
In several experimental conditions, alterations in baseline forearm vascular tone occurred 
as a result of the antagonists we administered.  While we present our primary data as a relative 
change from baseline, as this appropriately tracks changes in arteriolar calibre from conditions of 
altered baseline blood flow (Buckwalter & Clifford, 2001), we felt it was necessary to more 
directly address whether increased basal vascular tone per se may impact the vasodilator 
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response to a single contraction.  In a subgroup of subjects, we pre-constricted the forearm 
vasculature to a similar magnitude as observed in our experimental conditions with local 
infusions of the α1-adrenergic agonist phenylephrine.  Despite starting from a reduced level of 
forearm vascular conductance, there was no impact of pre-constriction on the vasodilator 
response following a brief contraction at 40% MVC (Figure 8).  Thus, although the mechanisms 
by which phenylephrine causes an increase in basal vascular tone may differ from those of our 
inhibitors, we do not believe our primary conclusions regarding vascular hyperpolarization, NO, 
and PGs are simply due to a direct effect of the inhibitors on basal vascular tone.  
 Given the magnitude of the effect on vasodilatation that we observed, it is reasonable to 
question whether vasodilator capacity per se was impaired in our subjects throughout the 
experimental trials.  To address this potential concern, in a subgroup of subjects, we 
administered sodium nitroprusside, an endothelium-independent vasodilator and demonstrated a 
preserved response following administration of all of our antagonists (Table 2).  This is 
consistent with recent findings from our laboratory demonstrating that combined BaCl2 and 
ouabain administration does not impair acetylcholine-mediated vasodilatation in humans 
(Crecelius et al., 2012).  Thus, the present observations do not reflect a generalized impairment 
in the forearm vasculature to respond to vasodilator stimuli (i.e. our findings are specific to 
muscle contractions).   
 While we have previously shown that BaCl2 and ouabain inhibit KCl-mediated 
vasodilatation (Crecelius et al., 2012) and a multitude of work supports that activation of KIR 
channels and Na+/K+-ATPase leads to vascular hyperpolarization in vitro (Nelson & Quayle, 
1995; Edwards et al., 1998; Burns et al., 2004), we are inherently limited in our human in vivo 
model in that we are unable to directly determine cellular membrane potential and thus 
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demonstrate vascular hyperpolarization nor are we able to inhibit K+ release from contracting 
muscle.  In this same regard, it is possible that although we administer BaCl2 at a concentration 
within the range to specifically block KIR channels (Dawes et al., 2002; Jackson, 2005), we 
cannot definitively exclude the possibility that we may be inhibiting other K+ channels, mostly 
likely KATP channels.  It should also be acknowledged that although we did not determine the 
efficacy of our inhibitors, we have clearly demonstrated efficacy of all drugs in various previous 
studies in the human forearm (Dinenno et al., 2003; Schrage et al., 2004; Crecelius et al., 2012).  
It is possible that any potential intensity-dependent differences in the magnitude of the observed 
responses was due to incomplete blockade and the ability of high intensity (i.e. 40% MVC) 
contractions to somewhat override our inhibitors.   This is particularly true for BaCl2 which can 
be overridden by high concentrations of K+ (Armstrong & Taylor, 1980; Jantzi et al., 2006).  
Similarly, the remaining minimal vasodilatation observed could be explained by a lack of 
complete blockade or alternatively, other additional mechanisms that may contribute to rapid 
vasodilatation in response to a brief muscle contraction. 
  
Perspectives 
As recognized in early studies and clearly appreciated in more recent investigations, the 
model of a single muscle contraction allows for the investigation of feed-forward mechanisms of 
exercising blood flow regulation.  Whereas much work has been done attempting to understand 
the underlying vasomotor signaling pathways of the metabolic feedback mechanisms of exercise 
hyperaemia, less attention has been paid to the feed-forward response (Clifford & Tschakovsky, 
2008).  We have previously shown that rapid vasodilatation is impaired in older healthy adults 
(Carlson et al., 2008; Kirby et al., 2009) and recent evidence suggests that obese individuals also 
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demonstrate attenuated rapid vasodilatation (Blain et al., 2012).  The underlying mechanisms of 
this impairment in these populations are currently unknown, but based on the present findings 
are most likely related to decreased  K+-mediated hyperpolarization and/or potentially attenuated 
production of NO and PGs.   
 
Conclusions 
 Rapid vasodilatation occurs following a brief skeletal muscle contraction and, to date, the 
underlying vasomotor signaling pathways involved in this response have yet to be determined.  
In the present study, we demonstrate that K+-stimulated vascular hyperpolarization via KIR 
channel and Na+/K+-ATPase activation significantly contributes to contraction-induced rapid 
vasodilatation as do NO and PGs, in combination.  Collective blockade of KIR channels, Na
+/K+-
ATPase, NO and PGs nearly abolishes this phenomenon in humans, thus remarkably explaining 
the vast majority of rapid vasodilatation.  Future studies designed to determine whether vascular 
hyperpolarization via these pathways, independently and in tandem with NO and PGs, continues 







Table 1. Baseline haemodynamics 
* P<0.05 vs Pre-Blockade; † P<0.05 vs BaCl+Ouab; ‡ P<0.05 vs LNMMA+Ket 















(ml min-1 100mmHg-1) 
Protocol 1: BaCl2+Ouab First     
     Pre-Blockade 56±2 88±2 30.5±3.8 34.5±4.0 
     BaCl2+Ouab 54±2 92±2* 22.6±1.4* 24.4±1.4* 
     BaCl2+Ouab+L-NMMA+Ket 53±1 97±1*† 20.2±0.8* 19.4±1.4* 
Protocol 2: L-NMMA+Ket 
First 
    
     Pre-Blockade 55±3 87±3 21.1±2.5 24.1±2.8 
     L-NMMA+Ket 51±2 88±2 17.0±1.3* 19.2±1.5* 




Table 2.  Subgroup: Forearm haemodynamics during sodium nitroprusside infusion 
*P<0.05 vs Pre-Blockade  
n=6; BaCl2=Barium chloride; FAV=forearm volume; FVC=forearm vascular conductance (ml 







2 μg dl FAV-1 min-1 
FVC 
ΔFVC (%) 
   Pre-Blockade 16.2±2.4 138.5±25.5 877±276 



















Trial 2: Dual Block 
Single Contraction Bout for a Given % MVC 
Contraction Contraction Contraction 
~1sec ~1sec ~1sec
3 min 3 min1.5 min 1.5 min





3 min 3 min 3 min 
Saline SalineSaline 
Trial 1: Control 
Figure 1. Experimental Timeline 
A. Each experimental protocol consisted of 3 trials of single dynamic forearm contractions at 3 
different intensities [10%, 20%, 40% maximal voluntary contraction (MVC)], all performed in 
triplicate.  In the first trial, saline was infused via brachial artery catheter for 3 minutes prior to 
each set of contractions.  In the second trial, depending on the experimental protocol, either 
BaCl2+ouabain (n=8; Protocol 1) or L-NMMA+ketorolac (n=8; Protocol 2) was administered for 
3 min prior to contractions.  In the third trial, all subjects received all antagonists prior to each set 
of contractions.  B.  For each intensity, three contractions were performed, each lasting ~1 sec.  













Trial 3: Quad Block 
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  10% MVC
Cardiac Cycle Post-Contraction



































































































































































































































Figure 2. Protocol 1: Effect of BaCl2+ouabain and BaCl2+ouabain+L-NMMA+ketorolac on 
dynamic vasodilator responses to single contractions 
Absolute forearm vascular conductance (A, C, E) and relative changes in forearm vascular 
conductance (B, D, F) are presented for 10%, 20%, and 40% MVC single contractions, 
respectively.  Across all intensities, prior infusion of BaCl2+ouabain (grey triangles) reduced the 
post-contraction vasodilatory response as compared to the pre-blockade (saline; black circles) 
condition.  Additional infusion of L-NMMA+ketorolac (open squares) further inhibited these 














































Figure 3. Protocol 1: Effect of BaCl2+ouabain and BaCl2+ouabain+L-NMMA+ 
ketorolac on peak post-contraction vasodilator response 
Infusion of BaCl2+ouabain (grey bars) significantly reduced the peak post-contraction 
vascular conductance (P<0.05 vs zero) at all contraction intensities.  Addition of L-
NMMA+ketorolac (open bars) further inhibited this response at 20% and 40% MVC. * 








































































Figure 4. Protocol 1: Effect of BaCl2+ouabain and BaCl2+ouabain+L-
NMMA+ketorolac on total post-contraction vasodilatation 
The area under the dynamic response curves was calculated to determine the total post-
contraction FVC.  Infusion of BaCl2+ouabain (grey bars) significantly reduced the total 
vasodilatory response from pre-blockade conditions (black bars) at all contraction 
intensities.  Addition of L-NMMA+ketorolac (open bars) further attenuated this response at 
20% and 40% MVC contractions, but not at 10% MVC.  * P<0.05 vs Pre-Blockade. † 




  10% MVC
Cardiac Cycle Post-Contraction















































































































































































































































Figure 5. Protocol 2: Effect of L-NMMA+ketorolac and L-NMMA+ketorolac+ 
BaCl2+ouabain on dynamic vasodilator responses to single contractions 
Absolute forearm vascular conductance (A, C, E) and relative changes in forearm vascular 
conductance (B, D, F) are presented for 10%, 20%, and 40% MVC single contractions, 
respectively.  Across all intensities, prior infusion of L-NMMA+ketorolac (grey triangles) 
reduced the post-contraction vasodilatory response as compared to the pre-blockade (saline; 
black circles) condition.  Additional infusion of BaCl2+ouabain (open squares) further 

































































Figure 6. Protocol 2: Effect of L-NMMA+ketorolac and L-NMMA+ketorolac 
+BaCl2+ouabain on peak post-contraction vasodilator response 
Infusion of L-NMMA+ketorolac (grey bars) significantly reduced the peak post-contraction 
vascular conductance (P<0.05 vs zero) at all contraction intensities.  Addition of 
BaCl2+ouabain (open bars) significantly augmented this inhibition at all contraction 











































































Figure 7.  Protocol 2: Effect of L-NMMA+ketorolac and L-NMMA+ketorolac 
+BaCl2+ouabain on total post-contraction vasodilatation 
The area under the dynamic response curves was calculated to determine the total post-
contraction FVC.  Infusion of L-NMMA+ketorolac (grey bars) significantly reduced the 
total vasodilatory response from pre-blockade conditions (black bars) at all contraction 
intensities.  Addition of BaCl2+ouabain (open bars) further attenuated this response at all 


























































































Figure 8. Subgroup Study: Effect of reducing baseline forearm vascular tone on dynamic 
vasodilator responses to a single contraction at 40% MVC. 
A.  Absolute forearm vascular conductance (FVC) is presented and demonstrates that infusion 
of the vasoconstrictor phenylephrine (α1-adrenergic agonist; open circles) reduces forearm 
vascular tone prior to contraction (cardiac cycle 0) as compared to the control (saline; black 
circles) condition.  The post-contraction changes in vascular conductance mimic those of the 
control condition, but are shifted to a lower absolute FVC.  B.  The relative vasodilator 
response (%ΔFVC) following a single contraction is unaffected by pre-constriction with 
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Figure 9. Protocols 1 and 2: Comparison of the effects of BaCl2+ouabain and L-
NMMA+ketorolac  
A.  Peak forearm vasodilatation (%Δ forearm vascular conductance) was attenuated by the 
inhibitors, in all conditions.  There did not appear to be any appreciable and consistent 
differences between BaCl2+ouabain and L-NMMA+ketorolac in terms of the magnitude of 
the effect on peak vasodilatation.  Additionally, the effects were not impacted by the order of 
inhibitor administration [note: order is in reference to BaCl2 + ouabain given first (Protocol 1) 
or given second (Protocol 2)]. B. Total post-contraction vasodilatation (area under the curve; 
AUC) was attenuated by the inhibitors in all conditions.  It appears as though the magnitude 
of the effect on AUC of BaCl2+ouabain was consistently greater than that of L-
NMMA+ketorolac. Similar to the effects on peak vasodilatation, the impact of the inhibitors 
was not affected by the order of administration.  Due to a lack of statistical power for 
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CHAPTER III – MANUSCRIPT II 
 
Vascular hyperpolarization via inwardly-rectifying potassium channels and Na+/K+-
ATPase contributes to onset and steady-state exercise hyperaemia in humans2 
 
Summary 
The signaling mechanisms that contribute to exercise hyperaemia at the onset of muscle 
contractions and during steady-state conditions are yet to be fully elucidated in humans.  
Evidence in animal models suggests a role for vascular hyperpolarization and most data, 
including that in humans, suggests a modest role for the endothelial autocoids nitric oxide (NO) 
and prostaglandins (PGs).  We tested the hypothesis that vascular hyperpolarization via 
activation of inwardly-rectifying potassium (KIR) channels and Na
+/K+-ATPase contributes to 
both the onset and steady-state hyperaemic response to exercise.  Further, we determined 
whether a role for NO and PG would exist in the presence of inhibition of vascular 
hyperpolarization.  In Protocol 1 (n=11), forearm blood flow (FBF; Doppler ultrasound) was 
measured during rhythmic handgrip exercise at 10% maximal voluntary contraction for 5 
minutes under control conditions (intra-arterial saline; T1), after combined inhibition of KIR 
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channels and Na+/K+-ATPase alone [via barium chloride (BaCl2) and ouabain, respectively; T2] 
and in the presence of combined nitric oxide synthase (L-NMMA) and cyclooxygenase 
inhibition (ketorolac; T3).  Drugs in this protocol were not infused during exercise due to 
potential confounding influences on basal vascular tone.  In T2, the total hyperaemic responses 
were significantly (P<0.05) attenuated from control at 30 seconds (-49±5%), 1 minute (-34±5%), 
and 2 minutes (-20±5%) of exercise and FBF was not different in the last 2 minutes of exercise.  
In T3, addition of L-NMMA+ketorolac reduced resting FBF but only had a further effect on 
exercise FBF in the first 15 sec.  In Protocol 2 (n=8), all study drugs were infused prior to and 
during exercise to more directly assess the impact of inhibition on steady-state hyperaemia.  
Steady-state FBF was significantly reduced during T2 vs T1 (133±15 vs 167±17 ml min-1; Δ 
from control: -20±3%), and further reduced during T3 (120±15 ml min-1; -29±3%).  The effect of 
inhibition on vasodilatation (forearm vascular conductance) was greater than FBF (Δ from 
control: T2: -28±2%; T3: -40±3%).  Our data indicate vascular hyperpolarization via activation 
of KIR channels and Na
+/K+-ATPase as a novel contributing vasodilatory pathway in the complex 
hyperaemic response to exercise at the onset and during steady-state exercise and reveal a role 
for NO and PG during steady-state hyperaemia when hyperpolarization via these means is 
inhibited.   
 
Introduction 
 The regulation of blood flow and oxygen delivery to contracting muscle is a complex 
response that involves mechanical factors, the sympathetic nervous system, and local metabolic 
and endothelium-derived substances that can influence vascular tone (Saltin et al., 1998).  
Regarding the latter, prior studies in animal models established that disruption of the 
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endothelium can attenuate the hyperaemic response to muscle contraction (Sagach et al., 1992; 
Berdeaux et al., 1994; Segal & Jacobs, 2001) and many subsequent studies have attempted to 
identify the endothelial-derived substances that may regulate blood flow during exercise.  
Additionally, local metabolic substances that elicit vasodilatation independent of the 
endothelium, such as K+, have been suggested to be involved in exercise hyperaemia (Hazeyama 
& Sparks, 1979a; Wilson et al., 1994; Juel et al., 2007), particularly at the onset of muscle 
contractions (Mohrman & Sparks, 1974; Armstrong et al., 2007).  However, to date, obligatory 
local vasodilators for exercise hyperaemia are still questioned in humans (Joyner & Wilkins, 
2007). 
Endothelium-dependent vasodilatation occurs via the synthesis of nitric oxide (NO) and 
vasodilating prostaglandins (PGs; i.e. prostacyclin) (Feletou & Vanhoutte, 2006) or through 
hyperpolarization of the vascular smooth muscle (Garland et al., 1995; Edwards et al., 1998).  In 
young healthy humans, combined inhibition of NO and PGs can reduce femoral blood flow 
during knee extension exercise (Boushel et al., 2002; Mortensen et al., 2007); however, no effect 
of prior blockade of these pathways is observed in the human forearm during mild- and 
moderate-intensity rhythmic handgrip exercise (Schrage et al., 2004; Crecelius et al., 2011b).  
The exact pathways by which endothelial-derived hyperpolarization occurs have not been 
established and thus fewer studies have attempted to address the contribution of this pathway to 
vascular regulation during exercise.  In animals models, disruption of hyperpolarization (Milkau 
et al., 2010) or conducted vasodilatation (Segal & Jacobs, 2001), to which vascular 
hyperpolarization largely contributes (Domeier & Segal, 2007), attenuates contraction-induced 
hyperaemia.  A few studies in humans have attempted to inhibit the synthesis of candidate 
hyperpolarizing pathways including cytochrome p450 metabolites (Hillig et al., 2003), calcium-
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activated potassium (KCa) channels (Mortensen et al., 2007), and ATP-sensitive potassium 
channels (KATP) (Schrage et al., 2006).  These studies observed only a modest, if any, reduction 
in skeletal muscle blood flow during steady-state exercise, even when combined with inhibition 
of NO and PGs.  Combined inhibition can be an important approach given evidence these 
pathways may be interrelated and able to compensate for one another (Taddei et al., 1999).  An 
important point is that in these prior human studies, it is difficult to assess the efficacy of the 
inhibitors utilized to attenuate a hyperpolarizing stimulus.  Further, hyperpolarization of vascular 
smooth muscle can occur independent of these means as well as be stimulated by non-
endothelial-derived sources, such as increased interstitial [K+] (Hazeyama & Sparks, 1979b; 
Edwards et al., 1998).  Thus, there are multiple lines of evidence that would suggest vascular 
hyperpolarization is involved in the hyperaemic response to muscle contractions and this 
question remains unanswered in humans.   
The dynamic nature of the hyperaemic response to muscle contractions is well 
appreciated and while the regulation of steady-state muscle blood flow is of interest, the 
transition from rest to exercise presents another intriguing aspect of vascular regulation (Behnke 
et al., 2002; Wray et al., 2005; Clifford, 2007).  Similar to steady-state exercise hyperaemia, 
inhibition of NO and PGs, independently or in combination, does not impair the change in blood 
flow observed at the onset of muscle contractions (Shoemaker et al., 1996; Shoemaker et al., 
1997; Radegran & Saltin, 1999; Nyberg et al., 2010) while only combined inhibition of NO and 
PGs in the leg lowers absolute leg blood flow at exercise onset (Nyberg et al., 2010).  Human 
studies investigating the role of vascular hyperpolarization in the initial hyperaemic response 
have not been performed. 
50 
 
Recently, we have shown that vascular hyperpolarization via the activation of inwardly-
rectifying potassium (KIR) channels and Na
+/K+-ATPase contribute to a large portion (~50%) of 
the hyperaemic response following a single muscle contraction in the human forearm, and 
combined with NO and PGs account for nearly all (~80%) of the total vasodilatory response 
(Crecelius et al., 2013a).  In addition, activation of KIR channels and Na
+/K+-ATPase can be 
stimulated by both K+ (Edwards et al., 1998; Crecelius et al., 2012) and adenosine triphosphate 
(ATP) (Crecelius et al., 2012), two substances proposed to be involved in vascular regulation 
during exercise in humans (Gonzalez-Alonso et al., 2002; Kirby et al., 2012; Saltin, 2012).  With 
this information as a background, the purpose of the present experiment was to test the 
hypothesis that vascular hyperpolarization via activation of KIR channels and Na
+/K+-ATPase 
contributes to exercise hyperaemia both at the onset of muscle contractions and during steady-
state levels of muscle blood flow.  Further, we sought to determine whether there would be a 




With Institutional Review Board approval and after written informed consent, a total of 
19 young healthy adults (Protocol 1: 7 men, 4 women; age = 23±1 years; weight = 71.6±2.6 kg; 
height = 172±3 cm; body mass index = 24.1±0.7 kg m-2; forearm volume (FAV) = 848±41 ml; 
Protocol 2: 4 men, 4 women; age = 24±2 years; weight = 69.0±3.0 kg; height =173±3 cm; body 
mass index = 23.1±0.8 kg m-2; FAV = 811±62 ml; means±S.E.M.) participated in the present 
study.  All subjects were sedentary to moderately active, non-smokers, non-obese, normotensive 
(resting blood pressure <140/90 mmHg), and not taking any medications.  Studies were 
51 
 
performed after an overnight fast and 24 hour abstention from caffeine and exercise with subjects 
in the supine position with the experimental arm abducted to 90° and slightly elevated above 
heart level upon a tilt-adjustable table.  Female subjects were studied during the early follicular 
phase of their menstrual cycle or placebo phase of oral contraceptive use to minimize any 
potential cardiovascular effects of sex-specific hormones.  All studies were performed according 
to the Declaration of Helsinki. 
 
Arterial catheterization, arterial blood pressure and heart rate 
A 20 gauge, 7.6 cm catheter was placed in the brachial artery of the non-dominant arm 
under aseptic conditions after local anesthesia (2% lidocaine) for local administration of study 
drugs and blood sampling.  The catheter was connected to a 3-port connector as well as a 
pressure transducer for mean arterial pressure (MAP) measurement and continuously flushed at 3 
ml hr-1 with heparinized saline.  The two side ports were used for drug infusions (Kirby et al., 
2008; Crecelius et al., 2010).  Heart rate (HR) was determined using a 3-lead ECG (Cardiocap/5, 
Datex-Ohmeda, Louisville, CO, USA). 
 
Forearm blood flow and vascular conductance 
A 12 MHz linear-array ultrasound probe (Vivid 7, General Electric, Milwaukee, WI, 
USA) was used to determine brachial artery mean blood velocity (MBV) and brachial artery 
diameter.  The probe was securely fixed to the skin over the brachial artery proximal to the 
catheter insertion site as previously described (Crecelius et al., 2010).  For blood velocity 
measurements, the probe insonation angle was maintained at <60 degrees and the frequency used 
was 5 MHz. The Doppler shift frequency spectrum was analyzed via a Multigon 500M TCD 
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(Multigon Industries, Mt Vernon NY, USA) spectral analyzer from which mean velocity was 
determined as a weighted mean of the spectrum of Doppler shift frequencies.  In Protocol 1, 
brachial artery diameter measurements were made in duplex mode from images recorded on a 
VHS tape at end-diastole and between contractions (in triplicate) during rest, and at 6, 12, 24, 60, 
90, 120, 180, 240, and 300 seconds of exercise.  All measurements were made by the same 
operator.  An exponential line of best fit was generated for these data and diameters were 
extrapolated from this function at relevant MBV timepoints.  We utilized this approach in an 
attempt to minimize the effect of random diameter measurement error on blood flow (Saunders 
et al., 2005).  In Protocol 2, diameter measurements were made in triplicate at rest and the end of 
exercise. Forearm blood flow (FBF) was then calculated as: FBF = MBV ×  π(brachial artery 
diameter/2)2 × 60,where the FBF is in ml min-1, the MBV is in cm s-1, the brachial diameter is in 
cm, and 60 was used to convert from ml s-1 to ml min-1.  Forearm vascular conductance (FVC) 
was calculated as (FBF/MAP) × 100, and expressed as ml min-1 100 mmHg-1.  All studies were 
performed in a cool (20-22°C) temperature-controlled environment with a fan directed toward 
the forearm to minimize the contribution of skin blood flow to forearm haemodynamics. 
 
Rhythmic handgrip exercise  
Maximal voluntary contraction (MVC; mean 41±2 kg, range 29 – 52 kg) was determined 
for the experimental arm as the average of three maximal squeezes of a handgrip dynamometer 
(Stoelting, Chicago, IL, USA) that were within 3% of each other.  Forearm exercise during the 
trials was performed with weight corresponding to 10% MVC (mean 4.1±0.2 kg, range 2.9 – 5.2 
kg) attached to a pulley system and lifted 4–5 cm over the pulley at a duty cycle of 1s 
contraction–2 s relaxation (20 contractions per minute) using both visual and auditory feedback 
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to ensure the correct timing as described previously (Kirby et al., 2008; Crecelius et al., 2010).  
We chose this mild intensity rhythmic handgrip exercise to limit the contribution of systemic 
haemodynamics to forearm hyperaemic responses and eliminate reflex activation of the 
sympathetic nervous system (Seals & Victor, 1991).  Thus, our experimental model aimed to 
isolate the local effects of muscle contractions on forearm hyperaemia without engaging 
potentially confounding systemic influences on vascular tone.  Previous studies in our laboratory 
have determined that MVC is not affected by any of the vasoactive substances, particularly 
barium chloride and ouabain, administered in these studies (Crecelius et al., 2013a)  
 
Vasoactive drug infusion 
All vasoactive drug infusions occurred via the brachial artery catheter to create a local 
effect in the forearm and saline was utilized as a control infusate.  Specific timing and duration 
of infusions is provided below in the Experimental Protocols section.   
To inhibit hyperpolarizing vasodilatory mechanisms (Crecelius et al., 2012), ouabain 
octahydrate (Na+/K+-ATPase inhibitor; Sigma 03125, St. Louis, MO, USA) was infused at 2.7 
nmol min-1 in combination with barium chloride (BaCl2; KIR channel inhibitor; 10% w/v 
BDH3238, EMD Chemicals, Gibbstown, NJ, uSA) at 0.9 μmol dl FAV-1 min-1 with a minimum 
dose of 8 μmol min-1 to a maximum dose of 10 μmol min-1.  This dose of BaCl2 is twice that 
which we have previously administered in our laboratory (Crecelius et al., 2012, 2013a) and 
which has been shown to elicit a plasma concentration of ~50 µM (Dawes et al., 2002).  Given 
that repeated muscle contractions cause a significant and prolonged elevation in blood flow, we 
increased the administered dose of BaCl2 in an attempt to maintain a concentration within the 
blood similar to that which we have shown before to effectively inhibit both potassium-mediated 
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vasodilatation (Crecelius et al., 2012) as well as the haemodynamic response following a single 
muscle contraction (Crecelius et al., 2013a) while still being selective for KIR channels (<100 
µM) (Jackson, 2005).  Pilot studies within our laboratory were performed that demonstrated this 
increased dose was still safe, well-tolerated by subjects and did not cause systemic 
haemodynamic or plasma electrolyte changes.  Ouabain and BaCl2 were prepared in saline and 
confirmed sterile and free of fungus/endotoxin and particulate matter with a standard 
microbiology report (JCB-Analytical Research Labs, Wichita, KS, USA) prior to use. 
 To block endothelium-dependent vasodilatory pathways of interest, we administered NG-
monomethyl-L-arginine [L-NMMA; NO synthase (NOS) inhibitor; Clinalfa/Bachem, Weil am 
Rhein, Germany] to inhibit the production of NO in combination with ketorolac [non-selective 
cyclooxygenase (COX) inhibitor; Hospira, Lake Forest, IL, USA] to inhibit the synthesis of PGs.  
The doses of L-NMMA and ketorolac were 5 mg min-1 and 1200 µg min-1 respectively.  We 
have previously demonstrated these doses to be effective during a similar exercise protocol 
(Dinenno & Joyner, 2003; Schrage et al., 2004; Crecelius et al., 2010)Forearm volume used for 
normalization for specific vasoactive drugs was determined from regional analysis of whole-
body dual-energy X-ray absorptiometry scans (QDR series software, Hologic, Inc, Bedford, MA, 
USA).   
 
Experimental Protocols 
Protocol 1:  Onset exercise hyperaemia 
 Both experimental protocols are presented in Figure 10.  The main purpose of Protocol 1 
was to determine the effect of inhibiting hyperpolarizing vasodilator mechanisms (via BaCl2 and 
ouabain) alone, and in combination with NOS-COX blockade (via L-NMMA and ketorolac, 
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respectively) on the hyperaemia that occurs at the onset of repeated muscle contractions.  In 
order to do this, subjects performed 10% MVC rhythmic handgrip exercise for 5 minutes in 
control conditions (Trial 1; saline), following combined infusion of BaCl2 and ouabain (Trial 2), 
and following combined infusion of BaCl2, ouabain, L-NMMA, and ketorolac (Trial 3).  Based 
on our previous observations regarding acute fluctuations in resting vascular tone with BaCl2  
and ouabain infusion (Crecelius et al., 2013a), we chose to stop the infusion of all blockers prior 
to the start of exercise, to best insure accurate resting blood flow measures and appropriately 
quantify the rapid blood flow responses compared with control conditions.  This method of drug 
infusion was previously used by our laboratory and shown effective at significantly reducing the 
blood flow response to a single muscle contraction (Crecelius et al., 2013a).   
In trial 1, saline was infused for three minutes prior to the start of resting blood flow 
measures. A single contraction (10% MVC) was performed at 30, 60, and 90 seconds of this 
infusion in order to facilitate delivery of the infusion to the vasculature of the muscle fibres 
recruited for this type of contraction (Crecelius et al., 2013a).  Resting blood flow measures were 
taken for 30-60 seconds and the subject was then instructed to begin the 5 minutes of 
contractions.  Beat-to-beat blood flow was measured throughout the entire exercise protocol.  
Subjects rested comfortably for 20 min before the start of the next exercise trial. Trial 2 followed 
a similar timeline with the difference being that ouabain was infused for 15 minutes and BaCl2 
for 3 minutes prior to the start of resting blood flow measures.  Trial 3 was performed in a 
similar fashion with the exception that the pre-exercise infusions consisted of 15 minutes of 





Protocol 2: Steady-state exercise hyperaemia 
 Based on our observations in Protocol 1 (see Results), we believed it was necessary to 
perform a second protocol where we continued infusion of our inhibitors throughout the muscle 
contractions in order to determine whether we had underestimated the effect of our blockers on 
steady-state exercise hyperaemia in Protocol 1.  The trials in Protocol 2 mimicked those of 
Protocol 1 (control, combined BaCl2+ouabain, and combined BaCl2+ouabain+L-
NMMA+ketorolac) with the difference that all inhibitors were continued throughout the entire 
exercise duration.     
 
Data acquisition and analysis 
Data were collected and stored on a computer at 250 Hz and were analyzed off-line with 
signal-processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  Mean arterial 
pressure (MAP) was determined from the arterial pressure waveform.  For Protocol 1, FBF and 
MAP were analyzed in 3-sec bins that corresponded to each contraction:relaxation (1:2 sec) 
cycle.  This type of analysis was carried out for the first 3 minutes, and 30-second averages were 
used at minutes 4 and 5 of exercise.  In the case that the MBV signal quality obtained during a 3-
second cycle was altered due to operator error, a mathematical average of the preceding and 
subsequent bins’ MBV was used.  This occurred in less than 2% of all bins analyzed.  HR was 
determined at rest, and each minute of exercise thereafter.   
In Protocol 1, the total exercise-induced hyperaemic and vasodilator responses were 
calculated as the sum of FBF and FVC, respectively, above baseline for 30, 60, 120, 180, 240, 
300 seconds of exercise [area under curve (AUC)].  To help characterize the onset of exercise 
hyperaemia, the mean response time was calculated as the time at which 63% of the increase in 
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FBF from rest to steady-state (average of min 4 and 5 FBF) was reached (Shoemaker et al., 
1997).  In Protocol 2, the last 30 seconds of exercise was averaged to represent steady-state FBF 
and FVC.   
To quantify the impact of vasoactive drugs in each protocol on FBF, the magnitude of 
inhibition of exercise hyperaemia was calculated as: (FBF inhibition - FBF control)/(FBF 
control) × 100. Changes in FVC, as well as AUC were calculated in a similar manner.   
 
Statistics 
Data are presented as mean±S.E.M.  In Protocol 1, 15 second averages of forearm 
haemodynamics were calculated and used in a two-way repeated measures ANOVA (timepoint × 
drug condition) and post hoc pairwise comparisons were completed with Student-Newman-Keuls 
pairwise tests.  In Protocol 2, paired, two-tailed Student’s t-tests were used to make the three 
comparisons between control, BaCl2+ouabain, and BaCl2+ouabain+L-NMMA+ketorolac 
conditions for forearm haemodynamic data.  In both protocols, for systemic haemodynamic 
variables (HR, MAP), a two-way repeated measures ANOVA [timepoint (rest vs exercise) × drug 
condition] was used and post hoc pairwise comparisons were completed with Student-Newman-
Keuls tests.  Significance was set a priori at P<0.05.  
 
Results 
Protocol 1: Onset exercise hyperaemia 
 In control (saline) conditions, FBF increased rapidly in response to muscle contractions 
(Figure 11A).  In trial 2, prior infusion of BaCl2+ouabain had no effect on resting FBF (Table 3) 
but significantly attenuated FBF for the first 2 minutes of exercise (Figure 11B) and there was a 
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significantly longer mean response time compared to control conditions (52 ± 5 vs 31 ± 5 sec; P 
< 0.05).  The total hyperaemic response was significantly attenuated with prior BaCl2+ouabain 
and this effect was more pronounced earlier in the exercise bout (30 sec: -49 ± 5%; 60 sec: -34 ± 
5%, 120 sec: -20 ± 5%, 180 sec: -13 ± 4%, 240 sec: -10 ± 4%, 300 sec: -8±3%; Figure 12).   In 
trial 3, infusion of L-NMMA+ketorolac in addition to BaCl2+ouabain prior to exercise 
significantly reduced resting FBF (Table 3) as expected.  Absolute FBF at the onset of exercise 
was further attenuated from the BaCl2+ouabain condition in the first 15 seconds of exercise but 
not thereafter, although was significantly lower than control conditions (Figure 11B).  A similar 
pattern was evident when the total hyperaemic response was quantified and the reduction from 
control conditions was calculated (30 sec: -65 ± 2%; 60 sec: -40 ± 3%, 120 sec: -23 ± 4%, 180 
sec: -15 ± 4%, 240 sec: -14 ± 4%, 300 sec: -14±4%; Figure 12).   The mean response time in this 
condition (55 ± 3 sec) was similar to following BaCl2+ouabain (P = 0.55) and significantly lower 
than control (P < 0.05).  FBF at minute 5 of exercise was slightly, but significantly lower in the 
BaCl2+ouabain+L-NMMA+ketorolac condition (Figure 11B).  In general, changes in FVC 
paralleled those observed in FBF (Table 3). 
 Systemic haemodynamics (HR and MAP) were largely unchanged throughout the trial 
and under all conditions.  Small (2-3 mmHg) but statistically significant increases in MAP were 
observed in the condition of prior BaCl2+ouabain+L-NMMA+ketorolac infusion versus control.  
Additionally, small (2-4 beats min-1) but again statistically significant reductions in HR were 
observed in the third trial versus both control and BaCl2+ouabain.  There was also a slight but 
significant effect of exercise on HR.  No significant interaction between time and drug condition 
was detected for MAP (P = 0.62) or HR (P = 0.35).   
Protocol 2: Steady-state exercise hyperaemia 
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 With continuous infusion of BaCl2 and ouabain throughout muscle contractions (trial 2), 
FBF and FVC were significantly lower than in control conditions (trial 1) after 5 minutes of 
rhythmic handgrip exercise (ΔFBF = -20±3%; ΔFVC = -28±2%, Figure 13A and 13B, 
respectively).  In trial 3, inhibiting NO and PG synthesis in addition to KIR channels and Na
+/K+-
ATPase via BaCl2 and ouabain, respectively, resulted in a further attenuation of exercise 
hyperaemia and vasodilatation (compared to control: ΔFBF = -29±3%; ΔFVC = -40±2%, Figure 
13A and 13B, respectively).  The percent reduction in FBF and FVC from control steady-state 
exercise levels was significantly greater for the condition of continuous BaCl2+ouabain+L-
NMMA+ketorolac infusion than BaCl2+ouabain alone, and these changes were also greater for 
FVC than for FBF (Figure 14).   
 Systemic haemodynamics for Protocol 2 are presented in Table 4.  Exercise resulted in 
small but significant changes in MAP and HR.  Additionally, minor statistically significant 
increases in MAP were observed in the different drug conditions. 
 
Discussion 
 The purpose of the current study was to determine the contributions of vascular 
hyperpolarization via activation of KIR channels and Na
+/K+-ATPase to exercise hyperaemia at 
the onset of muscle contractions and during the steady-state portion of the blood flow response 
and to determine whether inhibition of these pathways revealed a compensatory role of NO and 
PGs.  The primary novel findings of the present study are as follows.  First, activation of KIR 
channels and Na+/K+-ATPase contribute largely to the onset of exercise hyperaemia following 
repeated muscle contractions.  Additionally, in line with prior findings in the human forearm, 
NO and PGs do not play a significant role in this response except for the initial 15 seconds.  
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Second, we demonstrate for the first time in humans a significant contribution of vascular 
hyperpolarization via activation of KIR channels and Na
+/K+-ATPase to steady-state exercise 
hyperaemia.  Interestingly, inhibition of these pathways reveals a significant role for NO and 
PGs in mediating steady-state exercise hyperaemia which has not been previously observed in 
this model of mild-intensity rhythmic handgrip exercise.  Our collective findings indicate that 
vascular hyperpolarization contributes significantly to exercise hyperaemia, particularly at the 
onset of contractions.   
 
Onset exercise hyperaemia: contributing signaling pathways (Protocol 1) 
 Beginning with the first muscle contraction of exercise, there is a rapid increase in blood 
flow that occurs immediately (within one cardiac cycle) (Clifford, 2007; Kirby et al., 2007; 
Crecelius et al., 2013a).  With repeated muscle contractions, this increase in blood flow 
continues in a bi-phasic manner comprised of an initial rapid increase that plateaus by ~5-7 sec 
and a second, slower phase that begins ~20 sec after the onset of exercise and continues in an 
intensity-dependent manner until steady-state hyperaemia has been achieved (Tschakovsky & 
Sheriff, 2004; Saunders et al., 2005).  In the present study, we observe similar dynamic 
characteristics in the hyperaemic response to mild intensity forearm handgrip in control 
conditions (Figure 11A).  Previous studies in the human forearm demonstrated that inhibition of 
NO or PGs does not impact the rapid onset of exercise hyperaemia (Shoemaker et al., 1996; 
Shoemaker et al., 1997) nor does antagonism of muscarinic receptors (Shoemaker et al., 1997) 
that would be bound by acetylcholine either from an endothelial source (Martin et al., 1996) or 
spillover from the motor neuron junction (Welsh & Segal, 1997).  Studies in animals suggest that 
during muscle contractions, flow is controlled at the level of the feed arteries (Segal, 2005) via 
61 
 
conducted vasodilatation that originates in the distal resistance arterioles (Welsh & Segal, 1998).  
Hyperpolarization is known to contribute more robustly to distal vessel vasodilatation as opposed 
to vasodilator autcoids such as NO and PGs (Shimokawa et al., 1996; Sandow et al., 2002) and 
is capable of stimulating conducted vasodilatation whereas in general, NO and PGs do not 
(Hoepfl et al., 2002; Domeier & Segal, 2007).  Recently, we demonstrated that vascular 
hyperpolarization via activation of KIR channels and Na
+/K+ATPase largely contributes to the 
total vasodilatation following a single muscle contraction (Crecelius et al., 2013a), the first such 
observation in humans.  For the present study, we determined what role hyperpolarization via 
these pathways has in the onset of hyperaemia in response to repeated muscle contractions.   
When BaCl2 and ouabain were infused prior to contractions to inhibit Na
+/K+-ATPase 
and KIR channels, respectively, there was a significant attenuation of the initial hyperaemic 
response for the first 2 minutes of exercise (Figure 11B).  Beyond 2 minutes, there was no longer 
a significant effect on the absolute level of blood flow due; however, the initial impact on the 
hyperaemia was of a large enough magnitude to affect the total (area under the curve) 
hyperaemic response through the 4th minute of exercise (Figure 12).  In this protocol, due to 
fluctuations in resting blood flow that we have observed during infusion of BaCl2 and ouabain in 
our laboratory, we stopped drug infusions prior to the start of muscle contractions so we could 
appropriately quantify resting FBF and appropriately quantify the rapid blood flow responses 
compared to control conditions.  Given this approach, we sought to more directly address a role 
for vascular hyperpolarization via activation of KIR channels and Na
+/K+-ATPase during steady-
state hyperaemia in Protocol 2 where all inhibitors were coinfused during muscle contractions 
(see section below).   
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Several lines of evidence suggest that there is crossover between the various vasodilator 
pathways, and that in the presence of inhibition of one pathway, another may compensate in 
order to preserve blood flow and oxygen delivery, particularly during muscle activation or 
decreased arterial oxygen content (Taddei et al., 1999; Hillig et al., 2003; Markwald et al., 
2011).  Thus, we investigated whether in the presence of inhibition of KIR channels and Na
+/K+-
ATPase, there would be a role for NO and PGs, despite evidence suggesting they do not 
contribute to initial exercise hyperaemia in the human forearm (Shoemaker et al., 1996; 
Shoemaker et al., 1997).  Combined infusion of L-NMMA and ketorolac to enzymatically inhibit 
the production of NO and PGs, respectively, reduced resting blood flow as we anticipated (Table 
3).  Absolute FBF was also inhibited beyond that which occurred with BaCl2+ouabain at the start 
of forearm contractions.  However, this further impairment diminished rapidly over time, and by 
30 seconds there was no longer a significant reduction in forearm blood flow from the 
BaCl2+ouabain condition (Figure 11B).  Similarly, there was minimal additional effect of NO 
and PG inhibition on the total hyperaemic response (Figure 12).  It is possible that the reduction 
in resting blood flow during combined NO and PG inhibition attributed to the initial and brief 
reduction in exercise hyperaemia, similar to prior observations of lower resting blood flow and 
slower mean response times when the arm was positioned above versus below heart level 
(Shoemaker et al., 1996).  In the presence of BaCl2+ouabain +L-NMMA+ketorolac, muscle 
blood flow was still able to increase rapidly and achieve levels significantly greater than rest and 
near steady-state levels by three minutes of exercise, indicating redundant vasodilator signals, 





Steady-state exercise hyperaemia: contributing signaling pathways (Protocol 2) 
 To date, multiple studies have attempted to identify the various vasodilator pathways 
involved in exercise hyperaemia and most have focused on the steady-state portion of the 
response (Delp & Laughlin, 1998; Joyner & Wilkins, 2007; Saltin, 2007).  Steady-state muscle 
blood flow is thought to reflect a homeostatic balance between oxygen delivery via increases in 
blood flow and oxygen demand of the contracting muscle (Rowell, 1993).  In the human 
forearm, the results of previous studies have been extremely unimpressive in terms of the 
magnitude of reduction in muscle blood flow consequence to vasodilator inhibition.  In fact, 
combined inhibition of NO and PGs, two important endothelium-dependent dilators does not 
impact the rest to steady-state muscle blood flow response (Schrage et al., 2004; Crecelius et al., 
2011b).  Given animal studies that suggested an important role for the endothelium (Sagach et 
al., 1992; Berdeaux et al., 1994) and particularly for conducted hyperpolarizing stimuli (Segal & 
Jacobs, 2001; Milkau et al., 2010) in exercise hyperaemia and the lack of involvement of NO 
and PGs, we wanted to address the role of vascular hyperpolarization in muscle blood flow 
during exercise in humans.   
 One issue with attempting to address hyperpolarizing pathways in humans is a lack of 
specific antagonists and agonists of the proposed pathways involved in initiating and conducting 
hyperpolarization in the vasculature.  For instance, in human studies that have attempted to 
inhibit potential pathways of vascular hyperpolarization [cytochrome p450 metabolites (Hillig et 
al., 2003), KCa (Mortensen et al., 2007) and KATP (Schrage et al., 2006) channels], the efficacy of 
inhibition was not assessed, and thus caution is warranted when interpreting their negative 
findings.  Previously, we have demonstrated that combined administration of ouabain and BaCl2 
can inhibit KCl-mediated vasodilatation, a stimulus for direct vascular hyperpolarization 
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(Crecelius et al., 2012).  In the present study we use this established pharmacology (Crecelius et 
al., 2012, 2013a) to test the role of vascular hyperpolarization in muscle blood flow regulation 
during continued muscle contractions.   
 Due to observed fluctuations in resting blood flow in the present studies and in our past 
experience with ouabain and BaCl2 (Crecelius et al., 2012, 2013a), in Protocol 1 where we were 
focused on capturing the onset of exercise hyperaemia, we did not co-infuse these inhibitors 
during contractions.  However, when we did not observe a significant effect during steady-state 
exercise (Figure 10) we questioned whether there was “wash-out” of our inhibitors as blood flow 
increased.  Subsequently, we performed studies in Protocol 2 in which we coinfused our 
inhibitors throughout muscle contractions as is more typical of our approach for these types of 
exercise studies (Crecelius et al., 2011a; Crecelius et al., 2011b).  Under these conditions of 
continuous inhibition, we do in fact observe a significant contribution of vascular 
hyperpolarization via KIR channels and Na
+/K+-ATPase to steady-state exercise hyperaemia 
(~20%; Figures 13 and 14).  Our observed effect is more pronounced for FVC (~30%), likely 
due to a slightly greater pressor response during BaCl2+ouabain which may reflect a slight 
systemic effect of our drug infusions.  If this were the case, we could be potentially 
underestimating the effects of our inhibitors as the greater perfusion pressure could serve to 
maintain blood flow (Amann et al., 2011; Richards et al., 2011). 
 Interestingly, inhibition of NO and PGs in addition to vascular hyperpolarization resulted 
in a further attenuation of steady-state muscle blood flow (Figures 13 and 14).  This finding is in 
contrast with the lack of a combined role for NO and PGs in the human forearm in previous 
studies (Dinenno & Joyner, 2004; Schrage et al., 2004; Crecelius et al., 2011b) but highlights the 
ability of vasodilator pathways to compensate for one another, a phenomenon that has been 
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observed in a variety of previous studies (Taddei et al., 1999; Hillig et al., 2003; Markwald et 
al., 2011).  Similar to when BaCl2+ouabain were given alone, in the presence of 
BaCl2+ouabain+L-NMMA+ketorolac, the reduction in FVC (~40%) was greater than that of 
FBF (~30%).  It is important to emphasize the magnitude of the effect of combined inhibition of 
vascular hyperpolarization via KIR channels and Na
+/K+-ATPase and NO and PGs on FBF and 
FVC during steady-state exercise.  A 40% reduction in forearm vasodilatation (FVC) is 
profound, particularly in a small muscle mass such as the forearm that typically shows resistance 
to decreased blood flow following pharmacological inhibition of vasodilator pathways.  Further, 
this change approaches the observed effects of completely inhibiting conducted vasodilation on 
(~45% reduction in contraction-induced hyperaemia) (Segal & Jacobs, 2001). 
 
Potential stimuli for signaling through vascular hyperpolarization and NO and PGs during 
exercise 
 As previously stated, there are a variety of substances that can stimulate vascular 
hyperpolarization to occur, both those that are endothelium-dependent and some that occur 
independently of this cell layer.  Adenosine triphosphate (ATP) is a vasoactive agent released 
from endothelial and red blood cells in response to deoxygenation, hypercapnia, and mechanical 
stresses (Bodin et al., 1991; Sprague et al., 1996; Gonzalez-Alonso et al., 2002; Kirby et al., 
2012; Crecelius et al., 2013b) and causes profound vasodilatation that is endothelium-dependent 
(Duza & Sarelius, 2003).  We have shown in humans that ATP-mediated vasodilatation occurs 
primarily through vascular hyperpolarization via activation of KIR channels (Crecelius et al., 
2012).  Additionally, we have demonstrated a modest component of ATP-mediated 
vasodilatation that occurs through NO and PG synthesis (Crecelius et al., 2011a), and thus 
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particularly during steady-state exercise where a significant role for NO and PGs is revealed 
when hyperpolarization is inhibited, ATP may be one potential stimulus for these pathways.   
 Another potential stimulus for vascular hyperpolarization is increased interstitial K+ as a 
result of muscle contractions (Hazeyama & Sparks, 1979b; Edwards et al., 1998; Armstrong et 
al., 2007; Kirby & Carlson, 2008) or as an endothelial-derived hyperpolarizing factor (Edwards 
et al., 1998).  Agonist binding to receptors on endothelial cells can cause intracellular calcium 
changes that stimulate small- and intermediate-conductance KCa channels to open and K
+ to 
efflux into the interstitial space or microdomain signaling complexes at the physical intersection 
of vascular smooth muscle and endothelial cells (Ledoux et al., 2008).  In animal models where 
these small- and intermediate-conductance KCa channels can be specifically inhibited, a 
significant attenuation in contraction-induced hyperaemia is observed (Milkau et al., 2010).  
While the K+ ion would not account for the compensatory involvement of NO and PG during 
steady-state exercise (Crecelius et al., 2012), it could be involved in stimulating both KIR 
channels and Na+/K+ATPase (Edwards et al., 1998; Crecelius et al., 2012) that in the present 
study, we show contribute both to the onset and steady-state levels of exercise hyperaemia.    
 
Experimental Considerations 
 Our group has recently utilized the pharmacological approach of BaCl2 and ouabain to 
inhibit vascular hyperpolarization via KIR channel activation and Na
+/K+-ATPase, respectively 
(Crecelius et al., 2012, 2013a).  While these inhibitors are safe for use, given that they are not 
used clinically, we attempt to limit the total number of subjects exposed to these agents and the 
total dose given to any one subject.  Therefore, we have not repeated control experiments within 
this protocol to demonstrate effective inhibition of  hyperpolarization-mediated (KCl) 
67 
 
vasodilatation, preserved vasodilatory capacity [to endothelium-dependent (acetylcholine) and 
endothelium-independent (sodium nitroprusside) agonists], and preserved maximal force 
production (Crecelius et al., 2012, 2013a).  Similarly, given our extensive use of L-NMMA and 
ketorolac (Crecelius et al., 2010; Crecelius et al., 2011a; Crecelius et al., 2012) and various tests 
of efficacy (Dinenno & Joyner, 2003; Schrage et al., 2004), we have not repeated those control 
studies within this experiment.  Related to the effects of our inhibitors, as stated in our Methods 
section, we used double the dose of BaCl2 from our previous studies in an attempt to maintain a 
concentration in the blood during exercise that was similar to at rest, in spite of the large 
increases in blood flow that occur with contractions.  It is possible that our dose of BaCl2 may be 
slightly beyond the range of specific inhibition of KIR channels (typically <100 μM) and non-
selectively inhibit other potassium channels, particularly, KATP channels (Jackson, 2005).  
However, given that previously there was no significant effect of inhibiting KATP channels during 
steady-state exercise (Schrage et al., 2006), we do not feel this changes our primary conclusions.   
 The forearm model, while advantageous for many reasons also has some inherent 
limitations.  We acknowledge that the muscle mass engaged in rhythmic handgrip exercise is 
relatively small, and extrapolating our results to more traditional modes of whole-body exercise 
would need to be done cautiously.  It may be desirable to test ideas related to the role of 
hyperpolarization in regulating vascular control during larger muscle mass exercise that engage 
the sympathetic nervous system in order to assess the influence of these pathways on the 
interaction with sympathetic vasoconstriction and overall blood pressure regulation; however, 
safety concerns of systemic administration of BaCl2 in doses suitable to appropriately inhibit KIR 





Continuous skeletal muscle contractions result in a rapid and significant rise in muscle 
blood flow in order to deliver oxygen to meet the increased metabolic need of the tissue.  The 
regulation of muscle blood flow during exercise is a complex response and there is great interest 
in understanding the various vasodilator signals that contribute to this response.  Here, we show 
that vascular hyperpolarization via KIR channel and Na
+/K+-ATPase activation significantly 
contributes to the hyperemia observed at the onset and during steady-state muscle contractions.  
Additionally, NO and PGs have only a modest contribution to the initial (10-15 sec) rise in 
muscle blood flow and interestingly, in the presence of inhibition of KIR channels and Na
+/K+-
ATPase, we reveal a role for these dilators during steady-state exercise hyperaemia, an 
observation that was not previously made in this experimental model.   The primary stimuli for 
activation of  KIR channels, Na
+/K+-ATPase, and synthesis of NO and PGs remains unknown at 

















Control 36.4±3.4 93±2 56±3 
BaCl2+ouabain 31.8±2.3 94±3 57±4 
BaCl2+ouabain+L-NMMA+ketorolac 25.8±2.5*† 96±2 53±3 
Exercise 
Minute 1 
Control 140.2±9.8 94±3 61±4 
BaCl2+ouabain 109.3±7.6* 96±3 59±4 
BaCl2+ouabain+L-NMMA+ketorolac 99.5±5.7*† 98±2 57±4 
Exercise 
Minute 2 
Control 151.3±11.9 94±2 59±4 
BaCl2+ouabain 134.9±9.6* 96±2 59±3 
BaCl2+ouabain+L-NMMA+ketorolac 128.5±7.9* 97±2 56±4 
Exercise 
Minute 3 
Control 150.2±9.8 94±3 57±5 
BaCl2+ouabain 139.6±8.3* 96±3 59±4 
BaCl2+ouabain+L-NMMA+ketorolac 134.7±9.9* 97±2 57±3 
Exercise 
Minute 4 
Control 155.6±10.8 95±2 60±4 
BaCl2+ouabain 147.5±8.7 95±3 59±3 
BaCl2+ouabain+L-NMMA+ketorolac 142.7±10.3* 97±2 57±3 
Exercise 
Minute 5 
Control 166.0±15.3 95±2 59±4 
BaCl2+ouabain 157.1±10.3 95±2 59±4 
BaCl2+ouabain+L-NMMA+ketorolac 145.4±9.2* 97±2 58±4 
* P<0.05 vs control; † P<0.05 vs BaCl2+ouabain 
 
†MAP: Main effect of condition (BaCl2+ouabain+L-NMMA+ketorolac vs control; P < 
0.05) 
 
‡HR: Main effect of condition (BaCl2+ouabain+L-NMMA+ketorolac vs control and vs 
BaCl2+ouabain, P < 0.05); Main effect of timepoint (Min 1-5 vs Rest; P < 0.05); no 
significant interaction (P = 0.35) 
 
FVC=forearm vascular conductance; HR=heart rate; MAP=mean arterial pressure 
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Table 4.  Protocol 2: Forearm and Systemic Haemodynamics 
†MAP: Main effect of timepoint (Exercise vs Rest; P < 0.05) and condition (all conditions 
different; P < 0.05), no significant interaction (P = 0.07). 
 
‡HR: Main effect of timepoint (Exercise vs Rest; P < 0.01), no significant main effect of 
condition (P = 0.32) or interaction (P = 0.47) 
 










Control 84±2 56±3 
BaCl2+ouabain 90±3 54±3 




Control 86±3 60±3 
BaCl2+ouabain 95±2 60±3 
BaCl2+ouabain+L-NMMA+ketorolac 100±3 59±3 
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Figure 10. Experimental Timeline 
In both protocols, three trials were performed.  Trial 1 consisted of saline infusions as a 
control condition.  Trial 2 consisted of the combined infusion of barium chloride (BaCl2; 
KIR-channel inhibitor) and ouabain (Na
+/K+-ATPase inhibitor) and Trial 3 consisted of the 
combined infusion of BaCl2, ouabain, L-NMMA (to inhibit nitric oxide synthesis) and 
ketorolac (to inhibit prostaglandin synthesis).  During the loading period of drug infusions at 
rest, three single contractions were performed to facilitate drug delivery.  In Protocol 1, to 
avoid previously observed fluctuations in baseline haemodynamics, drugs were stopped 
before exercise commenced, and measurements were made at rest, the onset of 10% MVC 
rhythmic handgrip exercise, and throughout the 5 minute bout of exercise.  In Protocol 2, 
























































































Figure 11. Protocol 1: Effect of inhibition of hyperpolarizing and endothelium-
dependent vasodilator mechanisms on the onset of exercise hyperaemia 
A) Forearm blood flow across the three experimental conditions are shown at rest and 
during 10% MVC rhythmic handgrip exercise.  Data is in 3-sec bins corresponding to a 
contraction:relaxation cycle during exercise.  B) Statistical analysis was performed on 15 
sec averages of blood flow data (5 3-sec bins).  BaCl2+ouabain significantly reduced the 
onset of exercise hyperaemia and L-NMMA+ketorolac had an additional effect within the 














































Figure 12.  Protocol 1: Effect of inhibition of hyperpolarizing and endothelium-
dependent vasodilator mechanisms on the total hyperaemic response to exercise  
The total hyperaemic response (area under the curve) was calculated for 30 and 60-sec 
increments for all experimental conditions.  BaCl2+ouabain significantly reduced the 
hyperaemia until the 5th minute of exercise. The addition of L-NMMA+ketorolac to BaCl2-
+ouabain appeared to only have a greater effect within the first portion (30 sec) of exercise.     


















































































Figure 13.  Protocol 2: Effect of inhibition of hyperpolarizing and endothelium-
dependent vasodilator mechanisms on steady-state exercise hyperaemia 
In Protocol 2, with continuous infusion of the inhibitors, a significant reduction in FBF (A) 
and FVC (B) was observed with combined BaCl2+ouabain infusion.  Here, the additional of 
L-NMMA+ketorolac to BaCl2+ouabain further reduced both steady-state FBF and FVC.  
































































Figure 14.  Protocol 2: Changes in steady-state forearm haemodynamics with 
inhibition of hyperpolarizing and endothelium-dependent vasodilator mechanisms 
The reduction in steady-state exercise FBF and FVC was significantly greater with 
combined BaCl2+ouabain+L-NMMA+ketorolac than BaCl2+ouabain alone.  Additionally, 
the changes in FVC were more profound than those in FBF.  * P < 0.05 vs zero; † P < 0.05 
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CHAPTER IV – MANUSCRIPT III 
 
Preserved functional sympatholysis with combined inhibition of inwardly-rectifying 
channels and Na+/K+-ATPase in the human forearm3 
Summary 
Sympathetic vasoconstriction in contracting skeletal muscle is blunted relative to that 
which occurs in resting tissue.  The underlying signaling of this functional sympatholysis 
remains a debated issue in human physiology.  We recently demonstrated that activation of 
inwardly-rectifying (KIR) potassium channels and Na
+/K+-ATPase contributes to exercise 
hyperaemia, but whether these pathways are able to modulate α-adrenergic vasoconstriction 
during contractions has not been investigated.  We tested the hypothesis that α-adrenergic 
vasoconstriction is augmented during exercise following inhibition of KIR channel and Na
+/K+-
ATPase via barium chloride (BaCl2) and ouabain respectively, and unaffected by the inhibition 
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of nitric oxide (NO) and prostaglandins (PGs), two other potential vasodilators involved in 
vascular responses during exercise.  In 11 healthy, young humans, we measured forearm blood 
flow (Doppler ultrasound) and calculated vascular conductance (FVC) at rest, during steady-state 
stimulus conditions (pre-PE), and after 2 min of phenylephrine (PE; α1-adrenoceptor agonist) 
infusion via brachial artery catheter.  Subjects performed either moderate (15% maximal 
voluntary contraction) rhythmic handgrip exercise (RHG) or received adenosine (ADO) in all 
conditions: control (saline), combined enzymatic inhibition of NO and PG synthesis via L-
NMMA (NO synthase) and ketorolac (cyclooxygenase), and combined inhibition of NO, PGs, 
KIR channels and Na
+/K+-ATPase (L-NMMA+ketorolac+BaCl2+ouabain).  All trials occurred 
after local β-adrenoceptor blockade (propranolol).  PE-mediated vasoconstriction was calculated 
(%ΔFVC) in each condition.  As expected, in control conditions, vasoconstriction during 
exercise was significantly attenuated as compared to ADO (-21±3% vs -46±6%; P<0.05).  These 
responses were unchanged with L-NMMA+ketorolac (-24±3% vs -47±5%; P<0.05) as was 
steady-state exercise hyperaemia (231±21 ml min-1 vs 221±22 ml min-1; P=0.66).  Additional 
inhibition of KIR channels and Na
+/K+-ATPase significantly attenuated exercise hyperaemia 
(151±21 ml min-1; P<0.05) but in contrast to our hypothesis, had no effect on vasoconstriction 
during exercise (-27±3%) despite an augmented response during adenosine (-71±3%).  Thus, 
exercise still significantly blunted PE-mediated vasoconstriction relative to ADO during L-
NMMA+ketorolac+BaCl2+ouabain.  Our findings confirm that vasodilatation via KIR channels 
and Na+/K+-ATPase significantly contribute to exercise hyperaemia but are not likely to mediate 






 Muscle contractions stimulate vasodilatation of the resistance vasculature, leading to 
large increases in muscle blood flow to the active tissue.  Due to the profound capacity of 
skeletal muscle blood flow during exercise (Andersen & Saltin, 1985), some level of 
sympathetically mediated vasoconstriction is needed in order to maintain mean arterial blood 
pressure (Marshall et al., 1961; Buckwalter & Clifford, 2001).  It has been shown that the degree 
to which sympathetically mediated vasoconstriction occurs in the active muscle is blunted 
relative to inactive muscle (Anderson & Faber, 1991; Thomas et al., 1994; Tschakovsky et al., 
2002; Dinenno & Joyner, 2003; Kirby et al., 2008).  This phenomenon, termed functional 
sympatholysis (Remensnyder et al., 1962), is thought to allow for optimal blood flow and 
therefore oxygen delivery to the active tissue (Joyner & Thomas, 2003) while some 
vasoconstriction occurs in order to limit the overall decrease in total peripheral resistance.  
Various laboratories have demonstrated the existence of functional sympatholysis (Tschakovsky 
et al., 2002; Rosenmeier et al., 2003; Keller et al., 2004; Rosenmeier et al., 2004; Parker et al., 
2007; Wray et al., 2007; Kirby et al., 2008; Fadel et al., 2012); however, to date, the signaling 
pathways that contribute to this response have not been well described in healthy humans.   
 Functional sympatholysis can occur at the post-junctional level of α-adrenoceptors, 
(Thomas et al., 1994; Buckwalter et al., 1998; Rosenmeier et al., 2003) and as such, 
investigations have targeted a variety of vasodilator signaling pathways within the vessel itself 
which can contribute to exercise hyperaemia as potentially being involved in this response  
While some studies have suggested there may be a role for nitric oxide (NO) in blunting 
sympathetically-mediated vasoconstriction during muscle contractions (Thomas & Victor, 1998; 
Hansen et al., 2000; Grange et al., 2001; Chavoshan et al., 2002), other investigations of this 
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pathway propose little involvement (Dinenno & Joyner, 2003; Buckwalter et al., 2004).   
Further, when NO is inhibited in combination with prostaglandins (PGs), another endothelium-
dependent vasodilator, there is only a modest enhancement of sympathetically-mediated 
vasoconstriction during muscle contractions (Dinenno & Joyner, 2004).  Given that 
vasoconstrictor responses in a quiescent tissue were also slightly augmented in this study, it does 
not appear that NO and PGs are the primary mediators of functional sympatholysis in humans.  
Limited studies have explored other vasodilator pathways that may modulate sympathetically-
mediated vasoconstriction during muscle contractions (Thomas et al., 1997; Keller et al., 2004) 
and support is growing for the role of pathways that result in vascular hyperpolarization in blood 
flow control during exercise (Segal & Jacobs, 2001; Milkau et al., 2010; Crecelius et al., 2012b; 
Crecelius et al., 2013).   
To date, few exogenous vasodilator substances are capable of blunting sympathetically-
mediated vasoconstriction similar to what occurs during exercise.  Specifically, in humans, 
exogenous ATP has directly been shown to be sympatholytic (Rosenmeier et al., 2004; Kirby et 
al., 2008; Kirby et al., 2011) and we have shown ATP-mediated vasodilatation is largely 
independent of NO and PG synthesis (Crecelius et al., 2011a), primarily occurring through 
vascular hyperpolarization via inwardly-rectifying potassium (KIR) channel activation (Crecelius 
et al., 2012a).  Stimulation of KIR channels leads to membrane potential hyperpolarization which 
can also occur with activation of Na+/K+-ATPase (Jackson, 2005).  Additionally, in vitro 
evidence suggests a prominent role for KIR channels in amplifying hyperpolarization of any 
origin and facilitating robust cell-to-cell communication (Jantzi et al., 2006).  We have recently 
shown that activation of KIR channels and Na
+/K+-ATPase contributes to exercise hyperaemia in 
the forearm (Crecelius et al., 2012a) and there is also limited evidence that a hyperpolarizing 
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stimulus may be able to override noradrenaline-induced vasoconstriction in humans (Pickkers et 
al., 2004).   
Along these lines, there appears to be important associations between sympathetically-
mediated vasoconstriction, endothelial and vascular smooth muscle cell membrane potential 
(hyperpolarization and depolarization), and conducted vasodilatation, or dilatation that spreads 
electrically along a vessel length, including upstream from the site of stimulation (Segal, 1994).  
Specifically, it appears as though there is a reciprocal relationship between α-adrenoceptor 
stimulated membrane depolarization and conducted vasodilatation via hyperpolarization in that 
an agent that stimulates hyperpolarization and conducted vasodilatation can overcome 
sympathetically-induced vasoconstriction while at the same time, sympathetic stimulation 
attenuates conducted vasodilatation (Kurjiaka & Segal, 1995; Haug & Segal, 2005).  However, 
whether or not vascular hyperpolarization specifically contributes to the ability of voluntarily 
contracting skeletal muscle to blunt direct post-junctional α-adrenergic vasoconstriction is yet to 
be determined.  With this information as background, we tested the hypothesis that vascular 
hyperpolarization via activation of KIR channels and Na
+/K+-ATPase plays a role in functional 




With Institutional Review Board approval and after written informed consent, a total of 
11 young healthy adults (8 men, 3 women; age = 23±1 years old; weight = 67.6±2.9 kg; height = 
173±3 cm; body mass index = 22.4±1.1 kg m-2; forearm volume (FAV) = 913±58 ml; means ± 
SEM) participated in the present study.  All subjects were sedentary to moderately active, non-
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smokers, non-obese, normotensive (resting blood pressure <140/90 mmHg), and not taking any 
medications.  Studies were performed after an overnight fast and 24 hour abstention from 
caffeine and exercise.  The subjects were in the supine position with the experimental arm 
abducted to 90° and slightly elevated above heart level upon a tilt-adjustable table.  Female 
subjects were studied during the early follicular phase of their menstrual cycle or placebo phase 
of oral contraceptive use to minimize any potential cardiovascular effects of sex-specific 
hormones.  All studies were performed according to the Declaration of Helsinki. 
 
Arterial and venous catheterization, arterial blood pressure, and heart rate 
A 20 gauge, 7.6 cm catheter was placed in the brachial artery of the non-dominant arm 
under aseptic conditions after local anesthesia (2% lidocaine) for local administration of study 
drugs and blood sampling.  The catheter was connected to a 3-port connector as well as a 
pressure transducer for mean arterial pressure (MAP) measurement and continuously flushed at 3 
ml hr-1 with heparinized saline.  The two side ports were used for drug infusions of vasoactive 
drugs (Kirby et al., 2008; Crecelius et al., 2010).   In addition, an 18 or 20 gauge (depending on 
visual inspection of vein size), 5.1 cm catheter was inserted in retrograde fashion into an 
antecubital vein of the experimental arm for deep venous blood samples.  Saline was 
continuously infused through this catheter at a rate of approximately 3 ml min-1 for the duration 
of the study to keep it patent (Crecelius et al., 2011b).  Heart rate (HR) was determined using a 
3-lead electrocardiogram (Cardiocap/5, Datex-Ohmeda Louisville, CO, USA). 
 
Blood gas analysis  
Brachial artery and deep venous blood samples were immediately analyzed with a 
clinical blood gas analyzer (Rapid Point 400 Series Automatic Blood Gas System, Siemens 
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Healthcare Diagnostics, Deerfield, IL, USA) for partial pressures of oxygen and carbon dioxide 
(pO2 and pCO2), fraction of oxygenated haemoglobin (FO2Hb), oxygen content, pH, and [K
+]. 
 
Forearm blood flow and vascular conductance 
A 12 MHz linear-array ultrasound probe (Vivid 7, General Electric, Milwaukee, WI, 
USA) was used to determine brachial artery mean blood velocity (MBV) and brachial artery 
diameter.  The probe was securely fixed to the skin over the brachial artery proximal to the 
catheter insertion site as previously described (Crecelius et al., 2010).  For blood velocity 
measurements, the probe insonation angle was maintained at <60 degrees and the frequency used 
was 5 MHz. The Doppler shift frequency spectrum was analyzed via a Multigon 500M TCD 
(Multigon Industries, Mt Vernon NY, USA) spectral analyzer from which mean velocity was 
determined as a weighted mean of the spectrum of Doppler shift frequencies.  Brachial artery 
diameter was measured in triplicate at the end of rest, steady-state conditions pre-constriction, 
and end constrictor effect (see Experimental Protocol below).  Forearm blood flow (FBF) was 
calculated as: FBF = MBV × π (brachial artery diameter/2)2 × 60, where the FBF is in ml min-1, 
the MBV is in cm s-1, the brachial diameter is in cm, and 60 is used to convert from ml s-1 to ml 
min-1.  Forearm vascular conductance (FVC) was calculated as (FBF/MAP) × 100, and expressed 
as ml min-1 100 mmHg-1.  All studies were performed in a cool (20-22°C) temperature-controlled 
environment with a fan directed toward the forearm to minimize the contribution of skin blood 






Rhythmic handgrip exercise  
Maximal voluntary contraction (MVC; mean 41±4 kg, range 19-67 kg) was determined 
for the experimental arm as the average of three maximal squeezes of a handgrip dynamometer 
(Stoelting, Chicago, IL, USA) that were within 3% of each other.  Forearm exercise during the 
trials was performed with weight corresponding to 15% MVC (mean 6.1±0.6 kg, range 2.9 – 
10.1 kg) attached to a pulley system and lifted 4–5 cm over the pulley at a duty cycle of 1s 
contraction–2 s relaxation (20 contractions per minute) using both visual and auditory feedback 
to ensure the correct timing as described previously (Kirby et al., 2008; Crecelius et al., 2010).  
We chose this mild intensity rhythmic handgrip exercise to limit the contribution of systemic 
haemodynamics to forearm hyperaemic responses and eliminate reflex activation of the 
sympathetic nervous system (Seals & Victor, 1991).  Previous studies in our laboratory have 
determined that MVC is not affected by any of the vasoactive substances, particularly barium 
chloride and ouabain, administered in these studies (Crecelius et al., 2013)  
 
Vasoactive drug infusion 
All drug infusions occurred via brachial artery catheter to create a local effect in the 
forearm.  Phenylephrine (see below) is capable of stimulating β-adrenoceptor-mediated 
vasodilatation (Torp et al., 2001).  In order to avoid this potentially confounding effect, we 
infused propranolol (non-selective β-adrenoceptor antagonist, West-Ward Pharmaceutical Corp., 
Eatontown, NJ, USA) at a loading dose of 200 μg min-1 for 5 min  (total = 1000 μg) and 
continued infusions at a maintenance dose of 50 μg min-1 prior to any experimental trials and for 
the duration of the protocol.  This dose of propranolol has been documented to block forearm 
vasodilatation to isoproterenol (Johnsson, 1967) and we have used this approach in similar 
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studies where phenylephrine-mediated vasoconstriction has been investigated (Dinenno et al., 
2002a; Dinenno et al., 2002b).  Regarding any potential effects of β-adrenoceptor inhibition 
during exercise, evidence indicates that β-mediated vasodilatation does not contribute to exercise 
hyperaemia in a similar experimental model (Hartling et al., 1980). 
Given the large increase in blood flow that occurs as a result of muscle contractions, we 
infused adenosine (Akorn, Lake Forest, IL, USA) at variable doses to elevate forearm blood flow 
of a quiescent tissue to similar levels observed during exercise and this served as a ‘high flow 
control’ in each experimental condition.  We have previously demonstrated that contracting 
muscle blunts direct α1- and α2-adrenoceptor-mediated vasoconstriction, whereas vasoconstrictor 
responses are preserved during adenosine infusion (Tschakovsky et al., 2002; Kirby et al., 2008; 
Kirby et al., 2011).   
In order to stimulate sympathetically-mediated vasoconstriction, the selective α1-
adrenoceptor agonist phenylephrine (PE; Sandoz, Princeton, NJ, USA) was infused at 0.125 µg 
dl FAV-1 min-1.  The absolute dose of PE was adjusted to the appropriate hyperaemic condition as 
previously described by our laboratory (Kirby et al., 2008; Kirby et al., 2011) in order to 
normalize concentrations to this relative dose based on the observed level of forearm blood flow 
during adenosine infusion and exercise (see below).  This relative dose of PE is twice that which 
we have previously utilized in male subjects (Kirby et al., 2009; Kirby et al., 2011) and this was 
done in order insure that all subjects would demonstrate vasoconstriction during exercise in 
control conditions, and thus provide an appropriate control for any potential augmentation of this 
response due to our pharmacological inhibitors.   
NG-monomethyl-L-arginine (L-NMMA; Bachem, Germany) was administered to inhibit 
nitric oxide synthase-mediated production of NO and ketorolac (Hospira, Lake Forest, IL, USA) 
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was administered to inhibit cyclooxygenase-mediated synthesis of PGs.  Loading doses of L-
NMMA and ketorolac were 25 mg (5 mg min-1 for 5 minutes) and 6 mg (600 µg min-1 for 10 
min), respectively (Crecelius et al., 2011b; Crecelius et al., 2012a).  In subsequent trials, L-
NMMA and ketorolac were infused at maintenance doses of 1.25 mg min-1 and 150 µg min-1, 
respectively.   
To inhibit vascular hyperpolarization via Na+/K+-ATPase and KIR channel activation, 
ouabain octahydrate (Na+/K+-ATPase inhibitor; Sigma 03125, St. Louis, MO, USA) was infused 
at 2.7 nmol min-1 in combination with barium chloride (BaCl2; KIR channel inhibitor; 10% w/v 
BDH3238, EMD Chemicals, Gibbstown, NJ, USA) at 0.9 μmol dl FAV-1 min-1 with a minimum 
absolute dose of 8 μmol min-1 to a maximum dose of 10 μmol min-1 (Crecelius et al., 2012a; 
Crecelius et al., 2012b).  Ouabain and BaCl2 loaded for 15 and 3 minutes, respectively prior to 
the first trial (exercise or adenosine) of the inhibited condition and were continued at these same 
doses for the duration of the trial.  In the second trial of the blocked condition, infusion of all 
inhibitors began 3 min prior to the start of muscle contractions or adenosine infusion.  Ouabain 
and BaCl2 were prepared in saline and confirmed sterile and free of fungus/endotoxin and 
particulate matter with a standard microbiology report (JCB-Analytical Research Labs, Wichita, 
KS, USA) prior to use.  Forearm volume used for normalization for specific vasoactive drugs 
was determined from regional analysis of whole-body dual-energy X-ray absorptiometry scans 
(QDR series software, Hologic, Inc, Bedford, MA, USA).   
 
Experimental protocols 
 Figure 15 presents the overall experimental timeline (A) as well as the protocol for each 
individual trial (B).  After instrumentation and β-adrenoceptor inhibition, subjects performed a 
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bout of handgrip exercise or received intra-arterial adenosine infusion (final average dose: 
46.2±5.6 µg dl FAV-1 min-1) matched to the predicted/observed hyperaemic response to exercise.  
The total length of each trial was 9 minutes consisting of 3 minutes of baseline conditions and 6 
minutes total of exercise or adenosine infusion.  Steady-state conditions were achieved after 3 
minutes of hyperaemia (min 6 of Figure 15) and the dose of PE was calculated on the basis of 
FAV and FBF. Vasoconstrictor infusion then began after this (4 minutes into the stimulus) and 
lasted for 2 minutes.  Venous blood samples were taken at rest, in steady-state hyperaemic 
conditions (Pre-PE) and at end-PE.  Arterial blood samples were only taken at baseline as these 
samples interfere with the ability to measure FBF and we have shown arterial blood gases to be 
unchanged with mild-moderate intensity rhythmic handgrip exercise (Crecelius et al., 2011b).  In 
the first exercise and adenosine trials, saline was used as a control infusate. 
 Given evidence for interactions of hyperpolarization and endothelium-dependent 
vasodilators, particularly NO, (Bauersachs et al., 1996; Taddei et al., 1999) prior to investigating 
the role of vascular hyperpolarization via KIR and Na
+/K+-ATPase activation, we inhibited the 
production of NO via L-NMMA.  Redundancy and compensation has also been observed 
between NO and PG during physiological stressors (Schrage et al., 2004; Markwald et al., 2011) 
and thus to eliminate this, we inhibited PG synthesis via ketorolac.  Combined inhibition of NO 
and PGs also served to confirm the previous findings that these pathways do not contribute to 
functional sympatholysis (Dinenno & Joyner, 2004).  Following control trials, L-NMMA and 
ketorolac were administered in loading doses and exercise and adenosine (final average dose: 
59.5±6.9 µg dl FAV-1 min-1) trials were repeated in this condition of combined inhibition of NO 
and PGs.  After these third and fourth trials, BaCl2 and ouabain were infused and exercise and 
adenosine (final average dose: 45.2±7.5 µg dl FAV-1 min-1) trials were performed with combined 
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inhibition of NO, PGs, KIR channels and Na
+/K+-ATPase.  Exercise and adenosine trials were 
counterbalanced in each condition between subjects.  In cases where the adenosine trial preceded 
exercise, for the purposes of adjusting the adenosine dose, we predicted the level of hyperaemia 
based on our experience with exercise responses in control and inhibited conditions (Dinenno & 
Joyner, 2004; Schrage et al., 2004; Crecelius et al., 2011b; Crecelius et al., 2012b).  All trials 
were separated by 15 minutes of rest.  
 
Data acquisition and analysis 
Data were collected and stored on computer at 250 Hz and analyzed off-line with signal-
processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  FBF, FVC, MAP, and 
HR represent an average of the last 30 seconds of the corresponding timepoint within a trial 
(Figure 15; baseline, pre-PE, PE).  To quantify the vasoconstrictor effect of PE, the per cent 
change (% Δ) was calculated as: (FVCPE  - FVCPre-PE)/(FBFPre-PE) × 100.  We use %Δ in FVC as 
our standard index to compare vasoconstrictor responses as this appears to be the most 
appropriate way to compare vasoconstrictor responsiveness under conditions where there might 
be differences in vascular tone and blood flow, rather than pressure, is the main variable 
changing (Lautt, 1989; Buckwalter & Clifford, 2001).  Forearm oxygen consumption (VO2) was 
calculated as:  FBF × (O2 contentarterial – O2 contentvenous) and presented in ml min
-1.     
 
Statistics 
All values are reported as means ± SEM.  Given the complexity of our experimental 
design, many comparisons are possible.  We have utilized a statistical approach that focuses on 
the comparisons that are most relevant to our experimental questions.  Absolute hypereaemic 
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forearm haemodynamics were assessed by two-way [timepoint (pre-PE or PE) × condition 
(control, L-NMMA+ketorolac, or L-NMMA+ketorolac+BaCl2+ouabain)] repeated measures 
(RM) ANOVA inclusive of both adenosine and exercise trials.  Due to the predictably large 
change from rest to exercise/adenosine, resting forearm haemodynamics were analyzed 
separately by one-way RM ANOVA.  Systemic haemodynamics were evaluated by two-way RM 
ANOVA (timepoint × condition ) with all timepoints (rest, pre-PE, PE) included.  
Vasoconstrictor responses (%Δ) were compared with a two-way [stimulus (exercise or 
adenosine) × condition (control, L-NMMA+ketorolac, or L-NMMA+ketorolac+BaCl2+ouabain)] 
RM ANOVA.  Blood gas variables for the Pre-PE and PE timepoints of exercise trials were 
analyzed with two-way ANOVA while a one-way ANOVA was used for baseline values.   
Student-Newman-Keuls post hoc testing was performed to make pairwise comparisons.  Changes 
in the haemodynamic response to exercise were compared with paired Student’s t tests.   
Significance was set at P < 0.05.   
 
Results 
 Systemic haemodynamics in all experimental conditions are presented in Table 5.  Small 
increases in MAP and HR occurred with exercise and throughout the course of the experiment 
and these are detailed in Table 5.   
 As intended by experimental design, FBF during adenosine infusion and exercise was 
matched prior to PE infusion in all experimental conditions (Figure 16) as was FVC (Table 5).  
In all trials, PE reduced FBF from these matched pre-PE levels.  FBF at the end of PE infusion 
was always significantly greater in exercise conditions, as compared to control.   
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  Infusion of L-NMMA+ketorolac reduced baseline FBF in both the adenosine and 
exercise trial but had no effect on steady-state FBF pre-PE (Figure 16).  When quantified as a 
%Δ from control, there was no significant change in FBF and a minor decrease in FVC (Figure 
17).  For both adenosine and exercise, there was no impact of L-NMMA+ketorolac infusion on 
the vasoconstrictor responses (%Δ FVC) to PE (Figure 18).   
With infusion of L-NMMA+ketorolac+BaCl2+ouabain, baseline FBF was still 
significantly reduced from control in the exercise trial however this was not significant in the 
adenosine trial (P=0.27).  Steady-state pre-PE FBF was significantly lower during exercise and 
by design in the adenosine trial (Figure 16).  As shown in Figure 17, the magnitude of the effect 
on the exercise response was rather profound (FBF: ~40% reduction; FVC: ~45% reduction).  
Inhibition of NO, PG, KIR channels and Na+/K+-ATPase significantly augmented PE-mediated 
vasoconstriction during adenosine in contrast to exercise where the vasoconstrictor response was 
unchanged (Figure 18).  Accordingly, FBF with PE was still greater during the exercise trial as 
compared to during adenosine (Figure 16).   
Blood gases from the arterial and deep venous samples obtained prior to and during the 
exercise trials are presented in Table 6.  For simplicity, we have omitted presenting samples 
obtained during adenosine trials, as any observed differences were predictable based on changes 
in blood flow to a quiescent tissue and we were most interested in the exercise responses.  A 
venous catheter was unsuccessful in one subject and due to equipment malfunction, some 
variables were not analyzed for all samples resulting in a range of N values (7-10) for these data.  
The significant changes observed were largely predictable based on the vasoconstriction induced 
by PE in each condition.  Of note, oxygen extraction increased (increased a-vO2, decreased pO2 
and FO2Hb) pre-PE with infusion of L-NMMA+ketorolac+BaCl2+ouabain as compared to 
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control and L-NMMA+ketorolac conditions.  This coincided with decreased blood flow and 
resulted in VO2 being maintained near prior levels.  In control and L-NMMA+ketorolac 
conditions, a-vO2 significantly increased with PE infusion.  In contrast, this did not occur with L-
NMMA+ketorolac+BaCl2+ouabain and combined with attenuated FBF resulted in a significantly 
lower VO2 as compared to control levels.  Reduced VO2 was paralleled with lower pH and 
greater pCO2 and [K+] in this condition of combined inhibition of NO, PG, and vascular 




 The purpose of the current study was to determine whether  vascular hyperpolarization 
via activation of KIR channels and Na
+/K+-ATPase mediates functional sympatholysis in healthy 
humans.  We specifically hypothesized that inhibition of KIR channels and Na
+/K+-ATPase 
would significantly impair the ability of contracting skeletal muscle to blunt α-adrenergic 
vasoconstriction, as compared to the vasoconstrictor response observed in resting muscle.  The 
primary novel finding of the present study is that sympathetically-mediated vasoconstriction 
persists in contracting skeletal muscle during combined inhibition of NO, PGs, KIR channels and 
Na+/K+-ATPase, despite augmented constriction during a control vasodilator condition (Figure 
18).  The present results support our previous findings that activation of KIR channels and 
Na+/K+-ATPase contribute to exercise hyperaemia and vasodilatation in the human forearm 
(Figure 17) (Crecelius et al., 2012b) and that there is a minimal role for NO and PGs in 
mediating exercise hyperaemia (Schrage et al., 2004) and sympatholysis (Dinenno & Joyner, 
2003, 2004) in this model.  Collectively, these results suggest that vasodilator action beyond KIR 
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channels and Na+/K+-ATPase are requisite for the modulation of sympathetic vasoconstriction 
observed during muscle contractions in humans. 
 
Vascular signaling pathways underlying functional sympatholysis 
 Identifying the sympatholytic ‘factor’ during muscle contractions has been the aim of a 
number of different investigators and findings across a range of models and utilizing various 
approaches have yielding conflicting results.  Previous studies in the rat hindlimb clearly 
demonstrated a role for NO in functional sympatholysis (Thomas et al., 1998; Thomas & Victor, 
1998) and these findings have been indirectly substantiated in more recent human studies (Fadel 
et al., 2004; Fadel et al., 2012).  However, in the human forearm, direct α1- and α2-adrenoceptor 
responsiveness during exercise is unchanged by the inhibition of NO synthase and a NO donor is 
incapable of modulating sympathetic vasoconstriction similar to what occurs in the vasculature 
of contracting skeletal muscle (Dinenno & Joyner, 2003).  These findings are similar to those in 
experimental dogs with respect to inhibition of NO synthase not affecting direct α2-mediated 
vasoconstriction during exercise (Buckwalter et al., 2004).  Prostaglandins, another endothelium-
derived vasodilator have also been shown to be capable of blunting sympathetic vasoconstriction 
in certain conditions (Lippton et al., 1981; Faber et al., 1982); however, when synthesis of PGs 
was inhibited in the human forearm, similar to NO, vasoconstrictor responsiveness during 
exercise was unaltered (Dinenno & Joyner, 2004).  In this same study, synthesis of NO and PGs 
was inhibited in combination, given the potential compensatory crossover of these pathways 
(Barker et al., 1996; Osanai et al., 2000).  The observed sympathetic vasoconstrictor responses 
during exercise were slightly augmented compared to control conditions; however, they were 
substantially blunted compared with those at rest (Dinenno & Joyner, 2004).  Given this range of 
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findings, as well as evidence for interaction between NO and vascular hyperpolarization 
(Bauersachs et al., 1996; Taddei et al., 1999), before addressing a potential role of 
hyperpolarization via KIR channel and Na
+/K+-ATPase activation, we inhibited these pathways to 
eliminate any potential compensatory effects and also confirm a minimal role of NO and PGs in 
sympatholysis. 
The present findings support the previous work (Dinenno & Joyner, 2004) that α-
adrenergic vasoconstriction is significantly blunted during muscle contractions as compared to a 
resting condition under combined NO and PG synthesis (Figure 18).  Our current findings differ 
slightly from the previous work in that we did not see a significant augmentation of 
vasoconstriction during both rest and exercise conditions.  This may be due to our utilization of 
propranolol in the current study to inhibit any potential PE-induced β-mediated vasodilatation 
which likely would have a NO-dependent component (Dawes et al., 1997).  The current study is 
also in agreement with previous reports that combined inhibition of NO and PGs does not impair 
the magnitude of steady-state exercise hyperaemia attained during mild to moderate rhythmic 
handgrip exercise (Figure 17) (Dinenno & Joyner, 2004; Schrage et al., 2004; Crecelius et al., 
2011b).  Taken together, the collective human data suggests that vascular control during exercise 
and particularly the interaction with sympathetic vasoconstriction extends beyond NO and PGs. 
The majority of non-NO and PG mechanisms of vasomotion, particularly those that are 
endothelium-dependent, are thought to elicit hyperpolarization of vascular smooth muscle cells 
and there is significant interest in the role of this electrical communication within and between 
both the endothelial and smooth muscle cells (Emerson & Segal, 2000).  Limited animal studies 
have pursued whether or not hyperpolarizing mechanisms can modulate sympathetic 
vasoconstriction and may be involved in functional sympatholysis.  Investigations from Segal 
99 
 
and colleagues have utilized hamster preparations and determined there is a reciprocal 
relationship between α-adrenoceptor-mediated depolarization and pharmacologically-induced 
hyperpolarization; specifically, hyperpolarization that stimulates a conducted vasomotor 
response, or vasodilatation upstream from the site of agonist application.  A reciprocal 
relationship is evident in that sympathetic stimulation attenuates conducted vasodilatation while 
conducted vasodilatation can also overcome sympathetically-induced vasoconstriction (Kurjiaka 
& Segal, 1995; Haug & Segal, 2005).  Taken together, these data suggest that hyperpolarization 
and the resultant conducted vasodilatation may be the underlying pathway of functional 
sympatholysis.   
Regarding specific mechanisms of hyperpolarization, a variety of events can stimulate 
this negative change in membrane potential, with a prime candidate being K+ ion efflux through 
small- and intermediate-conductance calcium-activated potassium (KCa) channels (Jackson, 
2005).  Along these lines, non-selective inhibition KCa channels can augment PE-induced 
increases in perfusion pressure in an isolated rat kidney (Moreno et al., 2003).  More directly 
related to functional sympatholysis, Thomas and colleagues tested whether or not ATP-sensitive 
potassium (KATP) channels may mediate this response as they are metabolically sensitive and 
thus could be stimulated by a variety of factors within the milieu of exercising tissue (1997).  In 
the rat hindlimb, pharmacological activation of KATP channels was able to inhibit 
sympathetically-stimulated vasoconstriction in the rat hindlimb and inhibition of KATP channels 
during muscle contractions augmented sympathetic vasoconstriction (Thomas et al., 1997).  
Similarly, in humans, inhibition of KATP channels augmented carotid baroreflex induced 
sympathetically-mediated vasoconstriction during leg exercise (Keller et al., 2004); however this 
also occurred at rest, and thus functional sympatholysis per se may have been unaltered.  At rest, 
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activation of KATP channels via diazoxide infusion can limit norepinephrine-induced 
vasoconstriction in the human forearm (Pickkers et al., 2004).  These are the only studies to date 
we are aware of that have attempted to address the role of vascular hyperpolarization, via any 
pathway, in modulating sympathetic vasoconstriction during exercise and overall suggest this 
electrical signaling may have some role in regulating functional sympathoylsis.   
 We have recently demonstrated that inhibition of KIR channels and Na
+/K+-ATPase via 
BaCl2 and ouabain, respectively, abolishes a mild hyperpolarizing stimulus (low dose KCl 
infusion) in the human forearm (Crecelius et al., 2012a).  Stimulation of either KIR channels or 
Na+/K+-ATPase leads to vascular hyperpolarization and evidence suggests KIR activation is 
important in “amplifying” the spread of hyperpolarization through the vasculature (Jantzi et al., 
2006).  Thus, given the previous evidence to suggest that hyperpolarization may be involved in 
functional sympatholysis and our own data that showed activation of KIR channels and Na
+/K+-
ATPase contributes to exercise hyperaemia (Crecelius et al., 2012b), we utilized our established 
pharmacological approach to test whether these pathways contributed to the ability of muscle 
contractions to blunt sympathetically-mediated vasoconstriction.  Contrary to our hypothesis, in 
the presence of inhibition of KIR channels and Na
+/K+-ATPase, vasoconstrictor responses were 
maintained compared to control conditions and still significantly attenuated compared to resting 
(adenosine) conditions (Figure 18).  Interestingly, vasoconstriction during adenosine infusion, 
which served as a high-flow control, was significantly augmented with combined infusion of L-
NMMA+ketorolac +BaCl2+ouabain as compared to control and L-NMMA+ketorolac conditions.  
We are not certain as to why this occurred, particularly to the large magnitude that we observed.  
The fact that vasoconstrictor responsiveness in resting tissue was increased but unaltered during 
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exercise highlights the unique signaling that occurs during exercise versus other hyperaemic 
conditions.   
 
Effects of inhibition of KIR channel and Na
+/K+-ATPase activity on blood parameters 
 In the present study, we sampled blood from a deep antecubital vein and the brachial 
artery catheter in order to measure a variety of potential muscle metabolites that may be 
contributing to our observed responses, as well as determine the oxygen consumption of the 
forearm tissue during exercise.  These data (Table 6) strengthen the findings of our 
haemodynamic measures and add additional insight to the metabolic consequences of our 
inhibitors.  Exercise stimulated predictable changes reflective of increased metabolism and as 
would be anticipated, in control and L-NMMA+ketorolac conditions, PE-mediated 
vasoconstriction and reduced forearm blood flow was coupled with increased extraction of 
oxygen, and thus preserved oxygen consumption.   
Of interest, given the reduction in exercise hyperaemia that occurred during L-
NMMA+ketorolac+BaCl2+ouabain, extraction during exercise was significantly increased from 
the prior experimental conditions (control and L-NMMA+ketorolac).  It appears this was near 
maximal levels of extraction as there was no significant increase with PE infusion despite a 
reduction in blood flow.  Thus, oxygen consumption in the condition of combined inhibition of 
NO, PGs, KIR channels and Na
+/K+-ATPase was attenuated during sympathetic stimulation.  This 
observation may have important relevance for populations that demonstrate impaired exercise 
hyperaemia and sympatholysis, such as older healthy adults and hypertensive humans (Dinenno 
et al., 2005; Kirby et al., 2009; Vongpatanasin et al., 2011).  Given that all subjects were able to 
continue contractions, and thus muscle work still occurred, it is likely that non-oxidative 
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pathways compensated for the loss in ATP production and this is reflected in significantly lower 
pH and greater pCO2 values.  Whether this shift in metabolism would impair exercise tolerance 
over prolonged periods of time and concomitant sympathetic activation remains unknown.   
 
Experimental considerations 
 Given that our primary findings regarding the role of KIR channels and Na
+/K+-ATPase in 
sympatholysis were negative and contrary to our hypothesis, the efficacy of our pharmacological 
inhibition of these pathways could be questioned.  We do not believe this is likely the case as 
BaCl2+ouabain significantly augmented vasoconstriction during adenosine infusion and 
significantly attenuated the hyperaemic and vasodilatory response to muscle contractions.  It is 
possible that we have not reached complete inhibition of these pathways as this is difficult to test 
given the limitations in the magnitude of direct hyperpolarization that can be stimulated in the 
human forearm due to subject discomfort with high levels of KCl infusion.  In this context, it is 
important to acknowledge that our inhibition of KIR channels and Na
+/K+-ATPase blocks only K+ 
stimulated hyperpolarization and the amplification of a hyperpolarizing stimulus.  We are not 
presently able to inhibit hyperpolarization directly, nor the ability of electrical signals to be 
communicated through the vessel layers. 
Further related to the efficacy of our pharmacological inhibition, we observed no effect of 
L-NMMA+ketorolac on vasoconstrictor responses during exercise and adenosine infusion.  We 
did however, observe a significant reduction in resting blood flow as would be expected with 
sufficient inhibition of NO and PGs and utilized standard doses of L-NMMA and ketorolac 
which have previously been shown to be effective (Dinenno & Joyner, 2003; Schrage et al., 
2004; Crecelius et al., 2011a).   
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 We think it is important to adjust the absolute dose of PE administered in these types of 
studies to the observed level of forearm blood flow in order to approximately match a similar 
relative concentration within the blood in all conditions (Dinenno & Joyner, 2003, 2004; Kirby et 
al., 2008; Kirby et al., 2011).  It could be argued that as a result of the attenuated hyperaemic 
response to exercise during L-NMMA+ketorolac+BaCl2+ouabain, the flow-adjusted absolute 
dose of PE was lower, and this explains why the vasoconstrictor response was not augmented.  
We do not think this is the case as the response during adenosine was augmented and this was a 
flow- and absolute PE dose-matched condition.  Thus, our experimental approach of adjusting 
our PE dose does not explain the lack of effect of combined inhibition of NO, PGs, KIR channels 
and Na+/K+-ATPase on functional sympatholysis.   
 
Perspectives 
 Activation of KIR channels and Na
+/K+-ATPase are only two of many ways in which 
vascular cells can hyperpolarize.  In human in vivo studies, we are limited in the specificity and 
extent to which we can inhibit mediators of this important change in membrane potential.  One 
of the motivations to investigate the role of KIR channels and Na
+/K+-ATPase in functional 
sympatholysis was our previous findings regarding the contributions of this pathway to ATP-
mediated vasodilatation (~50%) (Crecelius et al., 2012a) and the unique ability of ATP to blunt 
sympathetic vasoconstriction similar to what occurs during exercise (Rosenmeier et al., 2004; 
Kirby et al., 2008).  
Interest in ATP and the potential role for this molecule in vascular control during exercise 
is significant and remains an unanswered question given the limitations in specifically inhibiting 
purinergic receptors ATP binds to, even in animal models.  Data from our laboratory 
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demonstrate the ability of exogenous ATP to cause vasodilatation and modulate sympathetic 
vasoconstriction (Kirby et al., 2008).  We have also shown that NO and PGs have only a modest 
role in ATP-mediated vasodilatation (Crecelius et al., 2011a; Crecelius et al., 2012a), and thus if 
ATP does contribute to functional sympatholysis, a minimal role for NO and PGs as observed 
previously (Dinenno & Joyner, 2004) and in the current study is in line with this hypothesis.  
Combined inhibition of NO, PGs, KIR channels and Na
+/K+-ATPase reduces ATP-mediated 
vasodilatation by over 50%; however, it is possible that the vascular signaling that contributes to 
the remaining portion of vasodilatation is the same as what allows exercise to maintain the 
ability to blunt sympathetic vasoconstriction following inhibition of these same pathways as 
observed in the present study.   
What then are these remaining signaling pathways that could explain our observed 
responses?  We propose that electrical communication, likely through intermediate- and small-
conductance KCa channels and direct transfer of electrical charge through the physical 
connections of endothelial and vascular smooth muscle cells occurs, and is able to still stimulate 
hyperpolarization and elicit a conducted response that is capable of profound vasodilatation and 
opposition to sympathetically-induced depolarization.  We have recently shown that slight 
augmentations in endothelial signaling, via infusion of acetylcholine can augment the ability of 
mild handgrip exercise to blunt sympathetic vasoconstriction and this occurs independent of NO 
and PG signaling (Kirby et al., 2013).  Thus, electrical communication and a balance between 
hyperpolarization and depolarization of vascular smooth muscle cells remains our proposed 
underlying mechanism explaining functional sympatholysis.  Further development of specific 
pharmacological inhibitors that can attenuate cell-to-cell communication and are safe for human 




Muscle contractions stimulate a large increase in blood flow and have the ability to blunt 
sympathetically-mediated vasoconstriction relative to what occurs in resting tissue.  This 
functional sympatholysis is thought to preserve oxygen delivery to active tissue in the face of 
increased sympathetic activity that is necessary for appropriate blood pressure regulation.  Many 
studies have investigated the contributing signaling pathways to this vascular response and the 
current data provides novel insight into this phenomenon.  We show that acute pharmacological 
inhibition of KIR channels and Na
+/K+-ATPase does not impact direct α-adrenergic 
vasoconstriction during muscle contractions.   Further, we support previous findings that these 
pathways contribute to exercise hyperaemia whereas NO and PGs do not contribute to exercise 
hyperaemia nor sympatholysis in this model.  The impact of combined attenuated hyperaemia 
and preserved vasoconstrictor responses during exercise with combined inhibition of NO, PGs, 
KIR channels and Na
+/K+-ATPase is metabolically significant and results in attenuated oxygen 
consumption and increased non-oxidative metabolism in the contracting tissue.  The collective 
data from the present study and preceding investigations fail to explain the majority of the 
physiological basis of functional sympatholysis and future work should examine electrical 
communication within and between vascular cell layers in an attempt to better understand this 





Table 5.  Systemic haemodynamics and forearm vascular conductance in all conditions 
PE, phenylephrine 
* P<0.05 vs adenosine (within condition); †P<0.05 vs control; ‡P<0.05 vs +L-NMMA+ketorolac 
§ P<0.05 Main effects of Timepoint and Condition; P<0.05 Timepoint × Condition 
◊ Timepoints: within all adenosine trials (P = NS); within all exercise trials, P<0.05 Baseline vs 


















Adenosine 94 ± 2 57 ± 2 31.3 ± 2.5 
Exercise 92 ± 2 60 ± 2 35.0 ± 2.1 
Pre-PE 
Adenosine 97 ± 2 59 ± 2 232.0 ± 20.8 
Exercise 96 ± 2 66 ±2 238.6 ± 18.5 
PE 
Adenosine 101 ± 3 59 ± 2 116.7 ± 11.0 





Adenosine 96 ± 2 54 ± 2   25.3 ± 2.7† 
Exercise 98 ± 2 57 ± 2   25.3 ± 2.2† 
Pre-PE 
Adenosine 98 ± 3 56 ± 2 204.3 ± 10.8 
Exercise 100 ± 2 62 ± 2 218.8 ± 18.9 
PE 
Adenosine 103 ± 2 57 ± 2 111.1 ± 13.8 







Adenosine 100 ± 3 56 ± 2 28.0 ± 2.7 
Exercise 101 ± 2 58 ± 2    26.4 ± 2.9†  
Pre-PE 
Adenosine 106 ± 2 57 ± 2      141.7 ± 18.0†‡ 
Exercise 110 ± 3 63 ± 3      136.6 ± 18.2†‡ 
PE 
Adenosine 109 ± 3 55 ± 2      38.8 ± 5.3†‡ 
Exercise 113 ± 4 62 ± 2       97.3 ± 11.9*†‡
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Table 6.  Deep venous blood gases in exercise trials 
a-v, arterial-venous; PE, phenylephrine 
Pre-PE and PE were statistically analyzed separately from baseline given the predictable large changes due to exercise.   


















Arterial 82.0±1.0 94.3±0.1 7.402±0.007 37.4±1.1 3.86±0.03   
Baseline 27.9±2.1 46.2±4.9 7.347±0.008 47.5±1.1 4.04±0.09 11.1±1.1   3.6±0.4 
Pre-PE 23.9±0.9 33.9±1.6 7.271±0.011 59.8±1.9 4.75±0.07 13.6±0.7 32.6±2.9 
PE   20.4±1.6†   24.5±3.1* 7.249±0.010 62.6±1.5 4.55±0.06   15.5±0.8* 30.0±3.0 
+L-NMMA 
+ketorolac 
Arterial 84.1±1.6 94.7±0.2 7.408±0.009 34.8±1.1 3.90±0.05   
Baseline 23.1±1.7   34.2±4.0† 7.321±0.009 49.2±2.0 3.93±0.12 13.5±1.0   3.5±0.3 
Pre-PE 22.7±1.0 31.3±1.8 7.278±0.014 56.0±1.9 4.68±0.13 14.1±0.6 32.3±4.1 





Arterial 81.9±1.8 94.1±0.3 7.396±0.003 36.4±0.5 3.94±0.09   
Baseline 26.1±2.7   44.1±5.7‡   7.328±0.009 44.7±1.4  3.30±0.11†‡ 12.3±1.1   3.5±0.3 
Pre-PE 18.3±1.3†‡ 19.9±1.6†‡ 7.239±0.016 61.4±3.2 5.10±0.15†‡ 16.4±0.5†‡ 25.4±3.7 
PE 17.3±2.0 15.8±3.6*† 7.196±0.019*†‡   68.4±3.7* 5.00±0.16†‡ 17.1±0.7   19.0±2.8†
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Figure 15. Experimental timeline 
A. After instrumentation of brachial artery catheter, subjects received propranolol to inhibit β-adrenoceptors and then 
underwent exercise and adenosine (ADO) trials (see Panel B) in control (saline) conditions.  L-NMMA and ketorolac were then 
administered in order in inhibit the synthesis of nitric oxide (NO) and prostaglandins (PGs), respectively and exercise and ADO 
trials were repeated.  Finally, barium chloride (BaCl2) and ouabain were infused in order to inhibit vascular hyperpolarization via 
activation of inwardly-rectifying potassium channels and Na+/K+-ATPase, respectively, in combination with NO and PGs.  In each 
individual trial (B), forearm blood flow (FBF) was measured for 3 minutes of baseline.  Subjects then performed exercise [15% 
maximal voluntary contraction (MVC) rhythmic handgrip exercise (RHG)] or received variable-dose ADO infusion to match 
hyperaemia observed with exercise.  After four minutes of the stimulus (adenosine or exercise) “steady-state” FBF was calculated 
and a dose of phenylephrine (PE; α1-adrenoceptor agonist) based on this FBF was then infused for 2 min and vasoconstrictor 
responses were determined.  Arterial blood samples were taken at rest and venous (retrograde antecubital catheter) samples were 















































†‡  † 
Figure 16. Absolute forearm blood flow responses across all experimental conditions 
Forearm blood flow (FBF) responses are presented at rest (black bars), pre-
phenylephrine (PE) vasoconstrictor stimulus (grey bars), and end-PE (open bars) in all 
experimental conditions.  As intended, FBF was matched between adenosine (ADO) infusion 
and 15% maximal voluntary contraction (MVC) rhythmic handgrip exercise.  PE elicited a 
significant reduction in FBF in all conditions.  In control (saline), FBF after PE was 
significantly greater during exercise than ADO infusion.  L-NMMA and ketorolac to inhibit 
nitric oxide (NO) and prostaglandin (PG) synthesis, respectively, reduced baseline FBF but had 
no effect on pre-PE or PE FBF for either ADO or exercise.  The addition of barium chloride 
(BaCl2) and ouabain to inhibit vascular hyperpolarization via inwardly-rectifying potassium 
channels and Na+/K+-ATPase significantly attenuated exercise hyperaemia, and FBF during PE 
was lower than in control and +L-NMMA +ketorolac conditions, but still greater than during 
the ADO trial within this condition.  *P<0.05 vs ADO (within condition); †P<0.05 vs control; 


















































Figure 17. Impact of experimental inhibition on steady-state forearm 
haemodynamics during exercise 
The relative change in steady-state forearm blood flow (FBF; black bars) and 
forearm vascular conductance (FVC; grey bars) due to pharmacological inhibition 
compared to the control (saline) condition is shown.  Inhibition of the synthesis of nitric 
oxide (NO) and prostaglandins (PGs) via L-NMMA and ketorolac, respectively had no 
impact on FBF and reduced FVC.  The additional inhibition of vascular hyperpolarization 
via inwardly-rectifying potassium (KIR) channels (barium chloride, BaCl2) and Na
+/K+-
ATPase (ouabain) had a substantial effect on both FBF and FVC, attenuating exercise 































































Figure 18. Phenylephrine-mediated vasoconstriction in all experimental trials 
The vasoconstriction elicited by phenylephrine (PE) infusion is presented for 
adenosine (ADO; black bars) and 15% maximal voluntary contraction rhythmic handgrip 
exercise (15% MVC Ex; grey bars) trials in the following conditions: control (saline), 
combined inhibition of nitric oxide (NO) and prostaglandins (PGs) via L-NMMA and 
ketorolac, respectively,  and combined inhibition of NO, PGs and vascular 
hyperpolarization via activation of inwardly-rectifying potassium (KIR) channels (barium 
chloride, BaCl2) and Na
+/K+-ATPase (ouabain).  In all conditions, exercise blunted PE-
mediated vasoconstriction.  Combined inhibition of NO, PGs, KIR channels and Na
+/K+-
ATPase augmented PE-mediated vasoconstriction during ADO infusions but did not alter 
the vasoconstrictor response during exercise. *P<0.05 vs ADO (within condition); 
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CHAPTER V – MANUSCRIPT IV  
 
Inwardly-rectifying potassium channels and Na+/K+-ATPase mediate reactive hyperaemia  




Rationale:  Reactive hyperaemia (RH) in the forearm circulation is an important marker of 
cardiovascular health yet the underlying vasodilator signaling pathways are controversial and 
thus remain unclear.  We hypothesized that vascular hyperpolarization via inwardly-rectifying 
potassium (KIR) channels and Na
+/K+-ATPase contributes to RH in young, healthy humans, 
whereas nitric oxide (NO) and prostaglandins (PGs) do not. 
Methods and Results:  In 24 (23±1 years) subjects, we performed RH trials by measuring 
forearm blood flow (FBF; venous occlusion plethysmography) following 5 minutes of arterial 
occlusion.  In Protocol 1, we studied 2 groups of 8 subjects and assessed RH in the following 
conditions; Group 1: control (saline), inhibition of KIR channels (barium chloride; BaCl2), 
combined inhibition of KIR channels and Na
+/K+-ATPase (BaCl2+ouabain, respectively), and 
combined inhibition of KIR channels, Na
+/K+-ATPase, NO and PGs (BaCl2+ouabain+L-
NMMA+ketorolac, respectively).  Group 2 received ouabain rather than BaCl2 in the 2
nd trial.  In 
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Protocol 2 (n=8), 3 RH trials were performed: control, L-NMMA+ketorolac, and L-
NMMA+ketorolac +BaCl2+ouabain.  All infusions occurred via brachial artery catheter.  
Compared to control, BaCl2 significantly reduced peak FBF (-50±6%; P<0.05) whereas ouabain 
and L-NMMA+ketorolac did not. Total FBF (area under the curve) was attenuated by BaCl2 (-
61±3%) and ouabain (-44±12%) alone and this effect was enhanced when combined (-87±4%), 
nearly abolishing RH.  L-NMMA+ketorolac did not impact total RH FBF prior to or after 
administration of BaCl2 and ouabain.   
Conclusions:  Vascular hyperpolarization via KIR channels is a primary determinant of peak RH, 
whereas activation of both KIR channels and Na




Following ischaemia caused by temporary arterial occlusion, there is significant 
vasodilatation and a rapid marked increase in blood flow in most tissues, including the human 
forearm (Patterson & Whelan, 1955; Gentry & Johnson, 1972).  This phenomenon of reactive 
hyperaemia is independent from neural vasodilatation (Duff & Shepherd, 1953)  and is thought 
to occur as a result of myogenic and local metabolic factors within the resistance vasculature and 
thus can be used as a test of microvascular function (Flammer et al., 2012).  Attenuated reactive 
hyperaemic responses have been documented in populations demonstrating a variety of risk 
factors that increase cardiovascular morbidity and mortality (Go et al., 2013) including 
hypertension (Conway, 1963; Takeshita & Mark, 1980; Iwatsubo et al., 1997; Higashi et al., 
1999), atherosclerosis (Dakak et al., 1998), peripheral artery disease (Fronek et al., 1973), 





Recently, peak reactive hyperaemic flow was determined to be predictive of future 
cardiovascular events in a healthy population (Anderson et al., 2011) as well as in at-risk patient 
populations (Huang et al., 2007) and this relationship may be stronger than that of commonly 
assessed macrovascular function via flow-mediated brachial vasodilatation (Philpott et al., 2009; 
Anderson et al., 2011).  Further, interventions that reduce the burden of cardiovascular disease 
(Go et al., 2013) such as exercise (Higashi et al., 1999) and angiotensin-converting enzyme 
inhibition (Iwatsubo et al., 1997) improve reactive hyperaemia in hypertensive patients.  Despite 
the utility of the reactive hyperaemia test as a measure of vascular health, the underlying local 
vasodilator signaling that contributes to this response in humans is largely unknown.   
 Given the strong associations between impaired reactive hyperaemia, cardiovascular 
disease risk, and attenuated endothelial-dependent and metabolic vasodilatation (Taddei et al., 
1997; Kirby et al., 2012), a variety of previous investigations in humans have attempted to 
determine the role of numerous endothelial-derived or -dependent vasoactive and metabolically-
dependent substances in mediating the response including nitric oxide (NO) (Tagawa et al., 
1994; Engelke et al., 1996; Dakak et al., 1998; Nugent et al., 1999; Bank et al., 2000; Raff et al., 
2010), prostaglandins (PGs )(Kilbom & Wennmalm, 1976; Carlsson et al., 1987; Engelke et al., 
1996; Addor et al., 2008), ATP-dependent potassium (KATP) channels (Banitt et al., 1996; Bank 
et al., 2000) and adenosine (Carlsson et al., 1987; Costa et al., 1999; Meijer et al., 2008).  The 
results of these studies are largely equivocal and to date, even when the production or action of 
these substances are inhibited in combination (Carlsson et al., 1987; Engelke et al., 1996; Bank 
et al., 2000), a significant portion of both the peak and total reactive hyperaemia remains 
unexplained.  There is growing interest in vasodilatation that occurs via non-NO and –PG 





Vanhoutte, 1995; Emerson & Segal, 2000).  In this context, we recently demonstrated the ability 
to block a direct hyperpolarizing stimulus (KCl) via inhibition of inwardly-rectifying potassium 
(KIR) channels and Na
+/K+-ATPase in the human forearm and show these pathways can 
contribute to vasodilator responses to pharmacological stimulation of the endothelium (Crecelius 
et al., 2012a) as well as increased metabolic demand (Crecelius et al., 2012b).  Whether or not 
vascular hyperpolarization via KIR channel and Na
+/K+-ATPase activation contributes to reactive 
hyperaemia in humans has never been tested.   
 With this information as background, we directly tested the hypothesis that vascular 
hyperpolarization via KIR channels and Na
+/K+-ATPase contributes to forearm reactive 
hyperaemia following temporary arterial occlusion and that NO and PGs have a minimal role in 




With Institutional Review Board approval and after written informed consent, a total of 
24 young healthy adults (18 men, 6 women; age=23±1 years (range: 18-34 years); 
weight=73.1±1.5 kg; height=175±1 cm; body mass index=23.9±0.5 kg m-2; forearm volume 
(FAV)=945±39 ml; means±S.E.M.) participated in the present study.  All subjects were sedentary 
to moderately active, non-smokers, non-obese, normotensive (resting blood pressure <140/90 
mmHg), and not taking any medications.  Studies were performed after an overnight fast and 24 
hour abstention from caffeine and exercise with subjects in the supine position with the 
experimental arm abducted to 90° and slightly elevated above heart level upon a tilt-adjustable 





phase of their menstrual cycle or placebo phase of oral contraceptive use to minimize any 
potential cardiovascular effects of sex-specific hormones.  All studies were performed according 
to the Declaration of Helsinki. 
 
Arterial catheterization, arterial blood pressure and heart rate 
A 20 gauge, 7.6 cm catheter was placed in the brachial artery of the non-dominant arm 
under aseptic conditions after local anesthesia (2% lidocaine) for local administration of study 
drugs and blood sampling.  The catheter was connected to a 3-port connector as well as a 
pressure transducer for mean arterial pressure (MAP) measurement and continuously flushed at 3 
ml hr-1 with heparinized saline.  The two side ports were used for drug infusions (Dinenno et al., 
2002; Crecelius et al., 2012a). Heart rate (HR) was determined using a 3-lead electrocardiogram 
(Cardiocap/5, Datex-Ohmeda Louisville, CO, USA). 
Forearm blood flow and vascular conductance 
Forearm blood flow (FBF) was measured via venous occlusion plethysmography using 
mercury-in-salistic strain gauges and techniques as previously described (Crecelius et al., 
2012a).  FBF was expressed as milliliters per deciliter of tissue per minute (ml dl FAV-1 min-1.  
As an index of forearm vasodilatation and to account for individual differences in baseline 
vascular tone, forearm vascular conductance (FVC) was calculated as (FBF/MAP) × 100 
expressed as (ml dl FAV-1 min-1) 100mmHg-1.  Immediately following the release of the 
occlusion cuff for the reactive hyperaemia (see below), the venous occlusion cuff cycled between 
inflation (4 seconds) and deflation (3 seconds) yielding one blood flow measurement every 7 
seconds for the first 56 seconds (8 flow measures).  Pilot studies in the laboratory demonstrated 





we felt it was prudent to capture the maximum possible number of flow measures in the initial 
portion of the hyperaemic response.  After 8 flow measures, the inflation:deflation cycle was 
changed back to 7:8 sec, as was used at rest.    
 
Reactive hyperaemia protocol 
 The same cuff that was placed around the upper portion of the arm and used for venous 
occlusion for the measurement of FBF was used to cause arterial occlusion for each reactive 
hyperaemia trial.  After measurement of baseline FBF, the occlusion cuff was rapidly inflated to 
200 mmHg for 5 minutes of ischaemia.  This location and duration of ischaemia was chosen to 
mimic the reactive hyperaemia protocol utilized in investigations of the contributions of various 
endothelial-derived vasodilator pathways to the reactive hyperaemic response (Kilbom & 
Wennmalm, 1976; Carlsson et al., 1987; Engelke et al., 1996; Nugent et al., 1999) and 
importantly, that has recently demonstrated peak reactive hyperaemic flow to be more strongly 
associated with cardiovascular disease risk than measures of flow-mediated vasodilatation 
(Anderson et al., 2011).  After 5 minutes, the cuff was rapidly deflated and flow measures 
commenced.  Forearm blood flow was measured and collected for 5 minutes post-cuff deflation; 
however, FBF in control conditions returned to baseline within 2.5 minutes (150 seconds) and 
thus we only present and statistically analyzed the data for this duration.   
 
Vasoactive drug infusion 
All drug infusions were through the brachial artery catheter to create a local effect in the 





baseline measures, prior to the 5 minutes of arterial occlusion and reactive hyperaemia.  Specific 
timing and duration of infusions is provided below in the Experimental Protocols section.   
To inhibit KIR channels, barium chloride (BaCl2; KIR channel inhibitor; 10% w/v 
BDH3238, EMD Chemicals, Gibbstown, NJ, USA) was infused at 0.9 μmol dl FAV-1 min-1 with 
a range of a minimum dose of 8 μmol min-1 to a maximum dose of 10 μmol min-1 for five 
minutes prior to each arterial occlusion.  We doubled the dose of BaCl2 from that which we have 
previously utilized (Crecelius et al., 2012a) in an attempt to maximize our blockade of KIR 
channels while still remaining in an estimated venous plasma concentration range that is 
relatively selective for KIR channels (Dawes et al., 2002).  Additionally, given we did not want to 
continue infusions throughout the arterial occlusion period and risk extravasation of drug, this 
higher concentration allowed for a greater amount of drug to be delivered during the loading 
period alone.  To inhibit Na+/K+-ATPase, ouabain octahydrate (Na+/K+-ATPase inhibitor; Sigma 
03125, St. Louis, MO, USA) was infused at 2.7 nmol min-1 for 15 minutes prior to arterial 
occlusion (Crecelius et al., 2012a).  On subsequent reactive hyperaemia trials, ouabain was 
reinfused for 5 minutes prior to arterial occlusion to provide continuous inhibition.  Ouabain and 
BaCl2 were prepared in saline and confirmed sterile and free of fungus/endotoxin and particulate 
matter with a standard microbiology report (JCB-Analytical Research Labs, Wichita, KS, USA) 
prior to use.  We administered NG-monomethyl-L-arginine (L-NMMA; NOS inhibitor; 
Clinalfa/Bachem, Weil am Rhein, Germany) to inhibit the production of NO in combination with 
ketorolac (non-selective cyclooxygenase inhibitor; Hospira, Lake Forest, IL, USA) to inhibit the 
synthesis of PGs.  The doses of L-NMMA and ketorolac were 5 mg min-1 and 1200 µg min-1 
respectively and given for 5 minutes prior to arterial occlusion.  We have previously 





the current protocol, observe significant reductions in resting blood flow (see Results) consistent 
with effective inhibition of these pathways (Lauer et al., 2001).  Forearm volume used for 
normalization of specific vasoactive drugs was determined from regional analysis of whole-body 
dual-energy X-ray absorptiometry scans (QDR series software, Hologic, Inc, Bedford, MA, 
USA).   
 
Experimental Protocols 
In all experimental protocols, subjects rested quietly for 30 minutes after insertion of the 
catheter before the first experimental trial and for 20 minutes between each trial.   
 
Protocol 1: Independent and combined effects of KIR channel and Na
+/K+-ATPase inhibition 
 This protocol was designed to primarily address the role of KIR channels and Na
+/K+-
ATPase in the reactive hyperaemia response.  In total, 16 subjects participated in this protocol.  
Eight of these subjects (Group 1) underwent reactive hyperaemia trials in the following 
conditions: (1) control (saline), (2) independent KIR channel inhibition (BaCl2), (3) combined KIR 
channel and Na+/K+-ATPase inhibition (BaCl2+ouabain), and (4) inhibition of KIR channels, 
Na+/K+-ATPase, as well as the production of NO and PGs (BaCl2+ ouabain+L-
NMMA+ketorolac).  In the other eight subjects (Group 2), the protocol was the same except that 









Protocol 2: Effects of combined inhibition of NO and PGs 
 To address the combined role of NO and PGs in reactive hyperaemia, we performed a 
second protocol (n=8) that consisted of reactive hyperaemia trials in the following conditions: (1) 
control (saline), (2) combined NO and PG inhibition (L-NMMA+ketorolac), and (3) inhibition of 




Protocol 3: Control vasodilator stimulus 
 In a subset of subjects (n=6), sodium nitroprusside (SNP; Nitropress, Hospira Inc., Lake 
Forest, IL) was infused at 2 µg dl FAV-1 min-1 for 5 minutes (Kirby et al., 2010) in control 
(saline) conditions and after prior administration of all four antagonists (BaCl2, ouabain, L-
NMMA and ketorolac) as a negative control to confirm intact capacity of the forearm resistance 
vasculature to vasodilate.  
 
Data acquisition and analysis 
Data were collected and stored on a computer at 250 Hz and were analyzed off-line with 
signal-processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  Mean arterial 
pressure (MAP) was determined from the arterial pressure waveform.  FBF was determined from 
the derivative of the forearm plethysmogram signal.  For resting hemodynamic measures, the 
average of the last minute of baseline was used.  One primary outcome variable of interest was 
the absolute peak hyperaemic FBF.  To quantify the reactive hyperaemia response, we averaged 
and plotted values from each subject at all FBF timepoints (7, 14, 21, 28, 35, 42, 49, 56, 60, 75, 





FBF [area under the curve (AUC)] was determined as the sum of FBF above baseline at each 
timepoint.  The peak reactive hyperaemic FBF and vasodilatation (FVC) was determined for 
each subject individually and these values were also averaged.  In all subjects, these individual 
peaks occurred at either the first, second, or third flow measurements.  When FBF/FVC 
measurements for all subjects were averaged at each timepoint, the peak nearly always occurred 
at the first flow measurement (see Results).  To quantify the impact of the vasoactive inhibitors, 
the magnitude of inhibition (%Δ) was calculated as: (FBFpeak/total inhibition – FBFpeak/total 
control)/(FBFpeak/total control)×100 and always quantified from the control condition.  For the 
SNP control trials, FBF was averaged across the last minute of baseline and SNP infusion.  Data 
for pharmacological dilator infusion was presented in as both absolute and percent changes in 
FBF and FVC.   
 
Statistics 
Data are presented as mean±S.E.M.  Dynamic post-occlusion FBF values were analyzed 
via a two-way repeated measures ANOVA (time × condition).  To make comparisons of peak 
and total reactive hyperaemic FBF and baseline hemodynamics between each of the 
experimental conditions within a given protocol, we used a one-way repeated measures 
ANOVA.  We were most interested in making comparisons to control and the prior trial in order 
to determine whether an additional impact of the added inhibitors occurred.  For comparisons 
between protocols, a one-way ANOVA was utilized.  In all cases, Student-Newman-Keuls post 
hoc pairwise comparisons were made when a significant F was observed.  Significance was set a 







No significant differences in subject characteristics were detected between the 3 
experimental groups.  Baseline systemic hemodynamics (HR, MAP) and FBF for all 
experimental protocols are presented in Table 7 and baseline FVC values are presented in Table 
8.  For all protocols, there were no significant changes in HR or MAP during or following the 5 
minutes of arterial occlusion (data not shown). 
 
Protocol 1: Independent and combined effects of KIR channel and Na
+/K+-ATPase inhibition 
In Group 1 of Protocol 2, subjects received BaCl2 alone following the control trial in 
order to assess the independent role of KIR channels in reactive hyperaemia (Figure 19).  
Baseline FBF and FVC was lower with BaCl2 but was not significantly different from control 
levels in all subsequent trials of this protocol (Tables 7 and 8).   BaCl2 significantly reduced the 
peak reactive hyperaemia response (-50±6%; Figure 19A and B) and impaired FBF for the first 
75 sec (Figure 19A).  Taken together, the total reactive hyperaemic FBF was also significantly 
reduced from control levels (-62±3%; Figure 19C).  The addition of ouabain did not further 
impact peak reactive hyperaemic FBF (-60±7%; BaCl2 vs BaCl2+ouabain; P=0.25) but 
approached having a significant additional effect on total reactive hyperaemic FBF (-82±4%; 
P=0.07).  The addition of L-NMMA+ketorolac did not have a further impact (Peak: -68±7%; 
Total: -88±3%). Changes in peak vasodilatation (FVC) paralleled those of FBF (Table 8).   
In Group 2 of Protocol 2, subjects received ouabain alone following the control trial in 
order to assess the independent role of Na+/K+-ATPase in reactive hyperaemia (Figure 20).  
Ouabain had no effect on peak reactive hyperaemic FBF (2±6%; Figure 20A and B) but did 





the total reactive hyperaemic FBF (-44 ±12%; Figure 20C).  The addition of BaCl2 significantly 
reduced peak hyperaemic FBF (-62±8%) as well as further reduced total hyperaemic FBF (-
92±8%) whereas there was no additional effect of L-NMMA+ketorolac on either peak (-63±7%) 
or total hyperaemic FBF (-94±8%).  Changes in peak vasodilatation (FVC) paralleled those for 
FBF (Table 8).   
 
Protocol 2: Effects of combined inhibition of NO and PGs 
 In Protocol 3, we assessed the combined contribution of NO and PGs to reactive 
hyperaemia and subsequently inhibited KIR channels and Na
+/K+-ATPase (Figure 21).  As would 
be expected with effective inhibition, L-NMMA+ketorolac significantly reduced baseline FBF 
and FVC (Tables 7-9).  The FBF response upon cessation of arterial occlusion is shown in Figure 
21.  The mean of the first FBF measures was augmented with L-NMMA+ketorolac (Figure 
21A); however, when each individual subjects’ peak response was averaged, this comparison 
only approached being significant (+18±8%; P=0.069; Figure 21B).  FBF was attenuated with L-
NMMA+ketorolac 30-60 sec following the end of arterial occlusion (Figure 21A), yet the total 
reactive hyperaemic FBF remained similar to control (-10±12%; P=0.24; Figure 21C).  The 
additional inhibition of KIR channels and Na
+/K+-ATPase via BaCl2 and ouabain, respectively, 
significantly attenuated both peak (-61±8%; Figures 21A and B) and total (-69±6%; Figures 
21C) reactive hyperaemic FBF.   
 
Comparison of reactive hyperaemia protocols 
 A summary of the relative (%Δ) effects of independent and combined roles of KIR 





conditions is presented in Figure 22.  In these pooled comparisons, there was not a significantly 
greater effect on the reduction of peak FBF from BaCl2 alone to combined BaCl2+ouabain.  Total 
reactive hyperaemic FBF was attenuated by BaCl2 alone and ouabain alone and this effect was 
enhanced when these inhibitors were combined.  L-NMMA+ketorolac had no independent 
effects on peak or total reactive hyperaemic FBF nor did they enhance any inhibition beyond that 
which occurred with BaCl2+ouabain infusion.  
 
Protocol 3: Control vasodilator stimulus 
In order to confirm preserved vasodilator capacity after administration of 
BaCl2+ouabain+L-NMMA+ketorolac, SNP was administered in control (saline) conditions and 
at the end of the experimental protocol in a subgroup of 6 subjects.  Baseline FBF and FVC were 
reduced following infusion of BaCl2+ouabain+L-NMMA+ketorolac, however there was no 
significant reduction in the absolute level, absolute change, or relative change in FBF and FVC 
during SNP infusion (Table 9).   
 
Discussion 
 The primary novel finding from the current study is that vascular hyperpolarization via 
activation of KIR channels and Na
+/K+-ATPase explains the majority of the reactive hyperaemic 
response to temporary ischaemia, whereas NO and PGs have little combined role in this response 
(Figure 22).  KIR channels appear to be involved in both the peak and total FBF response; 
however, Na+/K+-ATPase only contributes to the total reactive hyperaemic FBF and not the peak 





response that has been shown to have clinical relevance in a variety of conditions that increase 
cardiovascular disease morbidity and mortality.   
 
Overview of classic vasodilator signaling pathways involved in reactive hyperaemia 
 Beginning with the initial observation of a rapid and profound hyperaemia in response to 
a period of ischaemia, there was interest in determining the underlying signals for this response 
(Duff & Shepherd, 1953; Patterson & Whelan, 1955; Kilbom & Wennmalm, 1976; Takeshita & 
Mark, 1980; Tagawa et al., 1994).  Early experiments determined that an intact nervous system 
was not requisite to observe this response (Duff & Shepherd, 1953; Zelis et al., 1968) and 
subsequent studies pursued investigating local mechanisms of vascular control that might be 
involved (Carlsson et al., 1987; Tagawa et al., 1994; Banitt et al., 1996; Engelke et al., 1996; 
Dakak et al., 1998; Nugent et al., 1999; Bank et al., 2000).  Alongside these studies aimed to 
determine the physiological basis of reactive hyperaemia, the test itself began to be used as a 
measure of vascular health in a variety of at-risk populations (Conway, 1963; Zelis et al., 1968; 
Fronek et al., 1973; Takeshita & Mark, 1980; Iwatsubo et al., 1997; Higashi et al., 1999).  
Different groups of subjects that demonstrated “endothelial dysfunction” as commonly assessed 
by intra-arterial infusion of endothelium-dependent vasodilators (e.g. acetylcholine) or flow-
mediated vasodilatation of the brachial artery were shown to have attenuated reactive 
hyperaemia responses (Conway, 1963; Zelis et al., 1968; Fronek et al., 1973; Takeshita & Mark, 
1980; Iwatsubo et al., 1997; Higashi et al., 1999).  This relationship of cardiovascular disease, 
endothelial health, and impaired reactive hyperaemia has further stimulated an interest in the 
potential mediators of this response.  Importantly, recent evidence indicates that peak reactive 





fact be a better predictor of cardiovascular events than the more commonly-assessed brachial 
flow-mediated vasodilatation (Anderson et al., 2011). 
 It is well known that NO contributes to cardiovascular health in humans due to its 
multifaceted cardioprotectve properties (Cohen & Vanhoutte, 1995).  Whether NO mediates 
reactive hyperaemia was a logical proposition and has been investigated in a variety of existing 
studies (Tagawa et al., 1994; Engelke et al., 1996; Meredith et al., 1996; Dakak et al., 1998; 
Nugent et al., 1999; Bank et al., 2000; Raff et al., 2010).  There is discrepancy within the 
literature, and our present finding that NO (in combination with PGs) does not contribute to peak 
reactive hyperaemic FBF fits with the results of most (Tagawa et al., 1994; Engelke et al., 1996; 
Nugent et al., 1999; Bank et al., 2000; Raff et al., 2010) but not all (Meredith et al., 1996; Dakak 
et al., 1998) of these studies.  Some of the previous work has shown a modest role for NO in the 
total hyperaemic response (Tagawa et al., 1994; Engelke et al., 1996; Bank et al., 2000).  
Additionally, previous studies demonstrated only a minimal contribution of PGs to peak and/or 
total reactive hyperaemia (Carlsson et al., 1987; Engelke et al., 1996; Addor et al., 2008).  Even 
when NO and PGs were inhibited in combination, there was no impact on the peak change in 
FBF in response to ischaemia, whereas there was some reduction (~35%) in the prolonged 
hyperaemic response(Engelke et al., 1996).  Our current findings agree with these observations 
that NO and PGs do not contribute to peak reactive hyperaemic FBF, and while we observed a 
reduction in absolute FBF in the latter portion of reactive hyperaemia, this was not of sufficient 
magnitude to impair the total reactive hyperaemic FBF (Figure 21).  An interesting observation 
in the present study was that peak reactive hyperaemia was somewhat augmented after combined 
NO and PG inhibition, and this could also reflect a critical role for vascular hyperpolarization in 





 Other potential metabolic candidates for regulating reactive hyperaemia include 
adenosine or KATP channel activation.  Augmenting adenosine signaling through caffeine 
(adenosine receptor antagonist) withdrawal or dipyridamole (inhibitor of cellular uptake of 
adenosine) does improve reactive hyperaemia; however, direct inhibition of adenosine receptors 
(via theophylline or caffeine) does not impair peak reactive hyperaemic FBF (Carlsson et al., 
1987; Meijer et al., 2008) and has a minimal effect on total FBF (Carlsson et al., 1987).  
Similarly, results from inhibition of KATP channels have been equally as unsuccessful in 
explaining reactive hyperaemia.  Inhibition of KATP channels via sulfonylureas such as 
tolbutamide or glibenclamide has been shown to modestly reduce total reactive hyperaemic FBF 
but have no impact on the peak response in some studies (Banitt et al., 1996; Bank et al., 2000), 
whereas other investigators have demonstrated no effect of KATP channel inhibition on either 
peak or total reactive hyperaemia (Farouque & Meredith, 2003) .  In the present study, we did 
not investigate these pathways based on these previous observations. 
 Endothelium-dependent vasodilatation that occurs independently of NO and PGs causes 
hyperpolarization of endothelial cells and vascular smooth muscle cells (Cohen & Vanhoutte, 
1995).  Smooth muscle cell hyperpolarization can also be stimulated from non-endothelial 
sources (Emerson & Segal, 2000).  Beyond KATP channels, to the best of our knowledge, 
hyperpolarization has not previously been studied in regards to a potential role in reactive 
hyperaemia.  Activation of both KIR channels and Na
+/K+-ATPase leads to hyperpolarization of 
vascular smooth muscle cells and recently KIR channels have been shown to be particularly 
important for the amplification of hyperpolarizing stimuli as they are directly responsive to 






Critical role for KIR channels and Na+/K+-ATPase in mediating reactive hyperaemia in 
humans 
Based on our comprehensive assessment in the present study, there is a significant role 
for KIR channels and Na
+/K+-ATPase in reactive hyperaemia in humans (Figure 22).  
Interestingly, only KIR channel activation, but not Na
+/K+-ATPase contributed to the peak 
reactive hyperaemic FBF.  Selective inhibition of KIR channels reduced the peak hyperaemic 
response ~50%, and a total of ~60% was observed when inhibition of Na+/K+-ATPase was 
performed simultaneously.  Inhibition of KIR channels and Na
+/K+-ATPase independently 
reduced the total reactive hyperaemic FBF by ~60% and ~40% respectively, and this effect is 
enhanced when these are inhibited in combination.  In this context, there is a remarkable 
reduction in the total response (-87±4%) from control, nearly abolishing reactive hyperaemia.  
Consistent with our findings of a lack of a combined role for NO and PGs when inhibited first, 
there was also not a consistent and significant additional effect of NO and PG blockade beyond 
that observed with combined KIR channel and Na
+/K+-ATPase inhibition.  Collectively, the 
magnitude of the observed attenuation due to KIR channel inhibition on peak hyperaemia, and 
combined KIR and Na
+/K+-ATPase on the total hyperaemic response, is by far the greatest in the 
known studies to date on this topic.   
 
Experimental considerations 
 All of the inhibitors utilized were administered prior to arterial occlusion and reactive 
hyperaemia.  This may lead one to question the efficacy of our inhibitors after the 5 minutes of 
occlusion and subsequent large increases in blood flow.  While not directly assessed, given the 





think this alters our primary conclusions.  If anything, we may be potentially underestimating a 
role for KIR channels and Na
+/K+-ATPase in reactive hyperaemia.  Further, the reactive 
hyperaemic responses to an identical stimulus as used in the present study have been shown to be 
repeatable over time (Engelke et al., 1996), thus the marked impact of our inhibitors on reactive 
hyperaemia cannot be attributed to reduced responses with repeated trials.   
 BaCl2 has been demonstrated to be primarily selective for KIR channels up to a 
concentration of 100 µmol L-1 (Quayle et al., 1997).  Dawes and colleagues demonstrated that a 
dose at half of what we used increased antecubital venous plasma concentrations in the infused 
forearm to 50 µmol L-1 (Dawes et al., 2002) and thus, it can be assumed that our dose would 
result in concentrations within the selective range for KIR channels.  At greater concentrations, 
BaCl2 has been shown to inhibit other potassium channels, most prominently KATP channels.  
While we believe that BaCl2 in the dose we administered is selective for KIR channels, if we are 
in fact inhibiting KATP channels, this likely does not provide an alternate explanation for  our 
findings as the majority of existing data shows little-to-no impact of inhibiting KATP channels on 
peak and/or total reactive hyperaemia response (Banitt et al., 1996; Bank et al., 2000; Farouque 
& Meredith, 2003). 
 Presently, the exact stimulus for vascular hyperpolarization in response to local ischaemia 
is unknown.  Potential candidates include substances that have been shown to cause 
vasodilatation through KIR channels and Na
+/K+-ATPase such as K+ (Edwards et al., 1998; 
Crecelius et al., 2012a), ATP (Crecelius et al., 2012a), and bradykinin (Dwivedi et al., 2005).  
Alternatively, direct anion influx or cation efflux might also stimulate vascular smooth muscle 
cell hyperpolarization, relaxation, and subsequent vasodilatation.  Along these lines, evidence 





endothelial cells contribute to the earliest portion of reactive hyperaemia (Koller & Bagi, 2002).   
Identifying the stimulus for hyperpolarization via KIR channel and Na
+/K+-ATPase activation 
that occurs during reactive hyperaemia represents an intriguing future area of research and 
potentially would provide valuable insight into explaining impaired reactive hyperaemia 
responses in clinical populations. 
 
Perspectives 
 The role of vascular hyperpolarization via KIR channels and Na
+/K+-ATPase in mediating 
vascular responses is a relatively new area of study in humans, and thus the direct impact of 
cardiovascular disease risk factors on these pathways has not been well studied in vivo.  There is 
limited evidence that suggests disruptions in hyperpolarizing pathways may be both consequence 
(de Kreutzenberg et al., 2003) and cause (Brahler et al., 2009) of cardiovascular disease-related 
conditions such as elevated free-fatty acid levels and hypertension.  Given the strong relation 
between attenuated reactive hyperaemia responses and cardiovascular disease morbidity and 
mortality (Anderson et al., 2011) and as a result of this study, reactive hyperaemia and vascular 
hyperpolarization via KIR channels and Na
+/K+-ATPase, these vasodilator pathways present an 
exciting future direction for studies in patient populations.  Moreover, these findings could be 
particularly important for populations that exhibit microvascular dysfunction and may serve as a 
target for specific therapies to improve microvascular blood flow control in humans.   
 
Conclusions  
Following temporary arterial occlusion, there is a significant increase in blood flow in the 





function and is an important marker of overall vascular health and future cardiovascular disease 
risk.  Here, we show that the majority of this response, in terms of both the initial peak 
hyperaemia as well as the total hyperaemia above baseline that occurs throughout the duration of 
the response depends on activation of KIR channels and Na
+/K+-ATPase.  Additionally, our 
findings support the previous investigations that showed very little role for NO and PGs in 
reactive hyperaemia in humans.  We propose that impaired vascular hyperpolarization via of KIR 
channels and Na+/K+-ATPase likely contributes to many of the observed microvascular deficits 






Table 7. Baseline forearm and systemic hemodynamics for all protocols 
 
n=8 in all groups; *P<0.05 vs 1st Trial (i.e. control); †P<0.05 vs 2nd Trial (i.e. ouabain); 
HR=heart rate (beats min-1); MAP=mean arterial pressure (mmHg); FBF=forearm blood flow 
(ml dl forearm volume-1 min-1) 
 
 
Protocol 1 – 
Group 1 
Control BaCl2 BaCl2+ouabain 
BaCl2+ouabain+      
L-NMMA+ketorolac
     HR 56±3 58±3 58±4 56±3 
     MAP 86±3 87±3 87±2 91±4 
     FBF    2.3±0.5     1.5±0.2*   2.3±0.3   1.9±0.2 
Protocol 1 – 
Group 2 
Control Ouabain Ouabain+BaCl2 
Ouabain+BaCl2+      
L-NMMA+ketorolac
     HR 57±4  57±4 58±4 58±5 
     MAP  83±1  84±2     89±2*†    91±3*† 
     FBF    2.5±0.3    2.3±0.4   2.2±0.2    1.8±0.1* 
Protocol 2 Control 




      HR 58±4 54±3 55±4 
     MAP 90±3 89±4 92±4 





Table 8. Resting and peak reactive vasodilatation in all protocols 
n=8 in all groups; *P<0.05 vs 1st Trial (i.e. control); †P<0.05 vs 2nd Trial (i.e. BaCl2) 
 Forearm Vascular Conductance (ml (dl FAV min-1) 100 mmHg-1) 
Protocol 1 – 
Group 1 
Control BaCl2 BaCl2+ouabain 
BaCl2+ouabain+    
L-
NMMA+ketorolac
     Rest   2.8±0.6   1.8±0.3*  2.6±0.4   2.1±0.3 
     Peak 36.3±3.4  18.0±3.2*  13.8±3.0*     10.4±2.8*† 
Protocol 1 – 
Group 2 
Control Ouabain Ouabain+BaCl2 
Ouabain+BaCl2+   
L-
NMMA+ketorolac
     Rest  3.0±0.4    2.7±0.4 2.5±0.2   2.0±0.3* 
     Peak 28.5±3.5  26.5±3.1     9.8±2.7*†     8.8±1.7*† 






     Rest  2.3±0.3    1.6±0.2* 1.6±0.1* 






Table 9. Protocol 3: Control vasodilator stimulus 
n=6; *P<0.05 vs control; FAV=forearm volume; FVC=forearm vascular conductance (ml (dl 






2 μg dl FAV-1 min-1 
Absolute Δ %Δ 
Control     
     FBF 2.2±0.3 12.4±1.5 10.2±1.4 499±66 
     FVC 2.5±0.4 15.3±2.1 12.7±1.8 546±72 
BaCl2+ouabain 
+L-NMMA+ketorolac 
    
     FBF 1.5±0.3* 10.1±2.0 8.6±1.7 611±107 




































































































Figure 19.  Protocol 1: Independent effects of KIR channel inhibition (Group 1) 
A. Dynamic forearm blood flow (FBF) response following 5 min of arterial occlusion in the 
following conditions: control (black circles), independent KIR channel inhibition (BaCl2; dark 
grey triangles), combined KIR channel and Na
+/K+-ATPase inhibition (BaCl2+ouabain; light 
grey squares), and combined inhibition of  KIR channels, Na
+/K+-ATPase, NO and PGs 
(BaCl2+ouabain+L-NMMA+ketorolac; white diamonds).  BaCl2 significantly inhibited the 
response for the first 75 sec and there was little additional effect of ouabain, or L-
NMMA+ketorolac.  *P<0.05 vs BaCl2; †P<0.05 vs BaCl2+ouabain; ‡ P<0.05 vs 
BaCl2+ouabain+L-NMMA+ketorolac.  B. Peak reactive hyperaemic FBF was significantly 
attenuated from control by BaCl2 and ouabain had no additional effect whereas there was a 
slightly greater reduction with the addition of L-NMMA+ketorolac.  *P<0.05 vs Control; 
†P<0.05 vs BaCl2.  C.  Similarly, total reactive hyperaemic FBF (area under the curve) was 
significantly reduced from control by BaCl2 and ouabain had no additional effect whereas L-




































































































































































































*† * † 
* 
Figure 20.  Protocol 1: Independent effects of Na+/K+-ATPase inhibition (Group 2) 
A. Dynamic forearm blood flow (FBF) response following 5 min of arterial occlusion in the 
following conditions: control (black circles), independent Na+/K+-ATPase inhibition 
(Ouabain; dark grey triangles), combined Na+/K+-ATPase and KIR channel inhibition 
(Ouabain+BaCl2; light grey squares), and combined inhibition of  Na
+/K+-ATPase, KIR 
channels, NO and PGs (Ouabain+BaCl2+L-NMMA+ketorolac; white diamonds).  Ouabain 
did not affect the initial FBF, but thereafter reduced the FBF from control until 90 sec post-
cuff deflation.  The addition of BaCl2 further attenuated FBF for the first 30 seconds, whereas 
addition of L-NMMA+ketorolac had no further effect. *P<0.05 vs Ouabain; †P<0.05 vs 
Ouabain+BaCl2; ‡ P<0.05 vs Ouabain+BaCl2+L-NMMA+ketorolac.  B. Peak reactive 
hyperaemic FBF was not affected by ouabain.  Infusion of BaCl2 significantly reduced peak 
FBF from control, and L-NMMA+ketorolac had no further impact.  *P<0.05 vs Control; 
†P<0.05 vs Ouabain.  C.  Total reactive hyperaemic FBF (area under the curve) was 
significantly reduced from control by ouabain and BaCl2 had an additional effect whereas L-






















































































































































Figure 21.  Protocol 2: Effects of combined inhibition of nitric oxide and prostaglandins 
A. Dynamic forearm blood flow (FBF) response following 5 min of arterial occlusion in the 
following conditions: control (black circles), combined inhibition of the synthesis of NO and 
PGs (L-NMMA+ketorolac; light grey squares), and combined inhibition of  NO, PGs, KIR 
channels and Na+/K+-ATPase (L-NMMA+ketorolac+BaCl2+ouabain; white diamonds).  L-
NMMA+ketorolac attenuated the response from control only from 30-60 sec post-cuff 
deflation.  The addition of BaCl2+ouabain significantly reduced the initial FBF response for 
the first 30 sec and there was no further effect thereafter.  *P<0.05 vs L-NMMA+ketorolac; 
†P<0.05 vs L-NMMA+ketorolac+BaCl2+ouabain.  B. Peak reactive hyperaemic FBF was not 
affected by L-NMMA+ketorolac and was significantly attenuated by L-
NMMA+ketorolac+BaCl2+ouabain.  *P<0.05 vs Control; †P<0.05 vs L-NMMA+ketorolac.  
C.  Similar to peak, total reactive hyperaemic FBF (area under the curve) was not affected by 
L-NMMA+ketorolac and was significantly attenuated by L-










































































































Figure 22.  Summary: Effects of inhibition of KIR channels, Na
+/K+-ATPase, nitric oxide 
and prostaglandins on peak and total reactive hyperaemia 
The combined results from the three experimental protocols are presented for both the relative  
impact (%Δ) on peak (A) and total (B) reactive hyperaemic forearm blood flow (FBF) in each 
experimental condition (BaCl2: n=8; Ouabain: n=8; BaCl2+ouabain: n=16; L-
NMMA+ketorolac: n=8; BaCl2+ouabain+L-NMMA+ketorolac: n=24).  BaCl2 reduced peak 
FBF and this attenuation was unchanged with the addition of ouabain or L-NMMA+ketorolac.  
Neither ouabain alone nor L-NMMA+ketorolac attenuated peak FBF.  BaCl2 and ouabain 
both independently reduced total FBF and in combination (BaCl2+ouabain), the reduction was 
enhanced.  There was no additional reduction by L-NMMA+ketorolac, nor did L-
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CHAPTER VI – OVERALL CONCLUSIONS 
 Vasoactive signaling pathways in humans have been identified over time, and the relative 
contributions of these pathways in response to a variety of stimuli are of interest to our pursuit of 
understanding the integrative regulation of tissue blood flow and oxygen delivery.  A variety of 
factors have been proposed to be involved in the hyperemic response to muscle contractions and 
arterial occlusion, as well as the modulation of sympathetic vasoconstriction during exercise.  
Primarily, to date, two of the most well-studied vascular signaling pathways in humans have 
been nitric oxide (NO) and prostaglandins (PGs).  The propensity of work in the literature on 
these pathways is likely due to their endothelium-dependency and the relationship of endothelial 
health and cardiovascular disease as well as the ability to enzymatically inhibit their synthesis in 
vivo.  However, recent evidence, mostly in experimental animals suggests that signaling beyond 
NO and PGs, through vascular hyperpolarization, may be involved in a variety of conditions.  
Thus, we have focused our experiments on determining the role of vascular hyperpolarization in 
vasomotor control in humans. 
 Specifically, vascular hyperpolarization can occur by a variety of means and this is one of 
the difficulties in establishing the role of this pathway, particularly in human studies where it is 
impossible to directly measure membrane potential.  Activation of inwardly-rectifying potassium 
(KIR) channels and Na
+/K+-ATPase leads to vascular hyperpolarization and we have recently 
demonstrated our ability to safely inhibit these pathways in the human forearm.  Thus, the 
preceding collection of experiments provides some of the first direct evidence establishing the 
significant role of vascular hyperpolarization in mediating vasodilator responses to muscle 
contraction and temporary arterial blood flow occlusion.   
 The key novel findings from present body of work are as follows: 1) vascular 
hyperpolarization via KIR channels and Na





vasodilation following a single muscle contraction and combined inhibition of these pathways 
along with NO and PGs nearly abolishes this response; 2) vascular hyperpolarization via KIR 
channels and Na+/K+-ATPase mediates a portion of the vasodilatory and hyperemic response to 
repeated muscle contraction, both at the onset and when steady-state levels are obtained, whereas 
NO and PGs, do not largely contribute to this response; 3) contrary to our hypothesis, vascular 
hyperpolarization via KIR channels and Na
+/K+-ATPase appears to not be involved in functional 
sympatholysis; and 4) reactive hyperemia in response to temporary arterial occlusion is primarily 
mediated by vascular hyperpolarization via KIR channels and Na
+/K+-ATPase, and NO and PGs 
do not have an independent role in this response.  Taken together, we believe that vascular 
hyperpolarization via KIR channels and Na
+/K+-ATPase represents a novel vascular signaling 
pathway in humans in response to muscle contractions and arterial occlusion.  Based on the 
collective literature on this topic and the results from the present investigations, it is likely that 
this pathway may be involved in some of the age- and disease-related impairments in the 
responses we have examined.  Thus, these findings may provide insight into understanding 
impaired vascular function in patient populations and as such, could represent a novel therapeutic 

















APPENDIX B – CONSENT FORM 
 
  Consent to Participate in a Research Study 
Colorado State University 
 
TITLE OF STUDY:  Regional Blood Flow Control and Vascular Function:  Effects of Aging and 
                                 Regular Physical Activity 
 
PRINCIPAL INVESTIGATOR:  Frank A. Dinenno, Ph.D.  491-3203 
 
WHY AM I BEING INVITED TO TAKE PART IN THIS RESEARCH?  You are a man or woman 
between the ages of 18-35 or 55-90 years.  You are either  1) not exercising vigorously and 
regularly, or 2) have exercised vigorously and regularly for a number of years.  Our research is 
looking at the effect of aging and exercise on regional blood flow control and how your blood 
vessels work. 
 
WHO IS DOING THE STUDY?  This research is being performed by Frank Dinenno, Ph.D  of 
the Health and Exercise Science Department, and also by Dennis Larson, M.D. and Gary 
Luckasen, M.D., of the Heart Center of the Rockies.  Trained graduate students, undergraduate 
students, research assistants, or research associates are assisting with the research.  These 
studies are paid for by the National Institute on Aging, a part of the US Government. 
 
WHAT IS THE PURPOSE OF THIS STUDY?  The way in which blood flow (and oxygen 
delivery) and blood vessels are regulated by local factors and nerves during exercise and during 
changes in the composition of air you breathe is being studied. Importantly, cardiovascular 
regulation under these conditions might change in older people, it might be different between 
men and women, and it might be affected by regular physical exercise.  The purpose of the 
research is to understand differences in how blood vessels work in various groups of adults, in 
different muscle groups (forearm, thigh, calf), as well as in the neck.  The makeup of muscle 
fibers is also being studied. 
 
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?  This 
whole research project will take place over a period of approximately five years.  However, your 
part of this study will be either:  
 __X___   1) one or two visits over a several day period, or                  ________  (your initials) 
______   2) several visits over a few to several weeks.                        ________  (your initials) 
 
WHAT WILL I BE ASKED TO DO?  This consent form applies to a large research project.  You 
are only being asked to participate in one part of the total project.  Depending on the part of the 
research project that you are involved in, you will be asked to participate in some of the 
following procedures.  Many potential procedures are described in the section below.  However, 
the procedures that you will be asked to do for this part of the study have a check mark next to 
them.  The check marks were put there by one of the researchers.  The time associated with 
each procedure reflects the amount of time you will spend performing or undergoing the 
procedure, not the total time of the study.  A member of the research team will fully explain each 
checked procedure that applies to your participation and specifically how long each session 






_X____ Health and Physical Activity Questionnaire.  You will be asked to answer some 
questions about your health and exercise habits to determine if you can participate in the study. 
(~20 minutes)                            
 ________  (your initials) 
 
_____ Pregnancy Test.  If you are female you will be required to have a sample of your urine 
tested for the presence of human chronic gonadotropin (HCG), a hormone which indicates 
whether you may be pregnant.  This will require approximately 1 cup of your urine. If you are 
pregnant or the test indicates that you are pregnant you will not be able to participate in this 
study. (~10 minutes) 
         ________  (your initials) 
 
__X___ Heart Rate and Blood Pressure.  Heart rate will be measured by placing three sticky 
electrodes on your chest and reading the electrocardiogram (ECG) signal.  Blood pressure will 
be measured with an automated machine that requires the placement of a cuff around your 
upper arm (bicep), or a small cuff on your finger. (continuous monitoring throughout study) 
          ________ (your initials) 
 
_____ Graded Exercise Test.  If you are in the 55-90 yr-old age group, you will be asked to 
perform a maximal exercise test on a treadmill under the supervision of a physician.  This test 
will occur in the Human Performance Clinical/Research Laboratory in the Department of Health 
and Exercise Science on the CSU campus.  Sticky electrodes will be placed on your chest, and 
you will walk briskly or jog while the steepness of the treadmill is increased.  Your blood 
pressure and heart beat will be closely measured during and immediately after the test. 
(~1 hour)                   ________  (your initials)    
 
_____ Maximal Oxygen Consumption.  VO2max testing will be performed on a treadmill while 
you are walking or running and the steepness of the treadmill is increased until you can’t 
exercise any more.  You will be asked to put your mouth around a scuba-like mouthpiece and 
wear a nose clip to prevent breathing through your nose.  The amount of oxygen your body 
uses for energy will be determined from the oxygen and carbon dioxide you breathe in and out 
during the exercise.  Your heart rate will be measured using a heart rate monitor.  Body mass 
and height will be measured on a medical beam scale. (~30 - 45 min)     
         ________  (your initials) 
 
__X__ Body Composition.  The fat, muscle, and bone in your body will be measured using an 
x-ray device (dual-energy x-ray absorptiometer) that will scan you from head to toe while you lie 
quietly on a special table for approximately 20 minutes.  The amount of x-ray radiation you will 
receive is extremely low. (~20 minutes)    ________  (your initials) 
  
_____ Forearm Volume.  The volume of your forearm will be measured via water displacement.   
You will place your forearm in a large water-filled cylinder, and the spillover of this water is 
collected in a large graduated cyclinder to determine the volume.  (~5 minutes)   






__X___ Forearm Exercise.  You will lay flat on a bed and squeeze your hand and forearm 
muscles using a handgrip device while your hand and arm are comfortably secured. The 
intensity of the exercise will range from very easy to moderately difficult, and you will be asked 
to perform this exercise for ~10 minutes several different times throughout the study with plenty 
of rest in between exercise trials. (1 – 2 hours) 
                                                                                                           ________  (your initials) 
 
_____ Calf Exercise.  You will sit in a special chair and squeeze your calf muscles (similar to 
standing on your toes) while your arms, hips, and shoulders are comfortably secured.  The 
intensity of the exercise will range from very easy to moderately difficult, and you will be asked 
to perform this exercise for ~10 minutes several different times throughout the study with plenty 
of rest in between exercise trials.  
(1 – 2 hours) 
                                                                                                             ________  (your initials) 
 
 
_____ Knee Extensor Exercise. You will sit in a special chair and squeeze your thigh muscles 
while your hips and shoulders are comfortably secured.  Your feet will be secured in specially 
designed boots and you will be asked to extend your leg against resistance until your ankle is 
about at the height of your knee, relax back to a regular seated position, and then repeat.  The 
intensity of the exercise will range from very easy to moderately difficult, and you will be asked 
to perform this exercise for ~10 minutes several different times throughout the study with plenty 
of rest in between exercise trials. (1 – 2 hours) 
                                                                                                             ________  (your initials) 
 
__X___ Maximum Voluntary Contraction. This will consist of 3-4 trials where you will squeeze 
your muscles (either forearm, calf, or thigh) and generate as much force as you can.  You will 
be asked to generate as much force over the course of ~3 seconds and hold this force another 
5 seconds.  After a 2-3 minute rest period, you will be asked to do this again.  This is typically 
used to determine how heavy of exercise you perform so everybody is exercising at similar 
percentages of their maximum. (~ 20 minutes) 
                                                                                                             ________  (your initials) 
 
_____  Exercise Training.   
 Forearm:  You will be instructed to exercise five times per week, for a total of four weeks.  
You will be given a special exercise device and will be instructed to exercise with your non-
dominant forearm squeezing your muscles 12 times per minute at 30-35% of your maximum 
until you can’t exercise any more.  When you are able to exercise at this initial workload for 30 
minutes, the workload will be increased.  You will need to visit the laboratory once per week to 
adjust the training workload as your performance improves.     ________  (your initials) 
 
 Calf:  You will be instructed to exercise five times per week, for a total of four weeks.  
You will be instructed to exercise with your calf muscles and squeeze this muscle 12 times per 
minute at 30-35% of your maximum until you can’t exercise any more.  You will be instructed to 
perform calf extension exercise in the upright position with added weight (if necessary) to 
achieve the pre-determined workload.  When you are able to exercise at this initial workload for 
30 minutes, the workload will be increased.  You will need to visit the laboratory once per week 






 Knee extensor:  You will be instructed to exercise 3 times per week, for a total of eight 
weeks.  You will be required to perform the training studies in the laboratory under supervision.  
Each training session will be 60 minutes.  The first two weeks will consist of short (5-10 min) 
high intensity exercise bouts, whereas the second two weeks will consist of long (15-45 min) low 
intensity exercise bout.  This pattern of training will be repeated to attain a total training period of 
eight weeks.  As your exercise performance improves, the training workload will be adjusted 
accordingly.            ________  (your initials) 
 
 Whole-body:  You will be instructed to exercise 5 times per week, 40-50 minutes per 
exercise session at 60-85% of your maximum heart rate, for a total of twelve weeks.  You will be 
asked to cycle, walk, jog, or run during this training period.  You will be taught how to use heart 
rate monitors (provided by the lab) in order to train at the proper intensity as well as to record 
your exercise sessions.        ________  (your initials)         
 
____  Ischemic Exercise.  You will exercise your calf or forearm with a blood pressure cuff on 
your thigh or upper arm that is inflated very tightly to temporarily block the blood flowing to your 
muscle.  You will be asked to perform this exercise for ~10 minutes several different times 
throughout the study with plenty of rest in between exercise trials. (20 – 30 minutes)  
         ________  (your initials) 
 
____  Cold Pressor Test.  You will place your hand or foot in ice water for 2-3 minutes on 
several occasions. (~10 minutes)   
         ________  (your initials) 
 
____  Lower Body Negative Pressure.  You will be placed in a sealed wooden chamber while 
you are laying flat on a bed.  The chamber is sealed at your waist.  Using a standard vacuum 
that is attached to the chamber, suction will be applied to mimic what happens when you go 
from laying to standing up. This will occur several times throughout the study for about 15 
minutes at a time. (~ 1 hour)       ________  (your initials) 
 
____  Up-right or head-down tilting.  You will be laying on a bed that is specially designed to 
be tilted ~60 degrees upright, or tilted downward ~10 degrees.  This mimics what happens when 
you go from laying to standing up, and vice versa. (~ 1 hour)   
         ________  (your initials) 
 
____  Forearm Negative/Positive Pressure.  You will place your forearm in a sealed chamber 
up to your elbow.  Application of suction (like a vacuum) increases blood flow to your arm, 
whereas the opposite pressure reduces blood flow to your arm. (1-2 hours) 
         ________  (your initials) 
 
____  Brachial Artery Compression.  A special device that is mounted to a frame above your 
forearm will be placed over your brachial artery at the elbow.  When this device presses down 
on your arm, it will temporarily reduce the amount of blood to your forearm.  This will be 
performed for approximately 5 minutes at a time, and will occur several times throughout the 






____  Breathing a low Oxygen or high Carbon Dioxide Gas Mixture.  The purpose of this 
test is to mimic what happens when you go up to altitude.  You will be asked to place your 
mouth around a scuba mouthpiece while wearing a nose clip to prevent breathing through your 
nose.  The amount of oxygen or carbon dioxide you are breathing will be changed carefully with 
a specially designed system, and you will breathe this for a maximum of 20 minutes at a time.  
You will be asked to do this several times throughout the study, with plenty of time in-between 
each trial.  The amount of oxygen that is in your blood will be measured with a light sensor on 
your fingertip or earlobe.  (1-1.5 hours)    
         ________  (your initials)  
 
__X__ Venous Occlusion Plethysmography.  The blood flow in your forearm or calf will be 
measured by the use of blood pressure cuffs around your upper arm or thigh, and around your 
wrist or ankle.  These cuffs will be inflated and deflated periodically.  A sensitive gauge (similar 
to a rubber band) will also be placed around the maximum circumference of your forearm or 
calf. (2-3 hours)                                                                                        
                                                                                                              ________  (your initials) 
 
__X__  Doppler Ultrasound.  The blood flow in your arm, leg, neck, or brain will be measured 
using an ultrasound machine which produces sound waves to measure your blood vessel size 
and the speed of your blood.  This also provides information about how elastic or stiff your blood 
vessels are. (2-3 hours)  
                                                                                                             ________  (your initials) 
 
__X__  Reactive Hyperemia.  A blood pressure cuff will be placed on your upper arm or thigh 
and inflated really tight to temporarily block the blood to your forearm or calf.  After 5, 10, or 15 
minutes, the cuff will be released and the blood flow in your forearm or calf will be measured.  
This test is a measure of how much your blood vessels can relax and will be repeated several 
times throughout the study. (1- 1.5 hours) 
            ________  (your initials)  
 
____  Flow-Mediated Vasodilation.  A blood pressure cuff will be placed on your forearm or 
your calf and inflated really tight to temporarily block the blood to your hand or foot.  After 5, 10, 
or 15 minutes, the cuff will be released and the diameter changes of the blood vessels in your 
arm or leg will be measured using Doppler ultrasound.  In some cases, your hand or foot will be 
warmed up for 15 minutes and the changes in blood vessel diameter will be measured. This will 
be repeated several times throughout the study. (1-1.5 hours)    
            ________  (your initials) 
 
____ Sympathetic Nervous System Activity.  The measurement of sympathetic nervous 
system activity involves measuring the activity of one of your nerves on the side of your knee.  
Two small microelectrodes (small needles) will be placed through your skin.  The position of one 
of the electrodes will be moved back and forth through your skin while a very small electrical 
impulse (1-2 volts) is passed through the electrode.  This search procedure will continue until 
the electrode being moved causes your foot to twitch.  This procedure will take between 5-60 
minutes.  When a foot or hand twitch is observed, measurement of the activity of the 
sympathetic nervous system will begin. (2-3 hours)                               ________  (your initials) 
 
____ Blood Sample.  Up to 100 ml (approximately 7 tablespoons) of your blood will be drawn 
from a vein on the front of your elbow or artery in a standard fashion using a sterilized 
hypodermic needle. (~15 minutes)   





** For Arterial Catherization, Venous Catheterization, or Muscle Biopsy:  If you are allergic 
to lidocaine or novacaine, or have had a negative reaction to medicines injected while at the 
dentist, you should notify us immediately and not have any of these procedures done.   
 
__X__ Venous Catheterization.  Your skin will be cleaned and a catheter (plastic needle) will 
then be inserted on the front side of your elbow and secured to the skin.  In some cases, a local 
anesthetic might be used to reduce any discomfort. (~2-4 hours) 
                                                                 ________  (your initials) 
 
__X__ Brachial Artery Catheterization.  Your skin will be cleaned and a local anesthetic will 
be given with a small needle to numb the area where the catheter will be placed (front side of 
your elbow).  The catheter (plastic needle) will then be inserted and secured to the skin. (~2-4 
hours)   
     ________  (your initials) 
   
____ Femoral Artery Catheterization.  Your skin will be cleaned and a local anesthetic will be 
given with a small needle to numb the area where the catheter will be placed (about half way 
between your hip bone and groin on the front side of your leg).  The catheter (plastic needle) will 
then be inserted and secured to the skin. (~2-4 hours)      
             ________  (your initials) 
 
_X___  Drug Administration (~ 2 - 4 hours).  The administration of one of more of the 
following drugs might occur several times throughout the study. 
Vasoconstrictors – cause temporary narrowing of the blood vessels (minutes) 
___ Tyramine 








X___ Barium Chloride 
_X__ Oubain 
 
Vasodilators – temporarily relax the blood vessels (minutes) 
_X__ Acetylcholine 
_X__ Adenosine 
X___ Sodium Nitroprusside 
___ L-Arginine 
_X__ Phentolamine 
X___ Adenosine Triphosphate (ATP) 
___  Potassium Chloride (K+) 
___ Isoproteronol 
 
No major effects 
___ Ascorbic Acid (Vitamin C) 
_X__ Propranolol 
___ Aminophylline 






Oral Supplement Administration  
 ____  Ascorbic Acid (Vitamin C)         
________  (your initials) 
 
 
____ Muscle Biopsy.  A sample of muscle will be taken from a muscle on the outside of your 
thigh.  This will take place under the supervision of a medical doctor in the Hartshorn Health 
Center on the CSU campus.  Your skin will be temporarily numb using lidocaine, a medicine 
similar to novacaine.  After deadening the skin, a ¼ inch incision, or cut, is made in the skin over 
the muscle using a sterilized scalpel.  The sample is obtained using a sterilized sampling 
needle.  The muscle sample obtained is usually about ½ the size of the eraser on the end of a 
pencil.  You will not have to reduce your activity afterwards, but should not perform any unusual 
or extremely vigorous activity for a few days.  You will receive written instructions regarding care 
of the incision, and a telephone number to contact if you have any questions. (30 - 45 minutes) 
                                                                                                          ________  (your initials)     
 
FUTURE USE OF BLOOD OR MUSCLE SAMPLES 
It is possible that we may want to use any extra blood or muscle tissue for future research not 
described in this consent form.  For example, this may include determination of certain gene 
expressions that relate to various measures of cardiovascular function measured as part of this 
study.  This information will remain private as will all of the data collected from the study.   
Only choose one of the following:    
 
_____ I give permission for the use of my blood or muscle tissue collected as part of the current 
study only.                   ________  (your initials) 
 
_____ I give permission for the use of my blood or muscle tissue for the current study as well as 
for future studies.                     ________  (your initials) 
 
 
ARE THERE REASONS WHY I SHOULD NOT TAKE PART IN THIS STUDY? 
If you are not 18-35 or 55-90 years of age, are pregnant, are a regular smoker, or have any 
diseases that would affect our measurements or significantly increase the risks associated with 
this study, we will not be able to include you in the research.  
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?  
(The procedures that apply to your proposed participation are checked)  
 
 _X____  Health and Physical Activity Questionnaire – there are no known risks associated 
with answering health questions.  All information is kept strictly confidential.                     
                     ________  (your initials) 
 
 _____  Graded Exercise Test – there is a risk of fatigue (temporary muscle tiredness), 
muscle strain, heart beat abnormalities (arrhythmias), a 0.01% chance of death (in people 
who have heart problems), a 0.02% risk of cardiac arrhythmias that would require you to go 
to a hospital (in people who have heart problems), and a risk of an increase or decrease in 
blood pressure.              






 _____ Maximal Oxygen Consumption – There is the possibility of fatigue, muscle strains, 
heart rhythm abnormality, and change in blood pressure.  There is the possibility of falling off 
of the treadmill.  Incidence of myocardial infarction (MI) is also a risk.  1 in 10,000 individuals 
with cardiovascular disease may die and 4 in 10,000 may have abnormal heart rhythms or 
chest pain. 
                      ________  (your initials) 
 
 _X____ Body composition (DEXA) scan – the risks associated with the DEXA are very low.  
The radiation you will receive is less than 1/3000th of the Food and Drug Administration 
(FDA) limit for annual exposure.  The FDA is a government organization responsible for 
medical safety.   In other words, you could receive 3000 DEXA scans in a single year and still 
not meet the FDA limit for radiation exposure.  In this study you will receive one scan.  The 
more radiation you receive over the course of your life, the greater the risk of having 
cancerous tumors or of inducing changes in genes.  The radiation in this study is not 
expected to greatly increase these risks, but the exact increase in such risks is not known.  
Women who are pregnant or could be pregnant should receive no unnecessary radiation and 
should not participate in this study.                                                   ________  (your initials) 
  
 
 _X____ Muscle contractions (Exercise) – There is a slight risk of muscle strain and muscle 
soreness resulting from brief strong muscle contractions.  Soreness should not last more 
than two days or affect your normal function.                                   ________  (your initials) 
 
 _____ Exercise training – There is a slight risk of muscle strain and muscle soreness  
     resulting from brief strong muscle contractions.  Soreness should not last more than two days 
     or affect your normal function and should get progressively less as training continues.                                    
                        ________  (your initials) 
 
 _____ Ischemic Exercise – There is a risk of temporary discomfort and possible cramping in 
the forearm or calf during and after the exercise.  These symptoms will be relieved when the 
exercise stops.                 ________  (your initials) 
 
 _____ Cold Pressor Test – There is a risk of temporary discomfort of the hand or foot.  In 
rare cases, subjects might feel light-headed or nauseous.  These symptoms will be relieved 
when the hand or foot is removed from the ice water and wrapped in a blanket. 
                  ________  (your initials) 
 
 _____ Lower Body Negative Pressure- There is a small risk of feeling nauseous or fainting.  
These symptoms will be relieved when the vacuum is turned off.  ________  (your initials)     
 
_____ Up-right or head-down tilting – Small risk of feeling nausea or fainting during up-right 
tilt.  These symptoms will be relieved when the table is tilted back and the subject is lying 
supine.  There are no known risks for head-down tilt.                     ________  (your initials) 
 
 _____ Forearm Positive/Negative Pressure – There is a small risk of slight discomfort or 
cramping if performing forearm exercise at the same time.             ________  (your initials) 
 
 _____ Brachial Artery Compression – There is a risk of slight discomfort at the site of 
compression (elbow).  There is also a risk of slight discomfort or cramping if performing 







 _____ Breathing a low oxygen or high carbon dioxide content gas mixture- The risks 
associated with this include light-headedness, headache and fainting.  However, we will be 
monitoring all of your vital signals and will stop the procedure if this occurs.  Symptoms will 
end momentarily after breathing normal room air.                           ________  (your initials) 
 
 _X____ Venous Occlusion Plethysmography- There is a risk of temporary discomfort of the 
hand or foot when the blood pressure cuffs are inflated.  
                    ________  (your initials) 
 
 _X____ Reactive Hyperemia/Flow-Mediated Vasodilation- There is a risk of temporary 
discomfort of the upper arm or thigh when the blood pressure cuffs are inflated.  The 
discomfort might be greater the longer the cuffs are inflated. 
                     ________  (your initials)  
 
 _____ Sympathetic Nervous System Activity – Some subjects experience a temporary 
(seconds) pain and discomfort while the microelectrodes are being inserted. After the 
procedure there is a small risk of numbness, pins and needles type sensations, or pain which 
lasts 1-3 days. In very rare cases, numbness, pins and needles type sensations, or pain in 
the leg or arm has lasted several weeks or months (1-3 in 1000).  These problems can be 
minimized by only having experienced individuals perform this technique. In addition, by 
minimizing the time to find the nerve to less than 60 minutes, the risk of unpleasant 
after-effects is reduced even more. 
                                                                                                               ________  (your initials) 
 
 _____ Blood sample – The risks associated with blood drawing include bruising, slight risk of 
infection, soreness, and fainting.  These are minor risks which usually do not last more than 
one day if they occur.                                                       ________  (your initials) 
 
 _X____ Venous Catheterization- The risk of allergic reaction to lidocaine is extremely low. 
There is a risk of bruising, slight risk of infection, local soreness, and fainting. 
                      ________  (your initials) 
 
 __X___ Arterial Catheterization – The risk of allergic reaction to lidocaine is extremely low.  
There is a risk that pain or discomfort may be experienced when the catheter is inserted in 
the artery, and local soreness after the study.  In about 1 in 10 cases a small amount of 
bleeding under the skin will cause a bruise.  There is about a 1 in 1,000 risk of infection or 
significant blood loss.  In about 1 in 4,000 damage may occur to the artery requiring surgery. 
                      ________  (your initials) 
 
 __X___ Drug/Supplement Administration - The risks associated with drug administration 
include temporary increases or decreases in blood pressure and heart rate.  In the case of 
clonidine and dexmedetomidine, you might experience mild drowsiness.  These symptoms 
should resolve when the drug stops.  With any of the vasoconstrictor drugs, there is a slight 
risk that ischemia (lack of blood to the tissues) could occur.   Risks of these effects are 
minimized by calculating the amount of drug given relative to the size of your forearm or leg, 
and not the entire body.  Finally, there is a potential risk of an allergic reaction to vasoactive 
drug administration.  If you are allergic to aspirin, you should not participate. 







 _____ Muscle Biopsy – The risks associated with the muscle sample procedure include 
discomfort, soreness in that muscle, bruising, infection, and minor scarring.  The discomfort 
and localized soreness are likely, but generally last only 24-48 hours.  Temporary scarring is 
also expected.  How wounds heal over time is different between people.  The scar will only 
be about ¼ inch long, and is usually difficult to distinguish 8-12 months after the procedure.  
The risk of bruising is low, and infections are extremely rare. 
                                                                                                               ________  (your initials) 
    
 It is not possible to identify all potential risks in research procedures, but the researcher(s) 
have taken reasonable safeguards to minimize any known and potential, but unknown, risks. 
 
WILL I BENEFIT FROM TAKING PART IN THIS STUDY?  There are no direct benefits to you 
for participating in this study beyond receiving information on your body composition and 
cardiovascular risk factors. 
 
DO I HAVE TO TAKE PART IN THE STUDY?   Your participation in this research is voluntary.  
If you decide to participate in the study, you may withdraw your consent and stop participating at 
any time without penalty or loss of benefits to which you are otherwise entitled.   
 
 WHAT WILL IT COST ME TO PARTICIPATE?  There is no cost to you for participating except 
that associated with your transportation to our facilities. 
 
WHO WILL SEE THE INFORMATION THAT I GIVE?  We will keep private all research records 
that identify you, to the extent allowed by law. Your information will be combined with information 
from other people taking part in the study. When we write about the study to share it with other 
researchers, we will write about the combined information we have gathered. You will not be 
identified in these written materials. We may publish the results of this study; however, we will 
keep your name and other identifying information private.  
 
We will make every effort to prevent anyone who is not on the research team from knowing that 
you gave us information, or what that information is.  For example, your name will be kept 
separate from your research records and these two things will be stored in different places under 
lock and key. You should know, however, that there are some circumstances in which we may 
have to show your information to other people.  For example, the law may require us to show 
your information to a court or to the Human Research Committee at CSU.   
 
CAN MY TAKING PART IN THE STUDY END EARLY?  Your participation in the study could 
end in the rare event of muscle strain, if you become pregnant, or if you miss an excessive 
number of appointments.   
 
WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY?  For 
experiments that involve the blood sample, muscle sample, fine wire electrodes, and arterial or 
venous catheterization, you will be paid $15/hour.  
Your identity/record of receiving compensation (NOT your data) may be made available to CSU 
officials for financial audits. 
 
WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?  Please be aware 
that for this study the University has made special arrangements to provide initial medical 





The research project will provide for the coverage of reasonable expenses for emergency 
medical care related to the treatment of research-related injuries, if necessary. 
 
LIABILITY: 
Because Colorado State University is a publicly-funded, state institution, it may have only limited 
legal responsibility for injuries incurred as a result of participation in this study under a Colorado 
law known as the Colorado Governmental Immunity Act (Colorado Revised Statutes, Section 
24-10-101, et seq.).  In addition, under Colorado law, you must file any claims against the 
University within 180 days after the date of the injury.  
 
In light of these laws, you are encouraged to evaluate your own health and disability insurance 
to determine whether you are covered for any physical injuries or emotional distresses you 
might sustain by participating in this research, since it may be necessary for you to rely on your 
individual coverage for any such injuries. Some health care coverages will not cover research-
related expenses. If you sustain injuries, which you believe were caused by Colorado State 
University or its employees, we advise you to consult an attorney. 
 
WHAT IF I HAVE QUESTIONS?  Before you decide whether to accept this invitation to take part 
in the study, please ask any questions that might come to mind now.  Later, if you have 
questions about the study, you can contact the principal investigator, Frank Dinenno, Ph.D., at 
(970)491-3203, or via email at fdinenno@cahs.colostate.edu.  If you would like to ask a medical 
doctor about your participation in the study, you may contact one of the physicians listed below 
at the corresponding phone number.   If you have any questions about your rights as a volunteer in this 
research, contact Janell Barker, Human Research Administrator, at 970-491-1655.  We will give you a 
copy of this consent form to take with you. 
 
This consent form was approved by the CSU Institutional Review Board for the protection of human 
subjects in research on November 18, 2010. 
 
Your signature acknowledges that you have read the information stated and willingly sign this 
consent form.  Your signature also acknowledges that you have received, on the date signed, a 
copy of this document containing 9 pages. 
  
_________________________________________      _____________________ 
Signature of person agreeing to take part in the study      Date 
 
_________________________________________ 
Printed name of person agreeing to take part in the study 
 
_______________________________________     _____________________ 
Name of person providing information to participant      Date 
 
_________________________________________    
Signature of Research Staff 
 
** List of Contact Numbers in Case of Medical Emergency 
    Gary Luckasen, M.D.     Work: 970-221-1000 (24 hours a day) 
    Dennis Larson, M.D.              Work: 970-221-1000 (24 hours a day) 
    Poudre Valley Hospital Emergency  970-297-6250 
    Frank A. Dinenno, Ph.D.    Work: 970-491-3203 
           Home: 970-266-1719 
